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ABSTRACT
Nicotinic acetylcholine receptors (nAChRs) and 5-hydroxytryptamine type 3 
receptors (5 HT3RS) are pentameric ligand-gated ion channels which form both 
heteromeric and homomeric complexes. Aspects of the assembly and 
pharmacological properties of the a  7 nAChR and 5 HT3R were examined through 
three independent studies.
The first study examined the mechanism by which the 5 HT3B subunit, when 
expressed alone, is retained within the endoplasmic reticulum (ER). The 5 HT3R 
forms both homomeric (composed of 5HT3a subunits) and heteromeric (composed of 
5HT3A and 5 HT3B subunits) complexes. In contrast to 5 HT3A, the 5 HT3B subunit 
cannot form a functional homomeric receptor. An ER retention motif (RAR) was 
identified in the 5HT3B subunit, which appears to be masked by the 5HT3A subunit. 
Evidence to support this conclusion was obtained from co-expression of the subunits, 
which resulted in the presence of 5 HT3B on the cell surface.
The a7  nAChR and 5 HT3R have similar N-terminal ligand binding domains and 
cross-reactivity of some ligands is observed. Both mouse 5HT3A and a  7 are 
potentiated by the aromatic moiety of 5-HT, 5-hydroxyindole (5-HI), whereas human 
5HT3A is not. In an attempt to define the 5-HI binding site, human/mouse 5HT3A 
subunit chimeras were constructed. Studies using the chimeras suggest that the 
action of 5-HI may be mediated by both the N- and C-terminal domains of 5 HT3A.
In the final study, the effects of the putative chaperone protein, RIC3, on a7 receptor 
expression were examined. The efficient functional expression of the a7  nAChR has 
been shown to be critically dependent on host-cell type, unlike the 5 HT3R. RIC3 
was shown to facilitate the efficient cell-surface expression of a7  in a mammalian 
cell line, where functional expression was not previously observed. The RIC3 
protein has been identified as an a7-interacting protein which promotes the efficient 
assembly and folding of the subunit. RIC3 was also shown to promote 5HT3aR 
assembly.
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CHAPTER 1
INTRODUCTION
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The nicotinic acetylcholine receptors (nAChRs) and 5-hydroxytryptamine 
(serotonin) type 3 receptors (5 HT3RS) are members of the superfamily of ligand- 
gated ion channels which also includes the y-aminobutyric acid type A  (G A B A a) and 
glycine receptors (Stroud et al., 1990). These receptors are oligomeric proteins 
consisting of five membrane-spanning subunits. The nAChR and 5 HT3R conduct 
cations and mediate fast excitatory neurotransmission whilst the G A B A a and glycine 
receptors conduct anions and mediate inhibitory neurotransm ission. 
Neurotransmission occurs when a chemical signal, released by a nerve cell, binds to 
an ion channel receptor and is converted into an electrical signal via the opening of 
the ion channel, allowing the passage of ions into the cell.
1.1 THE NICOTINIC ACETYLCHOLINE RECEPTOR (nAChR)
Acetylcholine (ACh) acts on two different classes of receptor classified by their 
activation by the plant alkaloids nicotine (nicotinic) and muscarine (muscarinic). 
The nAChRs are further divided into two classes based on their location. The 
“muscle-type” nAChRs are expressed at the neuromuscular junction (NMJ), whilst 
the “neuronal” nAChRs are expressed throughout the central and peripheral nervous 
systems (Lukas et al., 1999).
1.1.1 The nAChR from the Torpedo electric organ
The marine rays, Torpedo marmorata and Torpedo californica and the electric eel, 
Electrophorus electricus have electric organs which consist of stacks of modified 
muscle cells known as electrocytes. The membranes of these electrocytes are packed 
tightly with nAChRs which resemble the nAChR isolated from the vertebrate 
neuromuscular junction (Section 1.1.2). The electrocytes are flattened cells with 
nAChRs covering virtually the entire surface of one face. The arrangement of the 
electrocytes in stacks causes the voltage differences, across many cells to 
accumulate, resulting in a very large voltage that can be used to stun prey, upon 
nAChR activation.
19
The snake toxin, a-bungarotoxin (a-BTX) isolated from the venom of the Malayan 
many-banded krait, Bungarus multicinctus (Lee and Chang, 1966), can bind almost 
irreversibly to Torpedo electric organ nAChRs. Together with the rich source of 
receptor from Torpedo , a-BTX  binding enabled purification of the nAChR 
(Changeux et al., 1970).
The Torpedo electric organ nAChR is composed of four different membrane- 
spanning subunits (a , (3, 6 and y) arranged as a pentamer with the stoichiometry 
a2(3y6 (Unwin, 1993). The native receptor exists as a single pentamer but is found 
predominantly in a “dimeric” form, where two pentamers are cross-linked by a 
disulphide bond (Hamilton et al., 1979; DiPaola et al., 1989). The subunits form a 
ring around a central pore which forms the ion channel. In the resting state the 
channel is impermeable to ions (Unwin, 1993). Upon ligand binding and nAChR 
activation, a conformational change is induced causing the channel pore to open to 
allow the passage of ions through the plasma membrane (Miyazawa et al., 1999; 
Miyazawa et al., 2003).
1.1.2 The nAChR of the vertebrate neuromuscular junction
To isolate vertebrate homologues of the Torpedo nAChR subunits, mammalian 
cDNA libraries were screened with probes constructed from the nucleotide 
sequences of the Torpedo subunits. Mammalian a l ,  p i ,  y and & subunits were 
identified as well as a novel subunit, e, resembling the y subunit (Nef et al., 1984; 
LaPolla et al., 1984; Takai et al., 1985). Differences in gating and conduction 
between foetal and adult forms of the muscle nAChR can be accounted for by the 
developmentally regulated switch from the y-subunit which is expressed in the foetus 
(ah p ly d ), to the closely related e-subunit (a h p ie S )  which is expressed in adults 
(Mishina et a l ,  1986). The vertebrate neuromuscular nAChRs are situated 
postsynaptically within the membrane of the muscle endplate, and are involved in 
signalling between motor neurons and the muscle effector cells.
20
1.1.3 The neuronal nAChRs
Nicotinic receptors are also present throughout the central and peripheral nervous 
sytems (Greene et al., 1973; Hunt and Schmidt, 1978; McGehee and Role, 1995). 
Molecular cloning suggests classification into two families of neuronal nAChR 
subunits, termed a  and p. To date, twelve neuronal-type subunits, designated a2- 
alO  and p2-p4 have been identified and cloned (Sargent, 1993; McGehee and Role, 
1995; Elgoyhen et al., 2001). The a 8 subunit has been identified only in chick 
(Schoepfer et al., 1990; Sargent, 1993). The a  subunits are classified by a pair of 
adjacent cysteine residues that are present in the extracellular N-terminal region, at 
positions equivalent to Cysl92 and Cysl93 of the Torpedo electric organ nAChR a  
subunit, and are thought to contribute to the ligand binding site (Kao et al., 1984; 
Kao and Karlin, 1986; Galzi et al., 1991a). These cysteine residues are conserved in 
the a  subunits of the muscle-type and Torpedo electric organ nAChRs. The non-a 
subunits (p subunits) do not contain this cysteine pair (Lukas et al., 1999).
Neuronal nAChRs exhibit considerable subunit diversity. Whilst most nAChRs are 
assembled from two or more different subunit subtypes (and are therefore known as 
heteromeric nAChRs), there is evidence for the formation of receptors containing 
only one subunit subtype (homomeric nAChRs) (Millar, 2003). Heteromeric 
nAChRs consist of a combination of both a  and p subunits and can be stimulated by 
the application of nicotine, but are insensitive to the antagonist a-BTX (McGehee 
and Role, 1995; Itier and Bertrand, 2001). When expressed in Xenopus oocytes the 
a 2, a 3 and a 4 subunits are capable of forming functional receptors upon co­
expression of the p2 or P4 subunits (Boulter et al., 1987; Deneris et al., 1988; 
Sargent et al., 1993). The a5 subunit only forms a functional receptor when co­
expressed with at least two different subunit subtypes (Boulter et al., 1990; Couturier 
et al., 1990a; Millar, 2003). The p3 subunit requires co-expression with at least one 
other p subunit subtype for functional expression (Forsayeth and Kobrin, 1997; 
Boorman et al., 2000; Kuryatov et al., 2000). The a6  subunit can be functionally 
expressed with p2 and p4 (Fucile et al., 1998), but more robust expression is 
observed when it is co-expressed with more than one type of a  or p subunit (Fucile 
et al., 1998; Kuryatov et al., 2000).
21
The a l , a8  and a9  subunits are capable of forming homomeric receptors which are 
sensitive to a-BTX (Couturier et al., 1990b; Seguela et al., 1993; Elgoyhen et al., 
1994; Gerzanich et al., 1994; Gotti et al., 1994). Initially, studies suggested that the 
pharmacological properties of a l  were unaffected by co-expression of the a3 , a5, 
|32, |33 and |34 nAChR subunits (Couturier et al., 1990b; Seguela et al., 1993), but 
more recent data has suggested that a l  may co-assemble with other subunits such as 
|32, (33 or a5  in vivo (Yu and Role, 1998a; Yu and Role 1998b; Palma et al., 1999; 
Khiroug et al., 2002). Native a l  and a 8 in chick form heteromeric receptors 
(Keyser et al., 1993; Gotti et al., 1994; Gotti et al., 1997). When expressed in 
Xenopus  oocytes, a  10 does not form a functional receptor either alone or in 
combination with any of the neuronal (3 subunits. However, when a  10 is co­
expressed with a9  a functional heteromeric receptor is formed (Elgoyhen et al., 
2001; Sgard et al., 2002).
1.2 THE 5-HYDROXYTRYPTAMINE TYPE 3 RECEPTOR (5HT3R)
The actions of 5-hydroxytryptamine (5-HT; serotonin) are mediated by a number of 
receptor classes (5HT 1.7). The 5-hydroxytryptamine type 3 receptor (5HT3R) is the 
only ligand-gated ion channel of the 5-HT receptor family, the other members are G- 
protein coupled metabotropic receptors and mediate slow responses via second 
messenger signalling pathways (Hoyer and Martin, 1997). Three subunits of the 
5HT3R have been identified: 5HT3A, 5H T 3b and 5HT3c (Maricq et al., 1991; Miyake 
et al., 1995; Belelli et al., 1995; Davies et al., 1999; Dubin et al., 1999; Dubin et al., 
2001). Recently, two 5HT3R-like genes, 5H T 3d and 5H T 3e, have been identified 
(Niesler et al., 2003; Kamovsky et al., 2003).
The first 5HT3R subunit to be identified was 5HT3A, which was cloned from the 
mouse neuroblastoma/Chinese hamster embryonic brain cell hybrid (NCB-20) by 
Maricq et al. (1991). Subsequently, 5HT3A sequences were identified in a number of 
other species including rat (Johnson and Heinemann, 1992), human (Belelli et al., 
1995; Miyake et al., 1995), guinea pig (Lankiewicz et al., 1998) and ferret 
(Mochizuki et al., 2000).
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An alternatively spliced variant of 5HT3A has been identified in the murine 
neuroblastoma cell line, N1E-115 (Hope et al., 1993). This shorter variant, 5HT3a(s), 
differs from the originally identified 5 HT3A by a deletion of six amino acids in the 
putative large intracellular loop between transmembrane domains three and four. 
The 5HT3a(S) subunit has been identified in other species such as rat (Miquel et al., 
1995; Isenberg et al., 1993), guinea pig (Lankiewicz et al., 2000) and human 
(Miyake et al., 1995; Belleli et al., 1995). The 5HT3A(s) subunit appears to be the 
only functional 5HT3A subunit expressed in human. The 5HT3a(s) subunit appears to 
predominate in both mouse neuronal tissue and murine derived cell lines (Werner et 
al., 1994). There is little difference in pharmacological properties between the splice 
variants (Downie et al., 1994; Niemeyer and Lummis, 1998). There is evidence that 
they are differentially regulated during development (Miquel et al., 1995) and that 
intracellular regulatory kinases can discriminate between them (Hubbard et al., 
2000).
Most of the 5HT3A receptor subunits described thus far are capable of forming 
functional homomeric receptors. However, two human 5HT3A splice variants (a 
truncated form and a long form) which are incapable of forming functional 
homomers have been described (Bruss et al., 2000). The truncated human 5HT3A 
subunit contains a major part of the N-terminal region, including the ligand binding 
domain, followed by an altered and truncated C-terminal domain containing a single 
putative transmembrane domain (Bruss et al., 2000). The long form of the human 
5HT3A subunit has an additional 32 amino acids in the M2-M3 extracellular loop 
(Bruss et al., 2000).
The second 5 HT3R subunit to be identified was 5 HT3B (Davies et al., 1999; Dubin et 
al., 1999; Hanna et al., 2000). The discovery of this subunit helped to explain the 
previously observed functional differences between recombinant and native 5 HT3R.S. 
Homomeric 5HT3aRs exhibit a very low single channel conductance (sub- 
picosiemens (pS)) (Davies et al., 1999) unlike those of native receptors (Kelley et 
al., 2003). Heteromeric receptors, composed of 5HT3A and 5HT3B, have a much 
larger single channel conductance (9-17 pS) which is more similar to that of native 
5HT3RS. The 5 HT3B subunit shares approximately 45% amino acid sequence 
identity with 5 HT3A. When expressed alone, 5 HT3B can not form a functional
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homomeric receptor (Davies et al., 1999; Dubin et al., 1999; Hanna et al., 2000; 
Boyd et al., 2002). When 5 HT3B is co-expressed with 5HT3A, a functional 
heteromeric receptor is formed where the 5 HT3B subunit modifies receptor kinetics, 
voltage dependence, pharmacology and ion permeability of 5HT3A (Dubin et al., 
1999; Brady et al., 2001).
A third human 5HT3R subunit has been identified, 5 HT3C (Dubin et al., 2001), which 
has approximately 39% sequence identity with 5 HT3A. When co-expressed with 
5 HT3A, the 5HT3C subunit is reported to decrease the responses of 5 HT3A to 5-HT 
(Dubin et al., 2001). Recently, additional novel putative human 5HT3R subunits 
have been identified, 5 HT3D and 5 HT3E (Niesler et al., 2003), but to date have not 
been characterised in detail. Other 5HT3R-like genes, homologous to the 5 HT3C 
subunit gene, have been identified in other species additional to human (Kamovsky 
et al., 2003).
1.3 RECEPTOR STRUCTURE
1.3.1 Subunit structure
The nAChR and 5HT3R subunits contain an amino- (N-) terminal signal peptide 
which is cleaved to form the mature protein. The receptor subunits have a large 
hydrophilic extracellular N-terminal domain, four putative transmembrane domains, 
M1-M4, (Noda, 1983; Sargent, 1993; Maricq et al., 1991), and a short extracellular 
carboxy (C)-terminal domain (Mukerji et al., 1996). The extracellular N-terminal 
domain forms the ligand binding site (Eisele et al., 1993) and contains sites for 
asparagine (N)-linked glycosylation (Nomoto et al., 1986; McKeman, 1992; Quirk 
and Siegel, 2000). The large intracellular loop in between M3 and M4 contains 
several sites for phosphorylation (Huganir and Greengard, 1990; Lankiewicz et al., 
2000) (Figure 1.1 A).
Analysis of the putative 5 HT3D subunit sequence suggests that it encodes a protein 
that differs from the other 5 HT3R subunits, in that it has no signal peptide, a very
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Figure 1.1 P redicted  topology o f  the nAC hR and  5H T 3R  subunits a nd  schem atic  
representa tion  o f  assem bled  subunits as a p en ta m eric  receptor. A , The receptor 
subunits have a large hydrophilic extracellular N-terminal domain which contains 
potential sites for N-linked glycosylation and is proposed to form the ligand binding 
site. The N-terminal domain is follow ed by four putative transmembrane domains 
(M 1-M 4) and a short extracellular C-terminal domain. There is a large intracellular 
loop in between M3 and M 4 which contains several sites for phosphorylation. B, 
The nAChRs and 5HT3Rs contain five  subunits arranged around a central ion 
channel pore. Receptors may be assembled from a single subunit type (homomeric) 
or from more than one type o f subunit (heteromeric). Adapted from Millar, 2003.
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short N-terminal extracellular domain lacking the ligand binding site, and an 
intracellular C-terminal (Niesler et al., 2003).
1.3.2 Subunit stoichiometry and arrangement
1.3.2.1 nAChR subunit stoichiometry and arrangement
The native nAChR of the Torpedo electric organ is arranged as a pentamer with the 
stoichiometry c^Pyb (Unwin, 1993) (Figure 1.1B). The native receptor exists as a 
single pentamer and in a predominant “dimeric” form, where two pentamers are 
cross-linked by a disulphide bond (Hamilton et al., 1979; DiPaola et al., 1989). The 
subunits are arranged in a pentameric ring around the ion pore with the order, ayaSp 
(anticlockwise) (Karlin et al., 1983; Brejc et al., 2001; Unwin et al., 2002).
There is evidence that the neuronal nAChRs also form pentameric complexes 
(Anand et al., 1993a; Sargent, 1993) (Figure 1.1B). Heterologous expression studies 
of the a4|32 and a3|34 nAChRs have provided evidence that the stoichiometry of 
neuronal nAChRs is (X2P3, with the arrangement a p ap p  (Anand et al., 1991; Cooper 
et al., 1991; Boorman et al., 2000). The expression of different ratios of a4  and (32 
subunits in Xenopus oocytes has provided evidence for the existence of nAChRs with 
alternative stoichiometries (Zwart and Vijverberg, 1998; Nelson et al., 2003). The 
stoichiometry and arrangement of the neuronal nAChRs is complicated by subtypes 
containing more than one type of a  or p subunit (Millar, 2003).
1.3.2.2 5HT3R subunit stoichiometry and arrangement
The 5 HT3R is thought to consist of five subunits arranged around a central ion 
channel pore (Boess et al., 1995) (Figure 1 .IB). The 5HT3 subunits form homomeric 
receptors, containing 5 HT3A subunits, or heteromeric receptors, containing both 
5HT3A and 5 HT3B subunits. The stoichiometry and arrangement of the subunits of 
the heteromeric 5 HT3RS have not yet been determined, but studies in Xenopus  
oocytes have provided evidence for the existence of receptors with different 
stoichiometries (Dubin et al., 1999). When different ratios of 5HT3A to 5 HT3B
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cRNA are injected into oocytes, differences in agonist potency are observed (Dubin 
et al., 1999) suggesting the presence of a heterogenous receptor population. To date, 
the contribution of the more recently identified subunits, 5 HT3C, 5HT3D, and 5HT3E, 
to the 5 HT3R pentamers has not yet been reported.
1.3.3 The ligand binding site
The ligand binding sites of both the nAChR and 5HT3R are found in the N-terminal 
extracellular domain of the receptor subunits. Many biochemical and mutagenesis 
studies suggest that the binding site is located in the extracellular domain and further 
evidence has been provided by the construction of a chimeric receptor subunit 
comprising the N-terminal region of the a l  nAChR up to M l, fused to the remainder 
of 5HT3A (ci7 /5H T 3a). The a7 /5H T 3A  chimeric subunit forms a homomeric receptor 
and displays the pharmacological properties of a7, but the ion channel properties of 
5HT3A(Eisele et al., 1993).
A soluble protein, acetylcholine-binding protein (AChBP), has been identified in the 
snail Lymnea stagnalis (Brejc et al., 2001). AChBP forms a homopentameric 
structure which closely resembles the ligand binding domain of nAChR a-subunit. 
The determination of the structure of the AChBP, has aided in characterisation of the 
nAChRs and 5HT3R binding sites (Brejc et al., 2001; see Section 1.3.5.1).
1.3.3.1 The ligand binding site o f  the nAChR
The acetylcholine (ACh) binding sites of the Torpedo electric organ and muscle 
nAChR were localised to the interface between the a  subunit and the adjacent non-a 
subunit by affinity labelling studies (Galzi et al., 1991a; Changeux et al., 1998; 
Taylor et al., 2000). The muscle nAChR contains two ligand binding sites at the 
interfaces between the a  subunit and either the y or 6 subunit (Pedersen and Cohen, 
1990). The binding sites are not identical and show different pharmacological 
properties (Blount and Merlie, 1989), suggesting that residues from both subunits at 
the interface contribute to ligand binding (Reynolds and Karlin, 1978; Pedersen and 
Cohen, 1990).
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The heteromeric neuronal nAChRs with an 0x2 stoichiometry contain two ligand 
binding sites at the interfaces between the a  and non-a (|3) subunits (Changeux et al., 
1998). The homomeric neuronal nAChRs composed of five a  subunits contain five 
putative ligand binding sites at the a - a  subunit interfaces (Palma et al., 1996).
Six loops, termed A-F, have been identified in nAChR subunits and are proposed to 
be important in the formation of the ACh-binding site (Galzi et al., 1990; Fu and 
Sine, 1994; Corringer et al., 1995; Martin et al., 1996; Prince and Sine, 1996; Brejc 
et al., 2001). The a  subunit possesses the principal components of the binding site 
(loops A, B and C). The complementary component of the ligand binding site (loops 
D, E and F) is provided by the subunit adjacent to the a  subunit, forming the ligand 
binding interface (Figure 1.2).
Several residues involved in ligand binding within loops A-F have been identified by 
affinity labelling and site-directed mutagenesis. The Cysl92 and Cysl93 residues of 
loop C of the Torpedo electric organ nAChR a  subunit were labelled with 4-(N- 
maleimido)benzyltri[3H]-methyl ammonium ([3H]-MBTA), which competes for the 
b inding  site  (Kao et al., 1984). L ab e llin g  w ith  p-(N,N- 
dimethyl)aminobenzenediazonium fluoroborate (DDF) also identified Cysl92 and 
Cysl93 as well as a-Trp86 and a-Tyr93 (in loop A), a-Trpl49 (in loop B) and a- 
Tyrl90 and a-Tyr-198 (in loop C) (Galzi et al., 1991b; Galzi and Changeux, 1995). 
Nicotine and d-tubocurarine identified y-Trp55 and 6-Trp57 in loop D (Chiara et al.,
1998). Residues y-Tyrl 11 and S-Argl 13 (in loop E) were weakly, but specifically 
labelled by d-tubocurarine (Chiara et al., 1998; Chiara et al., 1999). Mutation of 6- 
Aspl80 (in loop F) to asparagine resulted in a reduced affinity for ACh, suggesting a 
role for this residue in ligand binding (Martin et al., 1996).
The residues identified in loops A-C are conserved in all of the a  subunits, except a5 
(Couturier et al., 1990b). The residues identified in loop D are conserved in the 
neuronal |32, p4, a l  and a8 subunits. The a l  nAChR therefore possesses both the 
principal and complementary components of the ligand binding site (Corringer et al., 
2000). Mutation of the conserved tyrosine and tryptophan residues in a l  alters the
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Figure 1.2 M odel o f  the nAC hR ligand  b ind ing  dom ain. A, Pentameric com plex  
o f  neuronal nAChR a  and p subunits. The ACh-binding site is located at the 
interface between the a  subunit and the adjacent [3 subunit. B, Representation o f  the 
principal component (a  subunit) o f  the ligand binding site with its three loops, A, B  
and C and two o f  the loops (D  and E) from the com plem entary com ponent (P 
subunit). Each loop is m odelled with the principal amino acids identified in the 
chick a  7 subunit. Adapted from Itier and Bertrand, 2001.
29
affinity of the receptor for agonists and competitive antagonists, demonstrating their 
involvement in ligand binding (Galzi et al., 1991b; Corringer et al., 2000).
1.3.3.2 The ligand binding site o f  the 5HT3R
The extracellular N-terminal ligand binding domain of the 5 HT3R is proposed to be 
similar to that of the nAChR and of the AChBP. The structure of the AChBP has 
been used in conjunction with experimental evidence to predict 5 HT3R agonist- 
binding residues (Reeves et al., 2003). The homomeric 5HT3aR is proposed to 
contain five identical ligand binding sites. In contrast, the ligand binding sites of the 
heteromeric 5HT3R have not yet been characterised, however, they are predicted to 
be formed at subunit interfaces as for the nAChR. The residues involved in binding 
to the 5 HT3R are predicted to be in the domains equivalent to the loops A-F, 
identified in the nAChR. Several residues identified as involved in binding to the 
5HT3R correspond to those identified in the binding site of the nAChR and AChBP. 
The Cys loop, which has been implicated in ligand binding in the nAChR a  subunit, 
is found to be conserved in the 5HT3R subunits.
Mutation of Glul06 (in loop A), analogous to Tyr93 in nAChR a  subunits, decreases 
the affinity of the 5 HT3R for 5-HT and several antagonists, suggesting this residue to 
be important in ligand binding (Boess et al., 1997). Mutation of Phel07 (in loop A) 
also alters the binding characteristics of the 5 HT3R (Steward et al., 2000). Mutation 
of the 5 HT3A subunit tryptophan residues, Trp95, Trpl02, Trpl21 (loop A; 
analogous to Trp86 in the nAChR a  subunit) and Trp214, results in receptors 
incapable of binding radioligand (Spier and Lummis, 2000). Trp95 and Trpl21 are 
conserved in all nAChR subunits and Trpl02 and Trp214 are conserved in most 
nAChR subunits (North, 1995). Mutation of Trpl83 (loop B) results in a decrease in 
ligand binding affinity (Spier and Lummis, 2000). This residue is homologous to 
Trpl49 in loop B of the nAChR a  subunit which is implicated in ligand binding. 
Trpl95 is also implicated in 5HT3R ligand binding (Spier and Lummis, 2000). The 
loop C region of the 5HT3R is involved in the binding of m-chlorophenylbiguanide 
(wCPBG) (Mochizuki et al., 1999a) and d-TC (Hope et al., 1999). Trp90 
(equivalent to Trp53 in AChBP, and Trp54 in the nAChR a  subunit), Arg92
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(equivalent to Gln55 in AChBP) and Tyrl94 in loop D are proposed to play a role in 
ligand binding (Yan et al., 1999; Spier and Lummis, 2000). Tyrl41, Tyrl43 
(equivalent to Argl04 in AChBP) and Tyrl53 in loop E are also involved in 5 HT3R 
ligand binding (Price and Lummis, 2004). Most of the residues identified as playing 
a role in ligand binding to the 5 HT3R are aromatic, the electron-rich side chains of 
which may interact with the positively charged ammonium group of 5 HT3R ligands. 
The structure of the ligand binding domain of the 5 HT3R appears similar to that of 
the nAChR and AChBP.
1.3.4 The ion channel
1.3.4.1 The ion channel o f the nAChR
The neuromuscular junction nAChRs are permeable to monovalent cations, but are 
relatively impermeable to divalent cations (see Itier and Bertrand, 2001). The 
neuronal nAChRs are permeable to both divalent and monovalent cations, showing a 
significant permeability to calcium (Sargent, 1993; McGehee and Role, 1995). 
When expressed in Xenopus oocytes, the homomeric a  7 nAChR displays a ratio of 
calcium permeability to sodium permeability (Pca/PNa) of approximately 20 
(McGehee and Role, 1995). Heteromeric neuronal nAChRs display a Pca/PNa in the 
range of 0.5-2.5 (McGehee and Role, 1995; Changeux et al., 1998).
The nAChR subunits assemble to form a ring around a central ion channel pore. The 
structure of the ion channel of the muscle-type nAChR was initially studied by 
photo-affinity labelling using non-competitive open channel blockers, such as 
chlorpromazine. Chlorpromazine was found to label residues in the putative 
transmembrane domain 2 (M2) of each of the five receptor subunits suggesting that 
this region formed the lining of the ion channel (Giraudat et al., 1986; Hucho et al., 
1986; Revah et al., 1990; Stroud et al., 1990). M2 has an a-helical structure with 
several serine and threonine residues in positions which point towards the lumen of 
the ion channel (Unwin, 1993; Miyazawa et al., 2003). Chlorpromazine labels 
Thr244, Ser248, Leu251, Val255 and Glu262 of M2 of the a  subunit (Giraudat et al., 
1986; Hucho et al., 1986; Revah et al., 1990). These residues are conserved within
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the other subunits resulting in rings of residues with similar charge, side chain size or 
hydrophobicity within the lumen of the ion channel (Figure 1.3).
The rings of residues within the pore are predominantly non-polar and therefore 
present a relatively inert surface to diffusing ions (Miyazawa et al., 2003). There are 
two rings of negatively charged residues (at a-Glu259 and a-Glu280) which may 
influence transport by attracting cations (Miyazawa et al., 2003). A third ring of 
negatively charged residues is at a-Glu241, which is at the inner mouth of the pore 
and may also attract cations (Miyazawa et al., 2003). Mutation of Glu237 to alanine 
at the cytoplasmic end of M2 in the a  7 subunit causes a 1000-fold decrease in 
calcium permeability, but does not alter permeability to monovalent cations (Galzi et 
al., 1992; Bertrand et al., 1993). Replacement of amino acids in the chick a l  
subunit with corresponding residues from GABAa or glycine receptor subunits 
results in the conversion of ion selectivity from cationic to anionic (Galzi et al., 
1992; Corringer et al., 1999).
A ring of conserved leucine residues is present near the centre of the membrane and 
may form the channel gate (Miyazawa et al., 1999; Miyazawa et al., 2003). In the 
a 7 nAChR subunit, Leu247 is predicted to be near the channel selectivity filter. 
Mutation of Leu247 to polar serine or threonine residues alters the ion channel 
properties (Revah et al., 1991; Palma et al., 1996). The mutation converts the 
receptor from a high affinity desensitised state into a state that conducts ions, 
confirming the role of Leu247 in forming the channel gate (Miyazawa et al., 2003).
1.3.4.2 The ion channel o f the 5HT3R
The ion channel of the 5 HT3R is proposed to be a relatively non-selective cation 
channel (Yang, 1990; Yang et al., 1992; Jackson and Yakel, 1995; Glitsch et al., 
1996; Mochizuki et al., 1999b). Initially, the 5 HT3R was considered to be 
impermeable to calcium (Eisele et al., 1993; Gilon and Yakel, 1995; Glitsch et al.,
1996), but studies using intracellular calcium indicators have clearly demonstrated 
calcium entry through the mouse 5 HT3R (Hargreaves et al., 1994; Nichols and 
Mollard, 1996). Recombinant heteromeric 5 HT3 receptors are much less permeable
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Figure 1.3 A m odel o f  the high affin ity  binding site  fo r  the open channel blocker, 
ch lo rp ro m a zin e . The M2 a -h e lic e s  o f the p and y subunits which line the ion 
channel pore are illustrated. The filled circles represent three rings o f amino acids 
w hich are photolabelled  by [3H J-chlorprom azine. The sphere represents 
chlorpromazine. Rings o f negatively charged residues are located at either end o f the 
channel pore and are implicated in ion transport. Adapted from Revah et a l ., 1990.
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to calcium than homomeric 5 HT3A receptors (Brown et al., 1998; Davies et al.,
1999). Unlike 5HT3A and the nAChR subunits, the 5HT3B subunit lacks the classical 
three rings of negatively charged residues which are thought to promote cation 
permeation (Imoto et al., 1988; Dubin et al., 1999).
The structure of the 5HT3R ion channel pore is proposed to be similar, but not 
identical to that of the nAChR (Reeves et al., 2001). Like the nAChR, the M2 
domain of the 5HT3R is suggested to be a-helical and to line the ion channel pore 
(Reeves et al., 2001). A ring of conserved leucine residues (at Leu287) is proposed 
to function in channel gating. Mutation of Leu287 to polar residues results in a 
decrease in the rate of desensitisation (Yakel et al., 1993). Similar to the a l  nAChR, 
substitution of residues in M2 of the 5HT3A subunit with the corresponding residues 
from G A B A a  or glycine receptors (V291T, E276A and introduction of a proline 
residue before residue 276) results in a conversion of ion selectivity from cationic to 
anionic (Gunthorpe and Lummis, 2001). Mutation of Ile294 in M2 of 5 HT3A to 
alanine ablates calcium permeability (Reeves and Lummis, 2000), in a similar way to 
mutation at the homologous position in the a l  nAChR (see Section 1.3.4.1; Bertrand 
et al., 1993), providing further evidence of structural and functional conservation 
between these receptors.
1.3.5 The 3-dimensional structure
1.3.5.1 The 3-dimensional structure o f  the nAChR
The structure of the Torpedo electric organ nAChR, and how the structure changes 
upon activation, have been examined by electron microscopy (Toyoshima and 
Unwin, 1990; Unwin, 1993; Miyazawa et al., 2003; Unwin, 2003; Unwin, 2005) 
(Figure 1.4). The high density and regular arrangement of Torpedo electric organ 
nAChRs have facilitated these studies. Isolated postsynaptic membranes convert 
readily into tubular crystals with receptors organised as they are in vivo (Brisson and 
Unwin, 1984).
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Figure 1.4 3-D im ensional structure o f  the nAC hR. A cross-section through the 
4 .6  A  resolution structure o f the T orpedo  electric organ nAChR determined by 
electron m icroscopy. The dashed line indicates the pathway to the binding site. 
Adapted from Miyazawa et al., 1999 and Karlin, 2002.
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The most recent structure of the Torpedo electric organ nAChR is at a resolution of 4 
A  (Miyazawa et al., 2003; Unwin, 2005). The total length of the receptor is about 
160 A ,  with a pseudo-5-fold symmetry of subunits identified as rods arranged around 
a narrow central pore which spans the membrane (Toyoshima and Unwin, 1990; 
Unwin, 1993; Unwin, 2005). The receptor extends approximately 65 A  above the 
extracellular surface of the membrane and approximately 15 A  below the 
intracellular surface of the membrane. The intracellular portion of the receptor has 
an associated density below it, which is partly formed by rapsyn, a 43 kDa protein 
involved in clustering of the muscle-type nAChR (Sealock, 1982; Moransard et al., 
2003). The putative ACh-binding sites are cavities in the a  subunits approximately 
40 A  above the surface of the cell membrane (Unwin, 2005). The ion channel is a 
wide opening of 25 A  in the extracellular domain which narrows as it passes through 
the membrane before widening at the intracellular domain (Itier and Bertrand, 2001). 
The channel gate is approximately 15 A  from the cytoplasmic surface of the 
membrane (Unwin, 1993; Miyazawa et al., 1999).
The four subunits of the Torpedo electric organ nAChR (a, p, 6, y) are of a similar 
size and share the same structure. The extracellular N-terminal ligand-binding 
domain of each subunit is composed of two sets of p-sheets, packed into a p- 
sandwich, and are joined by a disulphide bond which forms the characteristic Cys- 
loop. The extracellular domain also contains several of the loop regions involved in 
ligand binding (loops A-C). The membrane spanning region of the subunits is 
composed of four a-helices (M1-M4) and the M l-M2 and M2-M3 loops. The 
intracellular domain of the subunits is composed mainly of the M3-M4 loop which, 
apart from a single a-helix, has a disordered structure.
The wall lining of the ion channel pore is formed by the M2 transmembrane domain 
(Unwin, 1993), and M l, M3 and M4 form a lipid-facing scaffold. The M2 helix is 
kinked near the middle of the membrane where it comes closest to the pore, tilting 
radially outwards on either side, and is proposed to form the channel gate (Unwin, 
1993; Miyazawa et al., 1999). Binding of ACh causes a rotational movement of the 
inner structure of the a  subunits in the ligand binding domain. These movements are 
transduced, via the M2-M3 loop, to the M2 helices lining the pore. The movement in
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M2 pulls apart the weak interactions between the side chains of the residues in M2, 
breaking apart the gate, resulting in the opening of the channel pore (Unwin et al., 
2002; Miyazawa et al., 2003; Unwin, 2003; Unwin, 2005).
Determination of the structure of the homologous pentameric ACh-binding protein 
(AChBP), at a resolution of 2.7 A, has helped to elucidate the structure of the N- 
terminal ligand binding domain of the nAChR (Brejc et al., 2001; Smit et al., 2001; 
Sixma et al., 2003). AChBP is involved in the modulation of synaptic transmission 
through binding ACh. AChBP forms a homopentameric structure which closely 
resembles the ligand binding domain of nAChR. It does not possess transmembrane 
or intracellular domains, but is capable of binding nicotinic ligands. Like the 
nAChR, the binding sites of AChBP are found at the subunit interfaces and are 
composed of residues found in the loops A-F (Brejc et al., 2001). Models of the 
nAChR binding domain have been generated based on the structure of the AChBP 
(Le Novere et al., 2002; Schapira et al., 2002).
1.3.5.2 The 3-dimensional structure o f  the 5HT3R
To date, there have been few reported studies aimed at determining the 3- 
dimensional structure of the 5 HT3R. Electron microscopy of purified 5HT3A 
homomeric receptors reveals that the receptors form a pentameric ‘doughnut’ shape 
(Boess et al., 1995), with similar dimensions to the nAChR (Unwin, 1993). Use of 
the substituted cysteine accessibility method (SCAM) has confirmed that the M2 
domain of the 5HT3A subunit is a-helical (Cruz et al., 2001; Reeves et al., 2001). As 
the 5HT3R shares structural and functional similarities with the nAChR, much of the 
structural analysis performed on the nAChR (Unwin, 1993; Miyazawa et al., 1999; 
2003; Unwin, 2005) and the AChBP (Brejc et al., 2001) can be extrapolated to the 
5 HT3R (see Section 1.3.5.1). Recently, the structure of the extracellular domain of 
the 5 HT3R has been modelled on the AChBP (Reeves et al., 2003), but further 
experimental characterisation of the models is required to determine their accuracy.
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1.4 RECEPTOR ASSEMBLY
The formation of functional ligand-gated ion channels such as the nAChR and 
5HT3R is a complex and poorly understood process. The receptor subunits must fold 
with the correct membrane topology and associate with other subunits to form 
pentamers of the correct stoichiometry and arrangement, in the endoplasmic 
reticulum (ER) before export through the Golgi apparatus to the plasma membrane 
(Green and Millar, 1995). This maturation process is slow and relatively inefficient 
(Merlie and Lindstrom, 1983). Receptor subunits also undergo several post- 
translational modifications, within the ER, before functional expression is achieved. 
It has been suggested that the formation of pentameric complexes is a strict 
requirement for exit from the ER, but there is evidence for the occurrence of further 
folding events after exit from the ER (Green and Wanamaker, 1998; Green, 1999). 
Subunits that do not fold and assemble correctly are retained within the ER and 
degraded (Smith et al., 1987; Claudio et al., 1989; Verrall and Hall, 1992; Blount 
and Merlie, 1990).
1.4.1 Assembly models of the nAChR
The muscle-type nAChR is the most well characterised of the ligand-gated ion 
channels, in terms of its assembly. There are very few reports investigating the 
assembly mechanisms of the neuronal nAChRs or the 5 HT3R. There are currently 
two models that describe the assembly of the Torpedo electric organ/muscle-type 
nAChR. In the “heterodimer” model (Blount and Merlie, 1991; Gu et al., 1991) the 
a  subunit associates with y or 5 subunits forming ay or aS heterodimers. The 
heterodimers assemble with p subunits to form c^Pyb pentamers. In the second 
model, the “sequential” model (Green and Claudio, 1993; Green and Wanamaker, 
1997; Green and Wanamaker, 1998), the a , p and y subunits assemble rapidly into 
trimers. Post-translational folding of the a  subunit occurs when it is assembled as a 
trimer, leading to the formation of an a-bungarotoxin binding site. The 6 subunit 
assembles with the trimer to form the apyS tetramer and an ACh binding site is 
formed. Finally, the second a  subunit assembles creating the <X2py6  pentamer, and a 
second ACh binding site is formed.
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1.4.2 Chaperones and folding enzymes in the ER
Chaperone proteins recognise and stabilise intermediates during protein folding and 
oligomerisation (Keller et al., 1996). Association with chaperones is the most 
commonly observed primary mechanism of quality control in protein folding. The 
ER contains many chaperone proteins and folding factors which are essential for the 
successful folding and maturation of proteins.
One of the best characterised ER chaperones is the immunoglobulin-binding protein 
(BiP). BiP associates with newly synthesised muscle-type nAChR subunits and 
some ay and <xS complexes, but not with mature pentameric nAChRs. BiP is 
suggested to play a role in the conformational maturation and folding of nAChRs 
(Blount and Merlie, 1991; Paulson et al., 1991). BiP also associates with misfolded 
subunits, which are susceptible to degradation (Forsayeth et al., 1992). Another 
chaperone protein, calnexin, associates with newly synthesised, partially 
glycosylated proteins including a  and (3 muscle-type nAChR subunits (Gelman et al., 
1995; Keller et al., 1996; Keller and Taylor, 1999). Calnexin is thought to have a 
role in the folding of the subunits into an assembly-competent conformation. Co­
transfection of calnexin with muscle-type nAChR subunits, in COS and HEK293 
cells, enhances folding, assembly and cell surface expression of the receptors (Chang 
et al., 1997). Association with calnexin mediates retention in the ER of the 
interacting protein (Ellgaard et al., 1999). BiP and calnexin both associate with the 
5HT3R subunits, suggesting that they play a role in the assembly of the 5 HT3R and in 
the degradation of misfolded subunits (Boyd et al., 2002).
The 14-3-3 family of proteins are intracellular proteins with diverse functions. The 
14-3-3r| member of this family acts as a chaperone protein through interactions with 
the neuronal nAChR a4  subunit (Jeanclos et al., 2001). Phosphorylation of the a4  
subunit by cyclic AMP-dependent kinase (PKA), followed by association of 14-3-3r| 
increases the stability of the a4  subunit and a4|32 nAChR (Jeanclos et al., 2001).
The ER contains a number of other factors which play roles in the folding and 
assembly process. For example, the enzyme protein disulphide isomerase (PDI) is
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involved in the formation and rearrangement of disulphide bonds during folding. 
Cyclophilin A, which may act as a chaperone or as a folding enzyme (peptidyl prolyl 
isomerase), has been suggested to be required for the functional expression of homo- 
oligomeric nAChRs and the 5HT3R (Helekar and Patrick, 1997).
1.4.3 Post-translational modifications
Multi-subunit ion channels undergo many post-translational processes such as 
disulphide bond formation, signal sequence cleavage, glycosylation, phosphorylation 
and fatty acylation, such as palmitoylation, which occur in the ER and Golgi 
apparatus throughout the folding and assembly of subunits and complexes. Some of 
the post-translational modifications to the nAChR and 5HT3R are described below.
1.4.3.1 Post-translational modifications o f  the nAChR
Phosphorylation modulates the functional properties of many cellular proteins. The 
intracellular loop region between M3 and M4 of the nAChR contains potential sites 
for phosphorylation. Tyrosine kinase can phosphorylate the p, y and 6 subunits of 
the Torpedo electric organ nAChR (Huganir et al., 1984). Whereas, cyclic AMP 
(cAMP)-dependent kinase (PKA) phosphorylates the y and 6 subunits (Huganir and 
Greengard, 1983). The major functional effect of phosphorylation is the regulation 
of the rate of receptor desensitisation (Huganir and Greengard, 1990). Protein kinase 
C (PKC) phosphorylates the a  and 6 subunits (Huganir et al., 1984) which causes an 
increase in the rate of nAChR desensitisation and affects channel conductance 
(Eusebi et al., 1987). Forskolin, which activates adenylyl cyclase and subsequently 
PKA, causes desensitisation of muscle nAChRs, without affecting channel 
conductance, and also causes nAChR upregulation. There is a cAMP-dependent 
protein kinase consensus sequence in the a4  subunit and a potential PKC site in the 
P4 subunit in between M3 and M4. The intracellular domain of a l  is a substrate of 
PKA (Moss etal., 1996).
The extracellular N-terminal domain of the nAChR contains several putative sites for 
asparagine (N)-linked glycosylation (Boulter, 1986; Nomoto et al., 1986; Goldman
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et al., 1987). The role of N-linked glycosylation is poorly understood, but may 
provide protein stability and control receptor assembly, whilst also introducing lectin 
binding sites. The N-linked glycosylation of the nAChR, expressed in
Xenopus oocytes, appears to be necessary for the correct folding and expression of 
functional receptors (Gehle et al., 1997).
Palmitoylation of the a l  nAChR has recently been identified as a factor important in 
its expression (Drisdel et al., 2004). In cell lines such as HEK293, which are 
incapable of expressing functional, a-BTX-binding a l  nAChRs, receptors are not 
significantly palmitoylated (Drisdel et al., 2004). However, in cell lines such as 
PC 12, where a l  is functionally expressed, the receptors are shown to be 
palmitoylated (Drisdel et al., 2004). Palmitoylation of membrane proteins has been 
shown to be important in trafficking of proteins to the plasma membrane (reviewed 
in Smotrys and Linder, 2004).
1.4.3.2 Post-translational modifications o f  the 5HT3R
The 5HT3aR subunit contains a number of consensus sites for phosphorylation 
(Maricq et al., 1991). The 5 HT3B subunit contains four potential phosphorylation 
sites in the intracellular loop between M3 and M4 (Dubin et al., 1999). Serine 414 
of 5HT3A is found to be phosphorylated in vivo by PKA (Lankiewicz et al., 2000). 
Phosphorylation may play a role in receptor conductance levels and desensitisation 
(van Hooft and Vijverberg, 1995; Hubbard et al., 2000). Phosphorylation by casein 
kinase II enhances 5 HT3R currents when expressed in rodent NG108-15 cells (Jones 
and Yakel, 2003).
The 5 HT3A and 5HT3B subunits have several potential N-linked glycosylation sites, 
which have been shown to be important in receptor stability and assembly 
(McKeman, 1992; Boyd et al., 2002). The N-linked glycosylation sites of the mouse 
5HT3aR have roles in receptor regulation (Quirk et al., 2004). One site (N109) is 
necessary for receptor assembly, whereas N174 and N190 have roles in plasma 
membrane targeting and ligand binding (Quirk and Siegel, 2000; Quirk et al., 2004).
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1.4.4 Retention motifs
Control of protein transport from the ER, and retention of incompletely assembled 
proteins and of ER resident proteins such as chaperones involve several mechanisms. 
Many of the ER resident proteins contain motifs such as KDEL or KKXX which 
serve as ER retention/retrieval signals (Teasdale and Jackson, 1996). Membrane 
proteins themselves can contain ER retention/retrieval signals, as recent studies on a 
number of receptors have illustrated (Zerangue et al., 1999; Bichet et al., 2000; 
Margeta-Mitrovic et a l , 2000). The masking of these motifs by assembly with other 
subunits, interactions with other proteins or phosphorylation may regulate the 
forward trafficking of such proteins (Zerangue et al., 1999; Bichet et al., 2000; 
Margeta-Mitrovic et al., 2000). The identification of an ER retention motif in the 
5HT3B subunit is described in Chapter 3.
An ER retention motif (PL(Y/F)(F/Y)XXN) has been identified within the Ml 
domain of the muscle-type nAChR subunits (Wang et al., 2002; Mei and Xiong, 
2003). The motif is found to be conserved in all muscle-type nAChR subunits as 
well as neuronal subunits (a2-a6 and p2-|34). The motif is not conserved in the a7- 
a9  nAChR subunits. In unassembled subunits the motif is exposed and promotes 
degradation, but in pentameric assemblies the motif is buried allowing exit from the 
ER (Wang et al., 2002).
1.4.5 Interacting proteins
The identification of proteins that interact with the nAChR and 5 HT3R subunits and 
complexes may provide insight into the mechanisms involved in aspects of their 
folding, assembly and functional expression. To date, except for the chaperone 
proteins described in Section 1.4.2, relatively few specific nAChR- or 5 HT3R- 
interacting proteins have been identified.
Rapsyn (or 43K), a 43 kDa protein, causes clustering of nAChRs at the postsynaptic 
membrane of the neuromuscular junction and in the Torpedo electric organ (Sealock, 
1982; Froehner, 1991; Phillips et al., 1991a; Phillips et al., 1991b; Moransard et al.,
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2003). The mechanism by which rapsyn functions is unclear. Muscle nAChRs are 
suggested to assemble with rapsyn and then cluster via a tyrosine kinase-dependent 
pathway which is induced by agrin (Qu et al., 1996; Moransard et al., 2003). Rapsyn 
is not thought to associate with neuronal nAChRs. The lynxl protein, which is 
similar to the snake venom neurotoxins, co-localises with neuronal nAChRs and 
enhances ACh-evoked currents (Miwa et al., 1999; Ibanez-Tallon et al., 2002). The 
calcium sensor protein, Visinin-like protein 1 (VILIP), has also been identified as a 
nAChR regulatory protein which directly affects the function of the neuronal 
nAChRs (Lin et al., 2002). PDZ-containing proteins of the PSD-95 family have also 
been shown to associate with neuronal nAChRs (Conroy et al., 2003).
The recently identified family of RIC3 proteins has been shown to be important in 
the maturation of a number of nAChR subtypes (Halevi et al., 2002; Halevi et al., 
2003). Co-expression of C. elegans RIC3 (CeRIC3) and its human homologue, 
hRIC3, in Xenopus oocytes enhances the activity of the C. elegans DEG-3/DES-2 
and rat and human a l  nAChRs (Halevi et al., 2002; Halevi et al., 2003). The hRIC3 
protein is reported to exert effects on the 5 HT3R (Halevi et al., 2003). The co­
expression of hRIC3 with the a l  nAChR in a mammalian cell line has recently been 
shown to facilitate functional expression of the receptor (Williams et al., 2005). The 
function of the RIC3 proteins is investigated in Chapter 5.
1.5 DISTRIBUTION OF THE nAChR AND 5HT3R
1.5.1 Native neuronal nAChRs
The neuronal nAChRs can be broadly divided into two main classes, those that are 
sensitive to a-BTX, and those that are insensitive to a-BTX. In mammalian brain, 
the a-BTX sensitive nAChRs correspond to a7-containing nAChRs (Seguela et al., 
1993). In mammalian brain, one a-BTX insensitive nAChR contains a 4  and (32 
subunits, and binds the nicotinic ligands, ACh, nicotine and cytisine with high 
affinity (Whiting et al., 1987a; Zoli et al., 1998). In the ganglia, the major a-BTX- 
insensitive nAChR contains a3 and p4 subunits (Flores et al., 1996). The a4, |32 and
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a  7 subunits are the most widely expressed in brain, whereas the other subunits’ 
expression is more limited (Drago et al., 2003).
1.5.1.1 a-BTX-insensitive nAChRs o f  the central nervous system
The majority of high affinity nAChRs in the brain comprise the a4(32 subtype 
(Whiting et al., 1987a; Flores et al., 1992; Zoli et al., 1998). The expression of a4  
mRNA is high in the cerebellum and cortex, whilst the expression of (32 is fairly 
widely distributed throughout human brain (Paterson and Nordberg, 2000). An 
antibody to (32 (mAb270) immunoprecipitates more than 90% of the high affinity 
[3H]-nicotine binding sites from solubilised chick brain extracts (Whiting and 
Lindstrom, 1986; Nef et al., 1988; Schoepfer et al., 1988). The a4  subunit is also 
co-immunoprecipitated with mAb270 (Whiting et al., 1987b; Whiting et al., 1987c; 
Nef etal., 1988).
Knockout mice, in which a nAChR gene is silenced, have been used to investigate 
the endogenous role of nAChRs, and the effects of their ligands in the central 
nervous system (Cordero-Erausquin et al., 2000, Drago et al., 2003). Deletion of the 
(32 subunit results in the loss of high affinity nicotine binding sites (Picciotto et al., 
1995). Knockout of the a4  subunit results in the loss of [ H]-nicotine and [ H]- 
epibatidine binding sites which are observed in the cortex and hippocampus of wild- 
type mice (Marubio and Changeux, 2000). These studies provide further evidence 
for a4p2 as the major nAChR subtype in brain.
The a2  mRNA has a limited expression pattern. Moderate expression of a l  is 
observed in the interpenduncular nucleus of the brainstem (Wada et al., 1989). Low 
levels of a 3 are observed in most cortical regions and the hippocampus (Paterson 
and Nordberg, 2000; Drago et al., 2003). The a5 subunit mRNA has been detected 
in a number of localised sites and also in the cortex at a lower level (Drago et al., 
2003). The a6  subunit is expressed at high levels in limited brain areas such as the 
substantia nigra and is often observed with (33 subunits (Le Novere et al., 1999). The 
(33 subunit is also expressed in other areas such as the thalamus (Drago et al., 2003). 
The (34 subunit is widely expressed in areas including the cerebellum and striatum
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(Forsayeth and Kobrin, 1997). The co-localisation of the p4 and a3  subunits 
suggests that they may be co-assembled (Flores et al., 1996).
1.5.1.2 a-BTX-insensitive nAChRs o f  the ganglia
Chick ciliary ganglia and neonatal rat sympathetic ganglia have been studied widely 
and have been shown to express the a3 a5, (32 and (34 subunits (Corriveau and Berg, 
1993; Mandelzys et al., 1994; Zoli et al., 1995). The a l  subunit, which forms a- 
BTX-sensitive nAChRs is also expressed. The a4  subunit is expressed in adult rats 
(Rust et al., 1994), but is not observed in chick ciliary ganglia. Embryonic chick 
ciliary neurons express at least four different nAChR subtypes (Conroy et al., 1992; 
Vemallis et al., 1993; Conroy and Berg, 1995; Pugh et al., 1995).
1.5.1.3 a-BTX-sensitive nAChRs o f  the brain and ganglia
The a-BTX-sensitive nAChRs are predominantly homomeric a l  nAChRs. The a l  
subunit is detected, at a high level, in the hippocampus, hypothalamus, amygdala, 
olfactory areas and brainstem of the human brain. Lower levels of a l  expression are 
detected in the cortex, cerebellum and thalamus (Dominguez del Toro et al., 1997; 
Paterson and Nordberg, 2000; Drago et al., 2003). The expression of a l  mRNA is 
observed widely within peripheral ganglia (Rust et al., 1994). In chick brain, three 
classes of a-BTX-sensitive nAChRs exist. The majority are a 7 homomers; the 
others comprise a7a8  heteromers and a8 homomers (Gotti et al., 1994).
In rat brain, [ I]-a-BTX binding sites closely parallel a l  mRNA expression 
(Seguela et al., 1993). Knockout of the a l  subunit gene results in the loss of [125I]- 
a-BTX binding sites, but the level of [3H]-nicotine binding sites remains unchanged 
compared to wild-type animals (Orr-Urtreger et al., 1997). In a 4  or |32 knockout 
mice, levels of [125I]-a-BTX binding sites are unaffected (Zoli et al., 1998; Marubio 
e ta l , 1999).
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1.5.1.4 a9 and alO distribution
The a9  and alO  subunits are not easily classified as either muscle-type or neuronal 
nAChRs (Elgoyhen et al., 2001). Their expression is largely restricted to the hair 
cells of the inner ear and neither subunit is found in the central nervous system 
(Elgoyhen et al., 1994; Elgoyhen et al., 2001; Lustig et al., 2001).
1.5.2 Distribution of the 5HT3R
The 5HT3RS are expressed throughout the central and peripheral nervous systems 
(Barnes and Sharp, 1999). Radioligand binding studies, using compounds such as 
the 5HT3R antagonist [3H]-GR65630, have been used to map 5 HT3R distribution 
(Marazziti et al., 2001). In the peripheral nervous system, 5 HT3RS are mainly 
localised to the enteric nervous system and ganglionic neurons. In the brain, the 
highest density of binding sites is in the area postrema, followed by the nucleus 
tractus solitarus, trigeminal nucleus, dorsal vagal complex and substantia gelatinosa 
(Marazziti et al., 2001). 5HT3R expression in other areas of the brain is low, with 
the highest levels in the hippocampus, amygdala and superficial layers of the cortex 
(Barnes and Sharp, 1999). In situ hybridisation studies indicate that 5 HT3A 
transcripts are distributed similarly to the pattern of 5HT3R radioligand binding sites. 
5HT3A mRNA is found in the brain (cortex, brainstem, midbrain), spinal cord and 
heart (Maricq et al., 1991). 5HT3B mRNA is co-expressed with the 5HT3A subunit in 
the human brain in the cerebral cortex, amygdala, caudate nucleus, thalamus and 
hippocampus (Davies eta l., 1999; Dubin et al., 1999). In rat, 5HT3B subunit 
expression appears to be restricted to the peripheral nervous system (Morales and 
Wang, 2002). However, weak signals for 5HT3B mRNA have been detected in 
whole brain extracts (Sudweeks et al., 2002). Taken together, these data and that 
from other studies suggest that the 5HT3B subunit is not a major determinant of 
receptor function in the central nervous system (van Hooft and Yakel, 2003). Using 
reverse transcriptase-polymerase chain reaction in situ hybridisation (RT-PCR ISH), 
a very sensitive technique which can detect a single molecule of mRNA, both 5HT3A 
and 5 HT3B mRNA were detected in a small population of cells in spleen, tonsil, 
small and large intestine, uterus, prostate, ovary and placenta (Dubin et al., 1999).
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Little is known about the cells expressing these subunit mRNAs. The recently 
identified putative 5HT3D subunit was found to be expressed in the kidney, colon and 
liver, whilst 5HT3C and 5HT3E were found to be more widely expressed in many 
tissues including brain (Niesler et al., 2003). Interspecies differences in 5 H T3R 
distribution exist.
1.6 HETEROLOGOUS EXPRESSION OF RECEPTORS
The oocytes of Xenopus laevis (South African clawed frog) have been used widely as 
a heterologous expression system for the characterisation of nAChRs and 5 HT3RS. 
The reconstitution of functional recombinant nAChRs in Xenopus oocytes has been 
demonstrated by injection of mRNA encoding the nAChR subunits of the Torpedo 
electric organ (Sumikawa et al., 1981). Cell surface receptors were expressed with 
properties resembling those of native receptors (Barnard et al., 1982).
The Xenopus oocyte can be injected with known combinations of receptor subunit 
mRNAs or cDNAs and the resulting receptors can be compared to native receptors. 
Heterologous expression of receptor subunits in mammalian cell lines has also 
proved useful, and may provide an environment which more closely resembles the 
receptors’ native environment, compared to that provided by Xenopus oocytes 
(Sivilotti et al., 2000). The transient and stable expression of receptor subunits is 
possible in mammalian cell lines.
1.6.1 Native versus recombinant expression of nAChRs
The heterologous expression of nAChRs is an extremely useful tool for the 
characterisation of nAChRs. Properties of receptors often resemble those of native 
receptors, but differences have been observed. Properties of receptors may vary 
between different heterologous expression systems and with the use of different 
techniques. The environment of the host cell may affect the properties of the 
receptor being expressed. When expressed natively, the Torpedo electric organ 
nAChR occurs predominantly in a dimeric form, whereas expression in oocytes 
results in single pentameric receptors (Sumikawa et al., 1981; DiPaola et al., 1989).
47
The pharmacological properties of the chick a l  nAChR expressed in oocytes 
correlate well with, but are not identical to, the a-BTX sensitive nAChRs observed 
natively in chick (Anand et al., 1993a; Anand et al., 1993b; Gotti et al., 1994; Gotti 
et al., 1997). Recombinant a l  homomeric receptors have a fifty-fold higher affinity 
for cytisine than the a7-containing nAChRs of embryonic chick brain (Anand et al., 
1993b). In different expression systems, differences exist in the single channel 
conductance of the a  7 nAChR. In a mammalian cell line, BOSC23, two 
conductance states are observed for a7 , whereas in oocytes a single conductance 
state is observed (Revah et al., 1991; Bertrand et al., 1992; Ragozzino et al., 1997).
The different properties of the recombinant homomeric a  7 nAChRs compared to 
those of the native suggested that, in vivo, a  7 may co-assemble with other subunits 
(Anand et al., 1993b; Yu and Role, 1998; Palma et al., 1999; Khiroug et al., 2002; 
Virginio et al., 2002). The a l  and (32 subunits have been observed to co-precipitate 
when transiently transfected into a mammalian cell line and are shown to produce 
functional a7|32 receptors in Xenopus oocytes with properties differing from a l  
homomers (Khiroug et al., 2002).
1.6.2 Native versus recombinant expression of 5HT3RS
The heterologous expression of 5HT3RS has been useful in the characterisation of the 
5 HT3RS. Electrophysiological investigations revealed a striking difference in single 
channel conductance between heterologously expressed and native 5HT3RS (Maricq 
et al., 1991; Hussy et al., 1994; Brown et al., 1998). In various native tissues, the 
conductance of the 5HT3R ion channel is between 9 and 17 pS (Derkach et al., 1989; 
Hussy et al., 1994). The 5HT3R expressed in, for example, the NCB-20 or N1E-115 
cell line, or heterologous expression of the 5HT3A subunit, results in a receptor with a 
sub-pS conductance (Peters et al., 1992; Hussy et al., 1994). The cloning of the 
5HT3B subunit helped to account for the observed functional differences between 
native and recombinant receptors. Heterologous co-expression of the 5 HT3A and 
5HT3B subunits resulted in receptors with properties more similar to those of native 
5HT3RS (Davies et al., 1999; Dubin et al., 1999; Hanna et al., 2000). Native 
receptors do also exist in a low conductance homomeric (5HT3a) form, for example,
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in rodent superior cervical ganglion neurons the expression of both low and high 
(heteromeric; 5HT3a/5HT3b) conductance receptors is observed (Yang et al., 1992; 
Hussy et al., 1994).
In neuroblastoma cell lines, such as N IE -115, in which the 5 HT3R single channel 
conductance is similar to that observed for 5 HT3A homomers, the expression of both 
5HT3A and 5 HT3B mRNA is observed, suggesting that the 5HT3B subunit does not 
contribute significantly to the properties of 5 HT3R.S of neuroblastoma cells (Hanna et 
al., 2000; Stewart et al., 2003). The functional recombinant expression of 5 HT3A 
homomers has been demonstrated in dorsal root ganglion neurons (Smith et al.,
1997) and cortical neurons (Boyd et al., 2002).
1.6.3 Influence of the host cell environment
The expression of recombinant nAChRs, such as the homomeric a  7 and a  8 
receptors, has been observed to be critically dependent upon the nature of the host 
cell (Blumenthal et al., 1997; Cooper and Millar, 1997; Cooper and Millar, 1998; 
Sweileh et al., 2000; Drisdel et al., 2004), whereas expression of the closely related 
5 HT3R is not. Correctly folded and assembled cell surface nAChRs are only 
detected in a few cell lines, for example, the human neuroblastoma SH-SY5Y cell 
line (Cooper and Millar, 1997; Cooper and Millar, 1998). In several other cell lines, 
such as human embryonic kidney HEK293 cells, a l  subunit protein can be detected, 
but receptors are not expressed on the cell surface (Cooper and Millar, 1997; Cooper 
and Millar, 1998). The expression of the a l  subunit can vary between different 
populations of cells. For example, three isolates of the PC 12 cell line revealed 
differences in the ability to express functional a l  nAChRs (Blumenthal et al., 1997). 
Taken together, the results suggest the requirement of an additional factor, which is 
only present in certain cell types, for the correct folding, assembly and localisation of 
the a l  nAChR (Cooper and Millar, 1997; Dineley and Patrick, 2000; Sweileh et al., 
2000).
In contrast to a l , the 5 HT3R efficiently forms functional receptors in several cell 
lines, for example, HEK293 cells (Hope et al., 1996). The inefficient expression of
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a l ,  and several other nicotinic subunits, can be enhanced through the construction of 
subunit chimeras in which the C-terminal region of the nicotinic subunit is replaced 
with the corresponding region of the 5HT3A subunit (Eisele et al., 1993; Cooper and 
Millar, 1998; Cooper et al., 1999; Rakhilin et al., 1999; Harkness and Millar, 2002). 
A chimera consisting of the N-terminal region of a  7 fused to the C-terminal region 
of 5HT3A is efficiently expressed on the cell surface in cell types which inefficiently 
fold wild-type a l  (Eisele et al., 1993; Cooper and Millar, 1998).
1.7 PHYSIOLOGICAL FUNCTION AND DYSFUNCTION 
1.7.1 nAChR function and dysfunction in the central nervous system
The distribution of nicotinic receptors throughout the central nervous system has 
been well defined, whilst the physiological functions of nAChRs are still unclear. 
Nicotinic receptors have been implicated in a variety of brain functions, including 
cognitive functions, such as attention, learning and memory formation, sensory 
perception and reward (Gotti et al., 1997; Jones et al., 1999).
7.7.7.7 The role o f  presynaptic nAChRs
In the central nervous system, the primary role of presynaptic nAChRs is proposed to 
be in the modulation of synaptic transmission through the regulation of 
neurotransmitter release (Wonnacott, 1997; Role and Berg, 1996; Levin and Simon,
1998). The release of most of the classical neurotransmitters, including dopamine, 
noradrenaline, GABA and glutamate, has been shown to be affected by presynaptic 
nAChRs. High affinity nicotine binding sites are found on the terminals of dopamine 
neurones in the striatum (Wonnacott, 1997; Wonnacott et al., 2000). These receptors 
are thought to be a heterogenous population of a4p2 and a 3-containing receptors 
(Wonnacott, 1997).
The presynaptic nAChRs may also function as ‘ autoreceptors ’ on ACh-containing 
nerve terminals, modulating the release of ACh via a feedback mechanism. Release
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of ACh from a nerve terminal may cause stimulation of the autoreceptors, which then 
mobilise ACh from a reserve store to be available upon demand (Wonnacott, 1997).
An additional role for presynaptic nAChRs is in development. Nicotinic receptors 
are observed on growth cones, where they respond to ACh, which is spontaneously 
released by the growth cone, and may participate in the regulation of neurite 
outgrowth (Role and Berg, 1996; Wonnacott, 1997). When the neurite reaches a 
postsynaptic target, the release of ACh increases and signals for the growth to end, 
resulting in synapse formation and stabilisation (Wonnacott, 1997). The receptors 
mediating this action appear to be of the a l  subtype, their high calcium permeability 
playing a role in calcium-dependent activation of signalling pathways.
1.7.1.2 The role o f postsynaptic nAChRs
Postsynaptic nAChRs mediate nicotinic transmission in autonomic ganglia, within 
the spinal cord (at the Renshaw cell-motoneuron synapse), and at efferent synapses 
of the cochlea hair cells (Role and Berg, 1996). Determining the role of postsynaptic 
nAChRs in the brain has proved much more elusive than in the peripheral nervous 
system. The most clearly demonstrated role identified is in the fast ACh-mediated 
synaptic transmission in the hippocampus and in the sensory cortex (Jones et al.,
1999). The lack of definitive evidence for postsynaptic receptor function in the brain 
suggest that they participate in functions other than direct synaptic transmission 
(Role and Berg, 1996).
1.7.1.3 The role o f  nAChRs in tobacco dependence
A well established physiological role of the neuronal nAChRs is their mediation of 
nicotine-induced tobacco addiction. Tobacco smoking in humans and nicotine self­
administration in animals are associated with an increase in dopamine release that 
follows the action of nicotine upon mesencephalic dopaminergic neurones (see Lena 
and Changeux, 1998). Nicotine exploits the intrinsic reward pathways of the nervous 
system that mediate the reinforcing effects of natural rewards such as food, by 
increasing dopamine-mediated activity (Jones et al., 1999). The increase in 
dopamine-mediated activity is primarily via nAChRs in the ventral tegmental area
51
(VTA) of the midbrain (Nisell et al., 1994). The reward system includes the 
mesolimbic dopaminergic pathways which originate from the dopaminergic neurons 
of the VTA and project to the nucleus accumbens and prefrontal cortex. Nicotine 
alters the activity of the VTA to enhance dopamine release in the nucleus accumbens 
(Raggenbass and Bertrand, 2002). To date, three cell types in the VTA have been 
observed to express nAChRs: dopaminergic neurons, GABAergic neurons, and 
glutamatergic presynaptic terminals which synapse onto dopaminergic neurons 
(Mansvelder and McGehee, 2002). The principal excitatory input to VTA neurons, 
which ultimately increase dopamine release in the nucleus accumbens, are the 
glutamatergic terminals (Mansvelder and McGehee, 2000). The glutamatergic 
terminal nAChRs are a7-containing, and block with MLA prevents nicotine-induced 
increases in dopamine release. The principal inhibitory inputs to VTA neurons are 
GABAergic, including local intemeurons as well as projections from the nucleus 
accumbens. The majority of the nAChRs on the GABAergic neurons are proposed 
to contain a 4  and p i  subunits (Mansvelder and McGehee, 2000; Mansvelder and 
McGehee, 2002). Dopamine release from the VTA projections depends on the 
balance of excitatory and inhibitory inputs, and the intrinsic activity of the 
dopaminergic neurons. Nicotine-induced dopamine release in the nucleus 
accumbens does not occur in p i  knockout mice. Also, p i  knockout mice do not self- 
administer nicotine, suggesting the p i  subunit to be involved in nicotine addiction 
(Picciotto et al., 1998).
In rats, chronic exposure to nicotine results in an upregulation of high affinity [3H]- 
nicotine binding sites in the brain which correspond to a4|32. A similar upregulation
■j
of [ H]-nicotine binding sites is observed in postmortem brains of chronic smokers 
(Benwell et al., 1988). The upregulation of receptors varies with cell-type and 
receptor subtype and the receptors increase in number through increased assembly 
(Olale et al., 1997). Although the nAChRs increase in number upon chronic nicotine 
treatment, a net decrease in nAChR function is observed. This decrease in function 
may explain the tolerance for nicotine of tobacco smokers. The nicotine-upregulated 
receptors accumulate in a desensitised and inactive state (Peng et al., 1997).
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1.7.1.4 nAChR Pathology
Nicotinic receptors are implicated in several neurological disorders. In 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and 
Lewy-body disease, a decrease in high affinity nicotine binding sites is observed 
(Paterson and Nordberg, 2000; Picciotto and Zoli, 2002).
Alzheimer’s disease (AD) is characterised by a progressive deterioration of higher 
cognitive functions, such as the loss of memory. In addition to a number of 
neuropathological features, AD is characterised by the loss of cholinergic innervation 
of the cerebral cortex and hippocampus. Binding studies performed on postmortem 
brain tissue have indicated that the major subtype of nAChRs lost in AD is a4|32. 
The mRNA levels of a4  and p2 are also observed to decrease with age in the frontal 
cortex, and levels of p2 are reduced in the hippocampus. The level of a3  subunit 
mRNA is also reduced with age, but no significant difference between mRNA levels 
in AD brain and age matched controls is observed (Terzano et al., 1998). A 
significant correlation between reduced [3H]-epibatidine sites and reduced levels of 
the presynaptic marker, synaptophysin, in the frontal cortex of AD brains has been 
demonstrated, suggesting that the majority of nAChRs lost are presynaptic.
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a partial epilepsy 
which can result from a missense mutation in the a 4  subunit gene. A highly 
conserved serine at position 247 of the M2 channel lining domain of the subunit is 
replaced with a phenylalanine (S247F), resulting in impaired channel function 
(Weiland et al., 1996; Kuryatov et al., 1997). When a4(S247F) is co-expressed with 
P2 in Xenopus oocytes, a receptor with reduced calcium permeability, channel 
opening and recovery from desensitisation, compared to wild-type a4p2, is produced 
(Weiland et al., 1996). A second mutation involving the insertion of a leucine after 
position 259 in the M2 domain of the a4  subunit also causes ADNFLE. Epilepsy 
results from an excess of neuronal activation, so mutations causing a reduction in 
nAChR function are surprising. An explanation may be provided if the mutant 
receptors are located presynaptically on inhibitory nerve terminals.
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1.7.2 5HT3R function and dysfunction in the central and peripheral nervous 
systems
1.7.2.1 Presynaptic and postsynaptic 5HT3R function
The stimulation of 5HT3R affects cardiac, intestinal and lung functions and induces 
nausea and vomiting. The 5 HT3R.S are proposed to play roles in anxiety and 
cognition. Generally, the 5HT3R.S are thought to be involved in the presynaptic 
modulation of neurotransmitter release in the central nervous system, although their 
precise role in this function is unclear (Lambert et al., 1995; Barnes and Sharp, 1999; 
van Hooft and Vijverberg, 2000). Presynaptic 5HT3R.S are reported to be involved in 
the modulation of release of neurotransmitters such as dopamine, cholecystokinin 
(CCK), 5-HT and GAB A in a number of brain regions. Postsynaptic 5 HT3R.S present 
on GABAergic interneurons have been observed to mediate fast synaptic 
transmission in the central nervous system (Sugita et al., 1992; Roerig et al., 1997). 
Most of the initial evidence for the presence of functional 5 HT3RS in the brain was 
from reports of the behavioural effects of 5 HT3R ligands (mostly 5 HT3R 
antagonists). The use of 5 HT3A knockout mice has not contributed much information 
concerning the function of 5HT3RS (Barnes and Sharp, 1999).
A significant proportion of 5HT3RS in the amygdala are located on serotonergic 
terminals. Chemical lesion of the serotonergic system causes a decrease in the 
number of these receptors, whereas the number of receptors in the hippocampus or 
cerebral cortex are unaffected. However, experiments investigating 5HT3R-mediated 
5-HT release in the amygdala have not been performed. A 5HT3R-mediated 
enhancement of 5-HT release in the hippocampus has been reported.
Evidence has been provided from in vivo studies for the involvement of 5 HT3RS in 
the release of dopamine in the nucleus accumbens (Imperato and Angelucci, 1989), 
but the exact location of these receptors has not been determined.
The majority of cortical and hippocampal 5 HT3RS are located on CCK-containing 
GABAergic intemeurons and so it is likely that activation of these receptors leads to 
the release of both GABA and CCK. In synaptosome preparations from the cortex,
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5-HT is observed to enhance CCK release and this effect is antagonised by 5 HT3R 
antagonists (van Hooft and Vijverberg, 2000). However, 5HT3R antagonists have no 
effect on CCK release in in vivo studies (van Hooft and Vijverberg, 2000). There is 
little direct evidence for the role of presynaptic 5 HT3RS in GAB A release.
1.7.2.2 5HT3RS as therapeutic targets
Animal studies using 5 HT3R antagonists have suggested that they might be clinically 
useful in a number of areas including anxiety, cognitive dysfunction and psychosis, 
in addition to their anti-emetic use. However, no clinical studies have yet clearly 
demonstrated the effectiveness of 5 HT3R antagonists in the treatment of central 
nervous system disorders (Greenshaw and Silverstone, 1997).
The 5 HT3R antagonists, ondansetron and granisetron, are commonly used anti­
emetics for the treatment of chemotherapy- and radiation-induced emesis (Jones and 
Blackburn, 2002). In animal studies, it was shown that chemotherapeutic agents 
caused the release of vast quantities of 5-HT in the gut. This 5-HT then activated 
5HT3RS in the gut and in the dorsal vagal complex in the brainstem, resulting in 
emesis. Further animal studies demonstrated that this response was blocked by 
5HT3R antagonists.
1.8 CO-ASSEMBLY AND CROSS-PHARMACOLOGY OF THE nAChR 
AND 5HT3R
The nAChRs and 5HT3RS are structurally and functionally related proteins. Their 
structures are similar enough to enable construction of viable chimeras, such as those 
containing the extracellular N-terminal ligand binding domain of a nAChR (e.g. a l ,  
a4  or P2), fused to the C-terminal region of 5HT3A (Eisele et al., 1993; Cooper et al., 
1999; Harkness and Millar, 2001; Harkness and Millar, 2002).
The co-assembly of recombinant 5 HT3A and nicotinic subunits has also been 
reported. Heterologous expression of the 5 HT3A and a4  nAChR subunits resulted in
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co-assembly of the subunits, generating a 5-HT-activated channel with enhanced 
calcium permeability compared to the homomeric 5HT3A channel (van Hooft et al., 
1998). A further report suggested that the a4  nAChR subunit, in a4  and 5HT3A 
heteromeric complexes, contributes to the lining of the ion channel pore (Kriegler et 
al., 1999). The co-assembly of the 5 HT3A subunit with the p2 nAChR subunit was 
also reported (Harkness and Millar, 2001). The functional significance of this co­
assembly remains unclear. Co-expression of a4  and 5HT3A in a mammalian cell line 
did not result in efficient cell surface expression of a4/5HT3A heteromeric complexes 
(Harkness and Millar, 2001). Immunoprecipitation studies on porcine brain 
demonstrated that native 5 HT3RS do not contain nAChR subunits (Fletcher et al., 
1998). The 5 HT3R co-localises with the a 4  nAChR subunit on striatal nerve 
terminals, however, it is proposed that the receptors do not physically interact, but 
that interactions occur between their signalling pathways (Nayak et al., 2000).
Some pharmacological cross-reactivity is observed between the nAChRs and 
5HT3RS. For example, the endogenous 5 HT3R agonist, 5-HT, causes block of 
nAChRs (Palma et al., 1996; Fucile et al., 2002). The nicotinic agonists, nicotine 
and ACh are competitive 5 HT3R antagonists (Gurley and Lanthom, 1998). The 
5 HT3R antagonist tropisetron is reported to act as a partial agonist at the a l  nAChR 
expressed in X enopus  oocytes (Macor et al., 2001). Some overlap in 
pharmacological properties is observed, for example, PSAB-OFP which is a selective 
a l  nAChR agonist, is also a potent agonist of the 5 HT3R (Broad et al., 2002). The 
aromatic moiety of 5-HT, 5-hydroxyindole (5-HI), potentiates the responses of both 
the a l  nAChR and 5 HT3RS (van Hooft et al., 1997; Gurley et al., 2000; Zwart et al., 
2002).
1.9 AIM OF STUDY
The nAChRs and 5HT3RS are widely expressed throughout the central and peripheral 
nervous systems and are involved in a number of functional processes. The aim of 
this study was to gain a better understanding of the structural and functional 
properties of these receptors. A variety of molecular and cell biological techniques
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have been used to investigate the mechanisms involved in the folding, assembly, 
trafficking and function of these receptors. A better understanding of these 
mechanisms should help to elucidate the mechanisms involved in the functional 
expression of native receptors. The nAChRs and 5HT3RS are implicated in a number 
of physiological processes as well as several neurological disorders. 
Characterisation of these receptors is essential to further define their roles in the 
brain and other organs, and to realise their potential as therapeutic targets.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 PLASMID CONSTRUCTS AND SUBCLONING
2.1.1 Competent cells
2.1.1.1 Preparation o f  competent Escherichia coli strain XL 1-blue
Luria-Bertani (LB) medium (20 ml) was inoculated with Escherichia coli (E. coli) 
strain XL 1-blue from a frozen glycerol stock, and grown at 37°C with shaking at 225 
rpm overnight. The culture was transferred to 500 ml of SOB (20 g/1 bacto-tryptone, 
5 g/1 bacto-yeast extract, 0.5g/l NaCl, 2.5 mM KC1, 10 mM MgCL) and incubated at 
37°C with shaking at 225 rpm until an optical density at 550 nm of 0.5-0.55 was 
reached. The culture was centrifuged at 2500 rpm for 15 minutes at 4°C in a 
Beckman J2-M1 centrifuge, the supernatant discarded and the pellet resuspended in 
20 ml of ice-cold RF1 (100 mM RbCl, 50 mM MnCLALLO, 30 mM potassium 
acetate, 10 mM CaCl2.2H20, 15 % w/v glycerol, pH adjusted to 5.8 with 0.2 M 
acetic acid, filter sterilised (0.22 pm)) and incubated on ice for 15 minutes. The cells 
were centrifuged at 2500 rpm for 9 minutes at 4°C, the supernatant discarded and the 
pellet resuspended in 3.5 ml of ice-cold RF2 (10 mM RbCl, 10 mM MOPS, 75 mM 
CaCl2.2H20, 15 % w/v glycerol, pH adjusted to 6.8 with 0.2 M acetic acid, filter 
sterilised (0.22 pM)). Cells were incubated on ice for 15 minutes and aliquoted on a 
dry ice and ethanol bath. Cells were stored at -80°C.
2.1.1.2 Other E. coli strains
For most applications the XL 1-blue strain of E.coli was used. However, if the 
plasmid required restriction enzyme digestion with Bell whose activity is blocked by 
dam methylation then the GM2163 {dam') strain was used.
The MC1061/P3 strain was used for plasmids such as pCDM8 which carry the SupF 
gene. These cells contain a P3 episome which carries amber mutations in the 
ampicillin and tetracycline resistance genes. The SupF  gene enables the 
amber/termination codon to be passed over and therefore confers ampicillin and
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tetracycline resistance to transformed cells. All strains were made competent, 
essentially as above.
2.1.2 Transformation into E. coli
Bacterial transformations were performed using frozen stocks of competent E. coli 
cells as described above. DNA (1-30 ng) or 2-5 pi of ligation mixture was gently 
mixed with 50 pi of competent E. coli cells in a Falcon 352005 polypropylene tube 
and incubated on ice for 30 minutes. The cells were heat shocked for 90 seconds in a 
42°C water-bath. 500 pi of SOC (SOB plus 20 mM glucose) was added and the cells 
incubated at 37°C with shaking at 225 rpm for 1 hour. An aliquot (20-500 pi) was 
plated on to a LB-agar plate, containing the appropriate antibiotic for the plasmid 
used, and grown overnight at 37°C.
2.1.3 Preparation of plasmid DNA
2.1.3.1 Small scale preparation o f  plasmid DNA : Extraction by alkaline lysis method
A  single colony was transferred to 2 ml of LB containing the appropriate antibiotic 
for the plasmid used and grown for 6-14 hours at 37°C with shaking at 225 rpm. 
Cells (1.5 ml) were centrifuged at 12,000g for 30 seconds and the resulting cell pellet 
resuspended in 100 pi ice-cold solution I (50 mM glucose, 25 mM Tris.HCl, 10 mM 
EDTA) by vigorous vortexing. Solution II (200 pi) (0.2 NaOH, 1 % SDS) was 
added and mixed by inversion. Ice-cold solution III (150 pi) (100 ml contains: 60 ml 
5 M potassium acetate, 11.5 ml glacial acetic acid, 28.5 ml H2O) was added and 
mixed by vortexing in an inverted position and tubes were then stored on ice for 3-5 
minutes. The mixture was centrifuged at 12,000g for 5 minutes at 4°C and the 
supernatant transferred to a fresh tube. An equal volume of phenol/chloroform was 
added, mixed and the preparation centrifuged and the supernatant removed to a fresh 
tube. The DNA was precipitated with two volumes of 100 % ethanol at room 
temperature and allowed to stand for 2 minutes before being centrifuged at 12,000g 
for 5 minutes. The supernatant was removed and the pellet washed with 70 %
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ethanol allowed to air dry before being resuspended in 20-50 \i\ of milli-Q (MQ) 
water containing 50 (ig/ml RNAse A.
2.1.3.2 Large scale preparation o f  plasmid DNA
A plasmid purification kit from Qiagen (Qiagen Plasmid Maxi Kit), based on a 
modified alkaline lysis procedure, was used according to the manufacturers 
instructions. A single colony or a stab from a glycerol stock was grown overnight in 
250 ml of LB medium plus appropriate antibiotic at 37°C with shaking at 225 rpm. 
The cells were harvested by centrifugation at 6,000g for 10 minutes at 4°C. The cell 
pellet was resuspended in 10 ml of ice-cold buffer PI (50 mM Tris.Cl (pH 8.0), 10 
mM EDTA, 100 pg/ml RNase A) by vortexing and pipetting up and down until no 
cell clumps remained. Buffer P2 (10 ml) (lysis buffer: 200 mM NaOH, 1 % SDS) 
was added and mixed by inverting gently 5 times and incubated at room temperature 
for 5 minutes. Buffer P3 (10 ml) (neutralisation buffer: 3 M potassium acetate (pH 
5.5)) was added and mixed immediately by gently inverting and incubated on ice for 
20 minutes before centrifugation at ^20,000g  for 30 minutes at 4°C. The resulting 
supernatant was applied to a Qiagen tip (equilibrated with 10 ml buffer QBT ( 750 
mM NaCl, 50 mM MOPS, 15 % isopropanol, 0.15 % Triton X-100)) and allowed to 
empty by gravity flow. The Qiagen tip was washed twice with 30 ml of buffer QC (1 
M NaCl, 50 mM MOPS, 15 % isopropanol) and eluted with 15 ml buffer QF (1.25 M 
NaCl, 50 mM Tris.HCl (pH 8.5), 15 % isopropanol) into a glass 30 ml tube. The 
DNA was precipitated by addition of 0.7 volumes of room-temperature isopropanol 
and centrifugation at 15,000g for 30 minutes at 4°C. The supernatant was carefully 
decanted and the pellet washed with 5 ml of room-temperature 70 % ethanol. The 
pellet was air-dried for 5-10 minutes and resuspended in 1 ml of TE buffer (10 mM 
Tris.Cl, 1 mM EDTA), pH 8.0.
2.1.3.3 Determination o f yield
DNA concentration and purity were determined by measurement of absorbance at 
260 nm (A260) and 280 nm (A280) in a BIORAD SmartSpec™ 3000 
spectrophotometer. An A260: A280 value of 1.6-2.0 indicates a pure DNA preparation.
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Ratios significantly less indicate protein contamination and ratios above 2.0 indicate 
salt impurities.
2.1.4 Polymerase chain reaction
Polymerase chain reaction (PCR) thermocycling was performed in a Peltier Thermal 
Cycler, PTC-225 (MJ Research). Typical reactions were carried out in a 20 pi 
volume and contained 10-500 ng DNA, 0.25 pM of each of forward and reverse 
primer, 2.5 pM dNTPs, IX Pfu or KOD reaction buffer plus 2.5 mM MgSC>4 if using 
KOD and 2.5 U Pfu or KOD DNA polymerase made up to the final volume with MQ 
water. Pfu and KOD have a higher proof reading ability than Taq DNA polymerase 
as they possess 3’-5’ exonuclease activity as well as 5’-3’ DNA polymerase activity 
{Taq only has 5’-3’ exonuclease activity), and so DNA synthesis fidelity is increased. 
Taq polymerase was used for standard diagnostic PCR. Reactions using Taq 
included Taq buffer and 2.5 mM MgCk.
2.1.5 Restriction enzyme digestion
Typically, reactions were carried out in a 20 pi reaction volume. Plasmid DNA (1-3 
g) was digested with 5-10 U of restriction enzyme in an appropriate buffer for 1 hour 
at an incubation temperature for optimal enzyme activity (usually 37°C). For digests 
using two enzymes with incompatible buffers the first digestion was carried out in a 
20 pi volume for 1 hour. This digestion reaction was diluted with MQ water to 60 
pi, the second buffer added to a IX concentration and digestion continued for 1 hour.
2.1.6 Dephosphorylation of DNA
If subcloning involved digestion with a single enzyme, 5’-phosphate groups were 
removed using calf intestinal alkaline phosphatase (CIP) to prevent religation of the 
plasmid vector. Typically, reactions were carried out in a 90 pi volume which 
included 40 pi of a restriction digest reaction mixed with IX CIP buffer and 2-3 U 
CIP. This reaction was incubated for 30 minutes at 37°C when another 2-3 U of CIP 
was added and incubated for a further 30 minutes.
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2.1.7 Agarose gel electrophoresis
Electrophoresis through agarose gel allows the separation, visualisation and 
purification of plasmid DNA and DNA fragments. For most purposes, 1 % agarose 
gels were used. Electrophoresis-grade agarose was melted in TAE (Tris-acetate: 0.04 
M Tris-acetate, 0.001 M EDTA) and 0.3 pg/ml ethidium bromide added. DNA 
samples were run alongside 1 pg H indlll digested Lamda (X.) DNA standard 
markers, and PCR markers if appropriate, to enable estimation of the size of the 
DNA bands. Samples and markers were loaded in IX blue/orange loading dye.
If DNA fragments were required for subcloning they were separated on low melting 
point agarose gels. DNA bands were excised from the gel and purified using the 
Wizard™ DNA clean up system (Promega) according to the manufacturers 
instructions. Briefly, gel slices were melted in a hot block, resuspended in 1 ml 
Wizard™ DNA Clean-Up resin and forced through a mini-column using a 2 ml 
syringe. DNA bound to the column was washed with 2 ml isopropanol and the 
excess removed by centrifugation at 13,000 rpm for 2 minutes. DNA was eluted in 
30-50 pi pre-warmed (65°C) MQ water by centrifugation at 13,000 rpm for 1 minute.
2.1.8 DNA ligations
Ligation reactions were carried out in a 10 pi volume containing 1 pi of vector, 3-7 
pi of insert (depending on Wizard™ purification yield), 0.5 U T4 DNA Ligase and 1 
pi 10X T4 DNA ligase buffer. Reactions were incubated overnight at 14°C. To 
assess levels of vector re-ligation reactions containing no insert were performed.
2.1.9 Plasmid constructs and cDNA libraries
Rat a l  nAChR subunit cDNA was obtained from Dr Jim Patrick, Baylor College of 
Medicine, Houston. Human a l  and chick a8 nAChR subunit cDNAs (Schoepfer et 
al., 1990, Peng et al., 1994) were provided by Dr Jon Lindstrom (University of 
Pennsylvania, PA., USA). Mouse 5HT3a(l) in the mammalian expression vector 
pCDM6xl was from David Julius, University of California (Maricq et a l , 1991) and
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was subcloned into pRK5 using the Xbal site in this laboratory by Dr Elizabeth 
Baker. Mouse 5HT3a(s) was a gift to Eli Lilly & Company from Dr Sarah Lummis, 
University of Cambridge. Human 5 HT3A in pcDNA3 from Eli Lilly was used in 
studies directly related to Eli Lilly. Human 5 HT3A and 5 HT3B, in pCDM8, from 
Ewen Kirkness, Institute for Genomic Research, Rockville, Maryland were used in 
all other work. CeRIC3 was from Millet Treinin, Hebrew University, Israel and was 
subcloned into the mammalian expression vectors pRK5 and pcDNA3 in this 
laboratory by Dr Stuart Lansdell. The SH-SY5Y cDNA library was constructed in 
this laboratory by Dr Sandra Cooper. Dr Chris Connolly, University of Dundee, 
provided HA and myc tagged human 5HT3A and 5HT3B as well as the following 
truncated/mutant subunit cDNAs: HA tagged human 5 HT3B truncated at residue 267 
and at TM1 and TM2 termed 5HT3B(267), 5HT3B(TM1) and 5HT3B(TM2) 
respectively, HA tagged human 5HT3a(CRAR), myc tagged 5HT3b(SGER) and 
5HT3B(SGER)-myc truncated at residue 270 (5HT3b(SGER)270) and at TM2 
(5HT3B(SGER)TM2).
2.1.10 Expression vectors
Expression
Vector
Promoter Inducible/
Constitutive
Poly-A
Signal
Selection
pcDNA3 CMV Constitutive SV40 amp
pcDNA3.1 CMV Constitutive SV40 amp
pRK5 CMV/SP6 Constitutive SV40 amp
pcDM8/6XL CMV/SP6 Constitutive SV40 *SupF (amp/tet)
Table 2.1 Summary o f the plasmid expression vectors used in this study. 
Abbreviations: amp, ampicillin; tet, tetracycline; CMV, cytomegalovirus; poly-A, 
polyadenylation; SV40, Simian virus.
*SupF: Plasmids expressing the SupF gene require growth in a bacterial strain, such 
as M CI061, that contains the P3 episome. The P3 episome contains amp and tet 
selectable markers containing amber mutations which are corrected by SupF.
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2.2 CONSTRUCTION OF CHIM ERIC cDNA
Chimeric subunit cDNAs between human 5HT3A (1i5HT3a) and mouse 5HT3A 
(m5HT3A) were constructed (Figure 2.1). The long splice variant of the m5HT3A 
(m5HT3A(L)) was used. A chimeric subunit cDNA was constructed containing the 
extracellular N-terminal domain of the h5HT3A subunit fused to the transmembrane 
and intracellular domains of the m5HT3AR subunit, termed human/mouse (h/m) 
5HT3A chimera. A second, similar chimeric subunit cDNA contained the 
extracellular N-terminal domain o f the m5HT3AR subunit fused to the 
transmembrane and intracellular domains of the h5HT3AR subunit, termed 
mouse/human (m/h) 5HT3A chimera.
Ml M2 M3 M4
mouse/human 
5HT3A chimera
wmmmmmM%$$$%zzzzzzzzzzzzzzz%ffi human/mouse 5 HT3A chimera
human 5HT3A 
mouse 5HT3A
Figure 2.1 Chimeric 5HT3A subunits. The mouse/human 5HT3A chimera 
consisted of the extracellular N-terminal domain of the mouse 5HT3A subunit fused 
to the transmembrane and intracellular domains of the human 5HT3A subunit. The 
human/mouse 5HT3A chimera consisted of the extracellular domain of the human 
5HT3A subunit fused to the transmembrane and intracellular domains of the mouse 
5HT3A subunit. (Ml-M4=transmembrane domains)
The m/h5HT3A chimera in the pRK5 expression vector was constructed from h5HT3A 
in pcDNA3.1 and m5HT3A in pRK5 (Figure 2.2A). Mutations were introduced by 
site directed mutagenesis in h5HT3A to create a BamW\ site to enable subcloning 
using
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Figure 2.2 Construction o f chimeric 5HT3A subunits. A, The mouse/human 
5HT3A chimera: Mutations were introduced by SDM to create a BamHl site in the 
human subunit. The mutated subunit was digested with BamHl and Xhol to excise 
the C-terminal portion. The mouse subunit was digested with Bell and SalI to create 
a cloning cassette containing the N-terminal portion of the subunit. The human 
fragment and the mouse fragment and vector were ligated resulting in the m/h5HT3A 
chimera. B, The human/mouse 5HT3A chimera: The mutated human subunit, 
containing a BamHl site, was digested with BamHl to excise the N-terminal portion. 
The mutated subunit was also digested with BamHl and Xhol together to create a 
cloning cassette. The rat a 7 (V201)/mouse 5HT3A chimera was digested with Bell and 
Sail to excise the C-terminal mouse 5HT3A portion. The resulting two fragments and 
vector cassette were ligated to produce the chimeric subunit.
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the complementary Bell site present at the equivalent position in the m5HT3AR 
subunit. Mouse 5HT3A in pRK5 was digested with Bell and Sail to remove the C- 
terminal domain of m5HT3A (amino acids 1-246). Human 5HT3A in pcDNA3.1 was 
digested with BamHl and Xhol to excise the C-terminal domain which was then 
cloned into the BcWSail digested mouse 5HT3A in pRK5 generating the m/h5HT3A 
chimera in pRK5. Digestion with BelI and BamHl and also Sail and Xhol produces 
fragments with ends compatible for ligation, but ligation does not result in 
regeneration of the restriction enzyme sites.
The h/m5HT3A chimera in pcDNA3.1 was constructed from rat a7 (v201)/mouse 
5HT3A chimera in pRK5 and human 5 HT3A in pcDNA3.1 with a BamHl site 
introduced by SDM, as described above (Figure 2.2B). The wild-type mouse 5 HT3A 
was not used as the presence of an additional Bell site in the N-terminal domain was 
discovered. The rat a 7 (V201)/mouse 5HT3A chimera in pZeoSV was constructed by 
Dr Sandra Cooper (Cooper and Millar, 1997) and subcloned into pRK5 in this 
laboratory by Dr Elizabeth Baker. Human 5HT3A was digested with BamHl to 
generate a fragment containing the N-terminal domain of the subunit (amino acids 1- 
238). Human 5HT3A was also digested with BamHl and Xhol to excise the h5HT3A 
cDNA, and generate an empty vector suitable for subcloning. The rat a 7 (V201)/mouse 
5 HT3A chimera was digested with Bell and Sail to excise the C-terminal domain of 
the m5HT3A fragment. The two fragments and vector were ligated together and the 
h/m5HT3A chimera in pcDNA3.1 chimera generated.
The fidelity of the chimeric constructs was verified by sequencing. The h/m5HT3A 
chimera was found to be incapable of ligand binding. The reason for this lack of 
binding was identified and resolved (see Chapter 4, Section 4.3.2).
2.3 CLONING OF HUMAN RIC3 HOMOLOGUE
Human ric3 (hric3) was cloned from a human neuroblastoma cell line (SH-SY5Y) 
cDNA library by PCR. Oligonucleotide primers were designed to the 5’ and 3’ 
untranslated regions of the hric3 sequence identified in the human genome sequence
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database. The primers incorporated restriction enzyme sites to facilitate sub-cloning. 
The primers are detailed below.
OL650 (+): 5 ’ CGTCTGCACCTGCGAATTCCGTGAGCAGTCATGG 3 ’
OL651 (-): 5 ’ CTTGGGACTTGAGTAATGGATCCTTCAGACTGGC 3 ’
(+ )  =  forw ard prim er; ( - )  =  reverse  prim er; ATG =  start c o d o n  
GAATTC =  EcoKL site; GGATCC =  BamHl site
PCR was performed and resulted in the amplification of a fragment of about 1200 
base pairs (bp) which corresponded to the size of hric3. A second fragment of about 
600 bp was also amplified which corresponded to the size of a partial hric3 clone 
which had previously been identified in this laboratory. PCR fragments were treated 
with Taq polymerase, cloned into the TA cloning vector (pCR2.1; Invitrogen) and 
sequenced. Correct hric3 PCR clones were sub-cloned into the expression vectors 
pRK5 and pcDNA3.
2.4 CONSTRUCTION OF FLAG-EPITOPE TAGGED RIC3 PROTEINS
To facilitate biochemical analyses, CeRIC3 and hRIC3 were modified by the 
introduction of a FLAG epitope tag. The FLAG tag is a short hydrophilic peptide 
(DYKDDDDK) (Hopp et al., 1988). The topology of the proteins was assumed to be 
as predicted by Halevi et al., 2002 and Halevi et al., 2003 (Figure 2.3). The FLAG 
tag was introduced in the C-terminal domain of CeRIC3, CeRIC3FLAG'A (Figure 2.4). 
The FLAG tag was introduced at three different positions in hRIC3: in the C- 
terminal region (hRIC3FLAG'A), in between the two transmembrane domains 
(hRIC3FLAG*B) and close to the N-terminal (hRIC3FLAG'c) (Figure 2.4). The fidelity 
of all constructs was confirmed by nucleotide sequencing.
2.4.1 Introduction of the FLAG tag to the C-terminal region of CeRIC3
The Quikchange™ Site-Directed Mutagenesis Kit (Stratagene) (see Section 2.6) was 
used to introduce mutations creating a unique BstEll site at the position where the tag 
was to be inserted (after amino acid 373 (R)).
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membrane
cytoplasm
Figure 2.3 Structure and topology o f the RIC3 proteins (predicted by Halevi et 
al. 2002; Halevi et al., 2003). Structure predictions suggested that the RIC3 proteins 
have two hydrophobic, putative transmembrane domains separated by a proline-rich 
domain, followed by at least one coiled-coil region (CC), with their N- and C-termini 
being cytoplasmic.
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Figure 2.4 Positions o f the FLAG tags introduced into the RIC3 proteins (based 
on the topology predicted by Halevi et al., 2002; Halevi et al., 2003). The FLAG 
epitope tag was introduced into the C-terminal regions of CeRIC3 and hRIC3 
(FLAG-A). The FLAG tag was also introduced in hRIC3 between the two predicted 
transmembrane domains (FLAG-B) and close to the N-terminal (FLAG-C).
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CeRIC3 sequence (bp 111 1-1130):
5 ’ -CGAAGGCGGAGACCTAAAAA- 3 ’
3 ’ -GCTTCCGCCTCTGGAT T T T T - 5 ’
R R R R P K K
Primers to introduce BstEll site:
OL654 (+): 5’ GATAAAAATGTGCGAAGGCGGTTACCTAAAAAGACTTGA 3’
OL655 (-): 5’ TCAAGTCTTTTTAGGTAACCGCCTTCGCACATTTTTATC 3’
(+) = forward primer; (-) = reverse primer; AsfEII: G G TTA C C . Amino acids to be 
mutated are shown in bold.
The FLAG tag was introduced into CeRIC3 at the itofEII site by ligation of 
oligonucleotide primers which incorporated the FLAG tag and possessed 
complementary ends for subcloning into the ifofEII site.
OL545 (+): 5’ GTTACCTGACTACAAGGACGACGATGACAAGTG 3’
OL546 (-): 5’ GTAACCACTTGTCATCGTCGTCCTTGTAGTCAG 3’
FLAG tag: part of 13 sjEII she
The primers were mixed at an equimolar ratio and annealed by heating to 80°C for 
20 minutes in a hot block and allowed to cool slowly. The annealed primers were 
ligated with Bs/EII digested CeRIC3 DNA to produce the tagged construct, 
CeRIC3FLAG'A.
2.4.2 Introduction of the FLAG tag to the C-terminal region of hRIC3
Oligonucleotides incorporating the FLAG tag with ends complementary to the Zfa/EII 
site (OL545 and OL546; see Section 2.4.1) were used to insert the FLAG tag at an 
endogenous RsfEII site (bp 703-709) in the C-terminal region of hRIC3. The FLAG 
tag was introduced into hRIC3 after amino acid 223 (G), as described in Section
2.4.1 for CeRIC3, generating hRIC3FLA0'A.
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2.4.3 Introduction of the FLAG tag to the region between the two 
transmembrane domains of hRIC3
A FLAG epitope tag was introduced in the putative loop region between the two 
predicted transmembrane domains of hRIC3, after amino acid 58 (S), by site-directed 
mutagenesis. Complementary oligonucleotide primers incorporating the coding 
sequence for the FLAG tag were used:
OL700 (+):
5’ CAGGCACACTCAGACTACAAGGACGACGATGACAAGGATGGCCAGACT 3 ’ 
OL701 (-):
5’ AGTCTGGCCATCCTTGTCATCGTCGTCCTTGTAGTCTGAGTGTGCCTG 3 ’ 
(+) and (-) indicate a forward and reverse oligonucleotide primer, respectively; 
FLAG tag
2.4.4 Introduction of the FLAG tag to the N-terminal region of hRIC3
A FLAG epitope tag was inserted in the N-terminal region of hRIC3 after amino acid 
2 (A) by site-directed mutagenesis using complementary oligonucleotide primers 
incorporating the coding sequence for the FLAG tag:
OL725 (+):
5’ GCAGTCATGGCGGACTACAAGGACGACGATGACAAGTACTCCACAGTG 3’ 
OL726 (-):
5’ CACTGTGGAGTACTTGTCATCGTCGTCCTTGTAGTCCGCCATGACTGC 3’ 
(+) and (-) indicate a forward and reverse oligonucleotide primer, respectively; 
FLAG tag
2.5 NUCLEOTIDE SEQUENCING
Fluorescence-based cycle sequencing was carried out using ABI Prism® BigDye™ 
Terminator Cycle Sequencing Ready Reaction Kit versions 1.0 and 1.1 (ABI Applied 
Biosystems, Applera UK) according to the manufacturer’s instructions. Briefly, 200-
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500 ng template DNA and 3.2 pmol specific primer were mixed with 8 pi Terminator 
Ready Reaction Mix (containing dye-labelled ddNTP terminators, unlabelled dNTPs, 
AmpliTaq DNA polymerase, MgCh and buffer) in a reaction volume of 20 pi. 
Thermocycling of the reactions involved denaturation at 96°C for 30 seconds, 
annealing at 50°C for 15 seconds and extension at 60°C for 4 minutes for 25 cycles. 
Reactions were ethanol/sodium acetate precipitated by addition of 2 pi sodium 
acetate, pH 5.2 and 50 pi 99% ethanol per reaction, incubation on ice for 15 minutes 
and centrifugation at 13,000 rpm for 15 minutes. Pellets were washed with 500 pi 
70% ethanol, air-dried and resuspended in 10 pi formamide. Samples were 
sequenced using an ABI Prism® 3100-Avant Genetic Analyzer (ABI Applied 
Biosystems). Reactions were run on a 50 cm capillary array using POP 6 polymer 
(ABI Applied Biosystems). Data was extracted using 3100-Avant Data Collection 
Software Version 1.0 (ABI Applied Biosystems).
2.6 SITE-DIRECTED MUTAGENESIS
The QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) was used to create 
mutations in cDNA sequences according to the manufacturers instructions. Two 
complimentary oligonucleotide primers containing the desired mutation, flanked by 
unmodified nucleotide sequence were designed. Primers were between 25 and 45 
bases in length, with the desired mutation in the middle, had a melting temperature 
(Tm) greater than or equal to 78°C, a minimum GC content of 40 % and terminated in 
one or more G or C bases. Primers were purified by polyacrylamide gel 
electrophoresis.
Setting up the SDMPCR reactions
Reactions were carried out in a 50 pi volume containing: IX reaction buffer, 50 ng 
template DNA, 125 ng of each forward and reverse oligonucleotide primers, 1 pi 
dNTP mix and 1 pi PfuYwbo DNA polymerase (2.5 U/pl).
Thermocycling the reactions
Reactions were heated to 95°C for 30 seconds, then 12-18 (dependent on type of 
mutation desired) thermocycling steps were performed that included denaturation at
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95°C for 30 seconds, annealing at 55°C for 1 minute and extension at 68°C for 2 
minutes/kb of plasmid length. Reactions were cooled on ice.
Digestion o f the products
Reactions were digested with 1 pi Dpnl (10 U/pl) at 37°C for one hour. 
Transformation into XL J-Blue supercompetent cells
Digested DNA (1 pi) was mixed with 50 pi XL 1-blue supercompetent cells in a pre­
chilled Falcon 2059 polypropylene tube and incubated on ice for 30 minutes. 
Transformation was carried out via heat shock at 42°C for 45 seconds, followed by 
incubation in 500 pi NZY* broth (10 g/1 NZ amine (casein hydrosylate), 5 g/1 yeast 
extract, 5 g/1 NaCl, pH 7.5 with NaOH, 12.5 ml/1 1M MgCl2 and 12.5 ml/1 M gS04 
and 10 ml/1 of 2M glucose) for one hour at 37°C with shaking at 225 rpm. 
Transformation mix (250 pi) was plated onto LB agar plates containing 50 pg/ml 
ampicillin, prepared with 20 pi 10% (w/v) 5-bromo-4-chloro-3-indolyl-p-D- 
galactopyranoside (X-Gal) and 20 p i  100 mM isopropyl-l-thio-|3-D- 
galactopyranoside (IPTG) and incubated at 37°C for at least 16 hours.
2.7 CELL CULTURE AND TRANSFECTION
2.7.1 Cell lines
The tsA201 cell line was obtained from Dr William Green, University of Chicago, 
IL, USA. The tsA201 cell line is a transformed human embryonic kidney HEK293 
cell line which stably expresses an SV40 temperature-sensitive T antigen. HEK293 
cells were obtained from Eli Lilly. HEK293 cell lines stably expressing either the 
mouse 5HT3a(s) or human 5HT3A receptor subunit were a gift to Eli Lilly from Dr 
Sarah Lummis, University of Cambridge.
2.7.2 Cell culture
HEK293 and tsA201 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with Glutamax-1™ , supplemented with 10% heat inactivated fetal calf
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serum, 100 units/ml penicillin and 100 pg/ml streptomycin and maintained in a 
humidified incubator containing 5 % CO2 at 37°C.
2.7.3 Transient transfection
HEK293 and tsA201 cells were transiently transfected using Effectene™ 
Transfection Reagent (Qiagen) according to the manufacturer’s instructions. 
Effectene is a non-liposomal lipid formulation which is used in conjunction with a 
DNA-condensing enhancer solution in an optimised buffer. Cells were trypsinised 
and re-plated 6 hours before transfection to reach approximately 70% confluency. 
For transfection of a 10 cm dish, 0.6 pg DNA was added to a sterile microfuge tube 
and 120 pi Buffer EC, added. Enhancer solution (4.8 pi), which condenses the 
DNA, was added and incubated for 5 minutes followed by 13 pi Effectene, which 
coats the condensed DNA with cationic lipids. After 10 minutes incubation, 600 pi 
growth medium was added and the mixture added dropwise to cells in 3 ml medium. 
After approximately 17 hours, 6 ml growth medium was added. For cells cultured on 
13 and 19 mm coverslips, 0.05 and 1 pg DNA, respectively, were transfected. The 
DNA:Enhancer:Effectene ratios were maintained as above. Cells were used 40-46 
hours post-transfection. All transfections were performed using Effectene unless 
otherwise stated.
HEK293 cells were transiently transfected at Eli Lilly with FuGENE 6 transfection 
reagent according to the manufacturer’s instructions. One day before transfection, 
cells were plated at a density to yield 60-80% confluency on the day of transfection. 
FuGENE was added to an aliquot of serum-free medium and incubated for 5 
minutes. This transfection mix was added to DNA aliquots, mixed and incubated at 
room temperature for a further 15 minutes before being added dropwise to the cells. 
For FLIPR experiments the cells were incubated at 37°C for 48 hours and then 
replated on to poly-L-lysine pre-coated black-walled 96-well plates.
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2.8 RADIOLIGAND BINDING
2.8.1 Binding studies using [3H]-GR65630
For binding studies with [3H]-GR65630, a 5HT3R-specific radioligand, on cell 
membrane preparations, transfected cells on 10 cm dishes were washed with 
phosphate-buffered saline (PBS), then resuspended and assayed in 10 mM potassium 
phosphate buffer (pH 7.2) containing the protease inhibitors leupeptin and aprotinin 
(2 pg/ml) and pepstatin (1 pg/ml). Cells were incubated with radioligand (12.5 nM 
[3H]-GR65630) plus 100 pi of 10 % BSA in a total volume of 400 pi for 2 hours at 
4°C. Non-specific binding was determined by addition of 12.5 mM 5-HT. 
Radioligand binding was assayed by filtration onto 0.5 % polyethylenimine 
presoaked GF/B glass fibre filters (Whatman) followed by rapid washing with cold 
10 mM phosphate buffer using a Brandel cell harvester (Model M-36, Semaat, UK). 
Radioactivity was measured by scintillation counting.
2.8.2 Binding studies using [125I]-a-bungarotoxin
To study cell-surface a7  receptors, intact cells were incubated with 10 nM [125I]-a- 
bungarotoxin. Transfected cells were washed twice with PBS and gently 
resuspended in Hank’s Buffered Saline Solution (HBSS) containing 1 % bovine 
serum albumin (HBSS/BSA). Cells were incubated with radioligand, in HBSS/BSA, 
for 2 hours at room temperature. Non-specific binding was determined by addition 
of 1 mM carbachol and 1 mM nicotine in HBSS/BSA. Samples were harvested as 
above using GF/A glass fibre filters. Filters were washed 6 times with PBS and 
assayed in a Wallac 1261 gamma-counter. To study ‘total’ receptors, using 
membrane preparations, cells were resuspended and harvested in 10 mM potassium 
phosphate buffer.
2.8.3 Determination of protein concentration
The protein concentration of cell membrane preparations was determined using a 
BioRad DC protein assay kit according to the manufacturer’s instructions. Briefly,
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20 (xl of cell membrane preparation or BSA standard sample were added to a semi­
microcuvette and mixed with 100 \i\ Reagent A (alkaline copper tartarate solution). 
Reagent B (800 pi; a dilute folin reagent) was added, mixed and incubated at room 
temperature for 15 minutes. A colour change is observed following reduction of the 
folin reagent by the copper-treated protein. Protein concentration was determined by 
spectrophotometric measurement at 750 nm and comparison against a standard curve 
constructed using BSA at concentrations of 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.5 mg/ml.
2.9 ANTIBODIES
Antibody Species
Immunised
Specificity Source
mAbHA-7
(anti-HA)
mouse HA peptide* Sigma
9E10
(anti-myc)
mouse myc peptide*'* mAb, purified from mycl- 
9E10 hybridoma cell line 
(ECACC 85102202)
anti-FLAG mouse FLAG peptide*3 Sigma
pAbl20 rabbit extracellular region of 
5HT3A
Dr S. Lummis*4 
Spier etal., 1999
pAb5HT3 rabbit intracellular loop 
region of 5HT3A
Dr R. McKeman*5 
Turton et al., 1993
mAb319 rat intracellular loop 
region of a7
Sigma 
Schoepfer et al., 1990
mAbOARla 
mAbOARl lb
mouse extracellular 
conformational 
epitopes (a7)
Dr H. Betz 
Betz etal., 1984
Goat a-mouse 
IgG peroxidase
mouse Pierce
Goat a-rabbit 
IgG peroxidase
rabbit Pierce
Table 2.2 Summary o f antibodies used in this study
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* HA peptide: 9 amino acid synthetic peptide (YPYDVPDYA) corresponding to 
residues 98-106 of the human influenza virus haemagglutinin (Kolodziej and Young, 
1991).
*2 Myc peptide: 10 amino acid synthetic peptide (EQKLISEEDL) corresponding to 
residues 408-432 of the human c-myc protein.
*3 FLAG peptide: (DYKDDDDK) (Hopp et a l,  1988).
*4Dr S. Lummis (University of Cambridge).
*5Dr R. McKeman (Merck Sharp and Dohme Research Laboratories, Harlow).
2.10 METABOLIC LABELLING AND IMMUNOPRECIPITATION
Cells (tsA201) grown on 10 cm dishes were transiently transfected with receptor 
subunit cDNA overnight, washed and incubated for 20 minutes in L-methionine 
(Met) and L-cysteine (Cys) free medium to starve cells of methionine and cysteine. 
Cells were labelled with 150 pCi [35S]-Pro-mix (mixture of [35S]-Met and [35S]-Cys), 
in 4 ml Met/Cys-free medium for 3 hours at 37°C. The label was ‘chased’ by 
addition of 6 ml DMEM containing Met and Cys for 2 hours at 37°C. Cells were 
washed twice and harvested into 1 ml ice-cold PBS. Cells were pelleted in a 
benchtop centrifuge at 6000 rpm for 5 minutes at 4°C and resuspended in 500 pi ice- 
cold low salt lysis buffer (150 mM NaCl, 50 mM Tris/Cl, pH 8.0, 5 mM EDTA, 1 % 
Triton X-100) containing protease inhibitors (0.2 mM phenylmethylsulphonyl 
fluoride (PMSF), 2 mM N-ethylmaleimide (NEM) and 2 pg/ml each of pepstatin, 
leupeptin, aprotinin). Solubilised samples were pre-cleared by incubation with 40 pi 
Protein G-sepharose beads, pre-equilibrated in low salt lysis buffer containing 
protease inhibitors, and were rotated overnight at 4°C. Protein G-sepharose beads 
and non-solubilised material was pelleted by centrifugation at 13,000 rpm for 30 
minutes at 4°C in a benchtop centrifuge. The supernatant was transferred to a fresh 
tube and incubated with an appropriate antibody for 2-4 hours, rotating at 4°C. The 
antibody-receptor complexes were immunoprecipitated by incubation with 20 pi of 
protein G-sepharose beads for 2-3 hours, rotating at 4°C. Samples were centrifuged 
at 13,000 rpm for 5 minutes pelleting beads carrying antibody-receptor complexes. 
The beads were washed in 750 pi high salt (500 mM NaCl) lysis buffer, followed by
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medium (300 mM NaCl) and low salt lysis buffer washes. Beads were resuspended 
in 20 pi sodium dodecyl sulphate (SDS)-loading dye (50 mM Tris/Cl pH 6.8, 200 
mM dithiothreitol (DTT), 2% SDS, 0.2 % bromophenol blue, 10 % glycerol) and 
centrifuged at 13,000 rpm for 2 minutes. Supernatants were loaded and separated on 
a 7.5% SDS-polyacrylamide gel. The gel was fixed for 30 minutes in 30% methanol,
TW
10% glacial acetic acid and incubated in Amplify for 30 minutes. The gel was 
dried and exposed to Kodak X-OMAT photographic film at -80°C in a cassette 
containing intensifying screens.
2.11 ENZYME-LINKED ANTIBODY BINDING ASSAY
2.11.1 Assaying cell-surface receptors
Cells were plated onto glass coverslips coated with poly-L-lysine (10 pg/ml) and 
collagen, and transiently transfected. Cells were washed with HBSS supplemented 
with 25 pM MgCb and 25 pM CaCh (HBSS4*) and non-specific binding blocked by 
incubation for 15 minutes with HBSS44 containing 2 % BSA and 25 mM lysine 
(BLOCK). Cells were incubated with primary antibody in BLOCK with 5 % fetal 
calf serum added in a humidified chamber for 1 hour. Cells were washed 5 times in 
HBSS and fixed for 15 minutes using 3 % paraformaldehyde. Cells were incubated 
with a secondary antibody conjugated to horse-radish peroxidase (HRP) in BLOCK 
plus 5 % fetal calf serum in a humidified chamber for 1 hour. Cells were washed 5 
times followed by incubation in 750 pi of a liquid HRP substrate, 3,3’,5,5’- 
tetramethylbenzidine (TMB) to quantify labelled receptors. The supernatant was 
removed to a cuvette and colour change measured spectrophotometrically at 655 nm.
2.11.2 Assaying permeabilised cells
The assay described above was modified to obtain a measure of total receptor 
expression. Cells were washed with HBSS44, fixed and then permeabilised in 
HBSS44 containing 0.1 % Triton X-100 and the assay carried out essentially as for
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cell-surface antibody binding. All solutions contained in addition 0.1 % Triton X- 
100 including the first two wash steps.
2.12 INTRACELLULAR CALCIUM MEASUREMENT BY FLIPR
Transfected cells were replated onto black-walled 96-well plates (Marathon 
Laboratories, London) coated with poly-L-lysine, approximately 18-20 hours post 
transfection. Approximately 24 hours later cell medium was removed and the cells 
incubated in 50-100 pi of 1 pM Fluo-4 acetoxymethyl ester in HBSS with 0.02 % 
Pluronic® F-127 for 30-60 minutes at room temperature. Cells were rinsed 1-2 times, 
140-160 pi of HBSS added and the cells assayed using the Fluorometric Imaging 
Plate Reader system (FLIPR) (Molecular Devices, Winnersh) (Schroeder and 
Neagle, 1996). Cells were excited by light of 488 nm wavelength from a 4 W argon- 
ion laser and the emitted fluorescence passed through a 510 to 570 nm bandpass 
interference filter before detection with a cooled ‘charge coupled device’ (CCD) 
camera (Princeton Instruments). Drug dilutions were prepared in a separate 96-well 
plate. Parameters for drug addition to the cell plate were programmed on the 
computer and delivery was automated through a 96-tip head pipettor. Generally, 
drugs were added in 20-40 pi volumes and mixed twice by automatic pipetting. 5-HI 
was dissolved in DMSO and pre-applied manually or co-applied with 5-HT 
automatically. Data was exported and is presented as peak response (maximum 
fluorescence -  minimum fluorescence) unless otherwise stated.
2.13 OOCYTE RECORDINGS
Adult female Xenopus laevis frogs were obtained from Blades Biological 
(Edenbridge) and housed at Oxford Brookes University (Dr I. Bermudez, Oxford). 
Xenopus oocytes were defolliculated manually after treatment with collagenase type 
I (4 mg/ml in Ca2+-free Barth’s solution) for 1.5 hours at room temperature. 
Plasmids containing receptor coding sequences suspended in distilled water were 
injected into the nuclei of stages V and VI oocytes within 4 hours of harvesting, 
using a Drummond variable volume microinjector (Broomall, PA, USA). After 
injection the oocytes were incubated at 18 °C in a modified Barth’s solution
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containing (mM) (NaCl, 88; KC1, 1; NaHC03, 2.4; Ca(N03)2, 0.3; CaCl2, 0.41; 
MgS(>4, 0.82; HEPES, 15, and 50 mg/1 neomycin (pH 7.6 with NaOH; osmolarity 
235 mosM)). Experiments were performed after 3-5 days of incubation.
Oocytes were placed in a recording chamber and continuously perfused with a saline 
solution containing (mM): NaCl, 115; KC1, 2.5; CaCl2, 1.8, and HEPES, 10 (pH 7.3 
with NaOH; osmolarity 235 mosM) at a rate of ~ 10 ml/min. The perfusion chamber 
had an internal diameter of 3 mm. On some occasions, BaCl2 replaced CaCl2 in the 
saline solution in order to minimise the possible contribution of secondary Ca2+- 
activated Cf currents. Dilutions of agonists in external saline were prepared 
immediately before the experiments and applied by switching between control and 
drug-containing saline using an eight-channel bath perfusion system (BPS-8; ALA 
Scientific, Westbury, NY, USA). The eight channels were controlled by pinch 
valves. 5-HI was dissolved in DMSO, whilst 5-HT was dissolved in water.
Oocytes were impaled by two microelectrodes filled with 3 M KC1 and voltage 
clamped using a Geneclamp 500B amplifier (Axon Instruments) according to the 
method described by Stiihmer (1998). The external saline was clamped at ground 
potential by means of a virtual ground circuit using an Ag/AgCl reference electrode 
and a Pt/Ir current passing electrode. The membrane potential was held at -60 mV. 
Membrane currents were low-pass filtered (four-pole low pass Bessel filter, -3 dB at 
0.3 kHz), digitised (1000 samples/s), and stored on disk for off-line computer 
analysis. All experiments were performed at room temperature.
Ion current amplitudes were measured and normalised to the amplitude of control 
responses induced by the near-maximum effective concentration of 100 pM 5-HT for 
5HT3 receptors. Control responses were evoked alternately, in order to adjust for 
small variations in response amplitude over time. Concentration-response curves 
were fitted to the data obtained in separate experiments and mean ± standard 
deviation of estimated parameters were calculated for n oocytes. Agonist curves 
were fitted according to the equation: I/Imax=l/{l+(EC5o/[agonist])«H}. Curve fitting 
was performed using GraphPad prism.
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2.14 STATISTICAL ANALYSIS
Most of the data analysed statistically was in small samples (n £ 30) and unpaired. 
Firstly, a frequency histogram was produced to assess the distribution of the data. If 
the data appeared approximately normal, a Students t test, a modification of the ‘z* 
test for small samples, was used. Before performing the t test, the Fisher’s test (F 
test) was performed to ensure that the variances of the two samples were not grossly 
different from each other. The ratio between the two variances, with the smaller as 
the divisor, was calculated.
F  = variance! / variance2
The derived value was then looked up in tables of F  with [nr l] degrees of freedom 
on the horizontal axis and [n2-l] on the vertical axis, where nj is from the sample 
with the larger variance. If F  was not significant then a Students t test was used as 
described below. If F  was significant then a non-parametric test should be used.
t test:
t = Imeanj -  mean2l / V [(SE^2 + (SE^2]
where SE = standard error. The t value was then looked up in a table of t values with 
the appropriate degrees of freedom (v) to determine the significance of any 
difference between sample means.
v = (nr l) + (n2-l)
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2.15 MATERIALS
Chemicals and Reagents
All biochemicals were from BDH unless otherwise specified. Agarose, LMP- 
agarose and Lamda HindlW DNA markers were from Gibco. Polyacrylamide for
TW
SDS gels was from Amresco. Amplify and rainbow molecular weight markers 
were from Amersham. Carbamylcholine chloride (carbachol), 5-hydroxytryptamine, 
5-hydroxyindole, EDTA, yeast extract and 3,3’,5,5’-tetramethylbenzidine (TMB) 
were from Sigma. Protein G-sepharose beads were from Calbiochem. Liquid 
scintillation cocktail was from Beckman. All restriction enzymes and reaction 
buffers were from Promega unless otherwise specified. PCR markers, Taq 
polymerase, blue/orange loading dye and calf intestinal alkaline phosphatase (CIP) 
were also from Promega. Pfu was from Stratagene. KOD was from Novagen. T4 
DNA ligase kit was from Roche. Effectene™ transfection reagent was from Qiagen. 
Fluo-4 acetoxymethyl ester and Pluronic® F-127 were from Molecular Probes.
Radioligand Studies
[125I]-a-bungarotoxin, [35S]-Pro-mix and [14C]-methylated protein markers were 
from Amersham. [3H]-GR65630 was from PerkinElmer. GF/A and GF/B glass fibre 
filters were from Whatman. Liquid scintillation cocktail and Fast Turn Cap Poly Q 
Vials were from Beckman. BioRad DC protein assay kit was from BioRad. Semi­
microcuvettes were from Sarstedt.
Cell Culture
All tissue culture media and additives were obtained from Gibco unless otherwise 
specified. Fetal bovine serum was from Sigma. Effectene transfection reagent was 
from Qiagen. FuGENE 6 transfection reagent was from Roche.
E. coli, strain XL-1 blue, were from Stratagene. E. coli, strain MC1061/P3, were 
from Invitrogen.
83
Disposables
Tissue culture dishes (6 and 10 cm diameter) were from Coming. Tissue culture 
plates (96, 24 and 12 well) and tissue culture flasks (75 cm ) were from Nunclon. 
Serological pipettes (10 and 25 ml) and Falcon tubes (15 ml) were from Sarstedt. 
Centrifuge tubes (50 ml) were from Nunc. Stericup filtration systems (0.22 p,m) 
were from Millipore. Black-walled 96 well plates were from Marathon Laboratories.
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CHAPTER 3
Id en tifica tion  o f  an  e n d o p la s m ic  re ticu lu m  
r e ten tio n  s ig n a l in th e  
5 -h y d ro x y try p ta m in e  ty p e  3  r e c e p to r  
su b u n it , 5H T3B
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3.1 Introduction
Two subunits of the 5-hydroxytryptamine type 3 receptor (5HT3R) have been used in 
this study, 5 HT3A (Maricq et al., 1991) and 5 HT3B (Davies et al., 1999; Dubin et a l, 
1999). The 5 HT3A subunit is capable of forming functional homomeric receptors in 
heterologous expression systems. In contrast, the 5 HT3B subunit is not able to form 
functional homomeric receptors. However, the 5 HT3B subunit appears to be able to 
co-assemble with 5 HT3A to generate heteromeric receptors (Davies et al., 1999; 
Dubin et al., 1999; Hanna et al., 2000; Boyd et al., 2002). When expressed alone in 
heterologous expression systems, such as the human embryonic kidney cell line 
(HEK293), the 5 HT3B subunit is retained within the endoplasmic reticulum (ER) 
(Boyd et al., 2002). However, upon co-expression of 5 HT3A and 5HT3B, 5 HT3B is 
expressed on the cell surface in a functional heteromeric receptor complex (Boyd et 
al., 2002).
The release of proteins from the ER is an important quality control checkpoint for 
their cell surface expression. Proteins may be held in the ER by chaperone proteins, 
such as Immunoglobulin binding protein (BiP) and calnexin (Haas and Wabl, 1983; 
Pelham, 1989; Helenius and Aebi, 2001; Schrag et al., 2003), until they have folded 
and assembled correctly resulting in release. These chaperone proteins contain 
certain sequences/motifs which cause them to remain within the ER. They may 
interact with incompletely or incorrectly assembled proteins and prevent their export. 
Recently, a number of ER retention/retrieval motifs have been identified in cell 
surface expressed proteins. These motifs are thought to be exposed when the 
proteins are incompletely or incorrectly folded or assembled, thereby resulting in 
their retention within the ER. The aim of this project was to investigate the 
mechanisms involved in the ER retention of the 5 HT3B subunit.
3.2 Epitope tagged 5HT3A and 5HT3B constructs
Human 5 HT3 subunit cDNAs tagged with the myc (EQKLISEEDL) or HA 
(YPYDVPDYA) epitopes were provided by Dr Christopher Connolly, University of 
Dundee (Boyd et a l, 2002). These subunit constructs contain epitope tags inserted 
between amino acids 5 and 6 of the mature polypeptides and have been shown to be
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functionally silent (Boyd et al., 2002). All further 5 HT3R cDNAs described in this 
chapter were constructed and provided by Dr C. Connolly (see Chapter 2 (Materials 
and Methods), section 2.1.9 for more detail).
3.3 Expression and co-expression of 5HT3A and 5HT3B in mammalian cells
3.3.1 Radioligand binding assay
To study the heterologous expression of the 5 HT3R subunits in mammalian cells, 
human 5HT3A and 5 HT3B subunit cDNAs were introduced into tsA201 cells, a 
subclone of the human embryonic kidney cell line, HEK293, by transient 
transfection. Radioligand binding was performed on cell membrane preparations
'i
using a saturating concentration of the 5 HT3R specific antagonist [ H]-GR65630. 
Specific binding was determined by subtracting ‘non-specific’ binding, performed in 
the presence of 12.5 mM 5-HT, from ‘total’ binding, performed in the absence of 5- 
HT. Specific binding was observed for cells expressing 5HT3A (Figure 3.1). 
However, cells expressing 5 HT3B did not show any specific binding (Figure 3.1). 
Co-expression of 5 HT3B with 5HT3A appeared to decrease the level of [3H]-GR65630 
binding (Figure 3.1).
3.3.2 Functional studies using a FLIPR
The ability of the 5 HT3 subunits to generate functional 5 HT3RS in tsA201 cells was 
examined. Cells were transiently transfected and assayed using a Fluorometric 
Imaging Plate Reader system (FLIPR). Cells, grown on 96-well plates, were loaded 
with the Ca2+-sensitive dye, fluo-4, and responses to the 5 HT3R agonist 
chlorophenylbiguanide (CPBG; 1 p,M) recorded. Ionomycin was added 
approximately two minutes after agonist addition to give a measure of total 
intracellular calcium. In cells expressing 5HT3A alone responses to CPBG, recorded 
as elevations in intracellular calcium, were observed (Figure 3.2A). Untransfected 
cells gave no response to CPBG. Cells expressing 5HT3B alone gave no response to 
CPBG (Figure 3.2B).
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Figure 3.1 Specific [3H]-GR65630 binding to cell membrane preparations o f  tsA201 
cells expressing 5HT3R subunits. Cells were transiently transfected with the 5HT3A 
or 5HT3B subunit alone and together, and binding performed using 12.5 nM [ H]- 
GR65630. A high level of specific binding was observed in cells expressing 5 HT3A. 
No specific binding was observed in cells expressing 5 HT3B. Co-expression of 
5HT3B with 5HT3A decreased the level of binding. Data are means, ± standard error, 
from at least 4 independent experiments performed in triplicate.
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Figure 3.2 Functional assay o f  5HTsa and 5HTis expressed in tsA201 cells using a 
FLIPR. Cells transiently transfected with 5HT3A (A) or 5HT3B (B) and untransfected 
(UT) cells were assayed using a FLIPR. Cells were loaded with Fluo-4 and 
responses to 1 pM CPBG (filled arrow) recorded. Ionomycin was added (unfilled 
arrow) at the end of experiments to give a measure of total intracellular Ca2+. 
Responses, recorded as elevations in intracellular Ca2+, to CPBG were observed in 
cells expressing 5HT3A. Cells expressing 5 HT3B did not produce functional 
responses to CPBG. Traces are averages from 4 wells representative of more than 4 
independent experiments.
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3.3.3 Cell surface expression o f  homomeric and heteromeric 5HT3R
To study the subcellular distribution of the 5 HT3R subunits, intact and permeabilised 
tsA201 cells transiently transfected with tagged subunits were analysed using an 
enzyme-linked antibody binding assay (Section 2.11). The assay involves detection 
of the tagged subunit protein with a primary antibody to the epitope tag. The 
primary antibody is then detected by a secondary antibody conjugated to horseradish 
peroxidase (HRP). A liquid HRP substrate is added which is converted from 
colourless to a blue colour by HRP. Receptor expression is quantified by measuring 
the absorbance of the coloured product spectrophotometrically.
Cells expressing 5HT3A-myc or 5HT3B-myc and untransfected cells were labelled 
with the anti-myc antibody, 9E10. Clear evidence of the cell surface expression of 
5HT3A-myc was observed (Figure 3.3A). In contrast, no cell surface expression of 
5HT3B-myc could be detected, (Figure 3.3A). However, performing the assay on 
permeabilised cells revealed that the 5HT3B-myc protein was expressed, and at a 
level similar to that of 5HT3A-myc, (Figure 3.3A).
The effect of co-expressing 5HT3A with 5 HT3B was examined. Cells were 
transfected with 5 HT3B-HA alone or with 5HT3A-myc and labelled with mAbHA-7 
(anti-HA). When expressed alone, 5HT3B-HA was not detected on the cell surface. 
However, upon co-expression with 5HT3A-myc, 5 HT3B-HA was found to be 
expressed on the cell surface at a level similar to 5HT3A alone (Figure 3.3B).
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Figure 3.3 Expression o f  5 HT3R subunits in transfected tsA201 cells. Cells grown 
on coverslips were transiently transfected with various tagged 5 HT3R subunits. A, 
Cells were labelled with 9E10 (anti-myc antibody) either as intact cell monolayers 
(Cell Surface) or after permeabilisation (Total). A high level of specific cell surface 
9E10 binding was observed upon expression of 5HT3A-myc. No cell surface 9E10 
binding was observed upon expression of 5HT3B-myc. Upon permeabilisation a high 
level of specific binding was observed for both 5HT3A-myc and 5HT3B-myc. B, 
Intact cell monolayers were labelled with mAbHA-7 (anti-HA). 5 HT3B-HA 
expressed alone was not detectable, however, upon co-expression with 5-HT3A-myc 
a high level of surface expression was measured. Data is mean absorbance at 655 
nm, ± standard error, from at least 4 independent experiments performed in triplicate. 
The background signal from untransfected cells has been subtracted.
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3.4 Expression of truncated 5HT3B subunits
To investigate the mechanisms involved in the retention of the 5HT3B subunit and in 
an attempt to identify regions responsible, chimeric subunits were constructed using 
regions of 5HT3A and 5HT3B and were analysed using immunofluorescence by Dr C. 
Connolly (Boyd et al., 2003). These results implicated the C-terminal of 5HT3B in 
ER retention. To determine whether retention signals were present in 5 HT3B a 
number of truncated 5 HT3B subunits were constructed. The rationale for this 
approach was that progressive removal of C-terminal portions would eventually 
remove any retention signals present.
The cell surface expression of a number of the truncated 5 HT3B subunits was 
examined through the use of an enzyme-linked antibody binding assay. Cells were 
transfected with HA-tagged 5HT3A, 5HT3b, 5 HT3B truncated ju st after 
transmembrane domain 1 (5H T 3b(T M 1 )), 5HT3B truncated at residue 267, in between 
Ml and M2, (5H T 3b(2 6 7 ) )  or 5 HT3B truncated just after M2 (5H T 3b(T M 2 )) . Intact 
cell monolayers and permeabilised cells were labelled with mAbHA-7 (anti-HA). 
Labelling of intact cells revealed the presence of 5H T 3b(T M 1 ) and also 5H T 3b(2 6 7 )  
on the cell surface. However 5H T3b(T M 2 ) was not found to be expressed on the cell 
surface (Figure 3.4; Cell Surface). Labelling of permeabilised cells revealed similar 
total levels of expression for all constructs (Figure 3.4; Total). These results 
indicated a role for the region between Ml and M2 in the ER retention of the 5 HT3B 
subunit.
The amino acid sequences of 5HT3A and 5 HT3B between Ml and M2 were aligned 
(Figure 3.5). Alignment of these sequences revealed that the subunits differ by only 
3 residues in this region. 5 HT3B contains an RXR motif (RAR). The RXR motif has 
previously been reported to play a role in the ER retention of a number of other 
receptors (Zerangue et al., 1999; Margeta-Mitrovic et al., 2000; Scott et al., 2001; 
Shikano and Li, 2003).
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Figure 3.4 Expression o f  truncated 5HT3B subunits in transfected tsA201 cells. 
Cells grown on coverslips were transiently transfected with HA-tagged 5 HT3R 
subunits. Cells were labelled with mAbHA-7 (anti-HA) either as intact cell 
monolayers (Cell Surface) or after permeabilisation (Total). Data is mean 
(normalised to level of antibody binding for 5 HT3A-HA), ± standard error, from at 
least 3 independent experiments performed in triplicate. The background signal from 
untransfected cells has been subtracted.
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Figure 3.5 Alignment o f  5HTsa and 5H T^ between transmembrane domains 1 and 
2. Comparison of the homologous regions o f 5HT3A and 5HT3b between 
transmembrane domains M l and M2 revealed that the subunits differ by three 
residues. The residues in 5HT3b incorporate the RAR motif.
3.5 Expression of 5HT3a(CRAR) and 5HT3B(SGER)
To investigate the effects of the RAR motif, a mutant 5HT3A subunit containing 
CRAR, in place of SGER was generated (construct 5HT3a(CRAR)). The subcellular 
distribution of 5HT3a(CRAR)-HA was examined using an enzyme-linked antibody 
binding assay. Cells were transiently transfected with HA-tagged 5HT3a(CRAR) 
alone and co-transfected with 5HT3A-myc or 5HT3B-myc. Levels of mAbHA-7 
binding were quantified for both intact and permeabilised cells. When expressed 
alone, 5HT3a(CRAR)-HA was not detected on the cell surface at a significant level 
(Figure 3.6). This finding provided evidence for the role of RAR as an ER retention 
signal. Co-expression of 5HT3A with 5HT3a(CRAR)-HA resulted in cell surface 
expression of the subunit (Figure 3.6). This result indicated that the mutant subunit 
could fold and assemble correctly when co-expressed with 5HT3A, similar to the 
effect of co-expression of 5HT3A with 5HT3b. Co-expression of 5HT3b with 
5HT3a(CRAR)-HA did not result in cell surface expression of the 5HT3a(CRAR)- 
HA subunit (Figure 3.6). Performing the assay on permeabilised cells revealed that 
the total levels of expression for all subunits tested were approximately the same 
(Figure 3.6).
To assess the role of the RAR motif in 5H T3b, a mutant 5H T 3b subunit was generated 
containing SGER, from 5HT3A, in place of CRAR (construct 5HT3B(SGER)). The
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Figure 3.6 Expression o f 5HT3a(CRAR) in transfected tsA201 cells. Cells grown on 
coverslips were transiently transfected with the mutant 5HT3a(CRAR)-HA subunit 
(alone and with 5HT3A or 5HT3b) and levels of cell surface and total expression 
compared to 5HT3A and 5 HT3B expressed alone. Cells were labelled with mAbHA-7 
(anti-HA) either as intact cell monolayers (Cell Surface) or after permeabilisation 
(Total). Data is mean (normalised to level of antibody binding to 5 HT3A-HA), ± 
standard error, from at least 4 independent experiments performed in triplicate. The 
background signal from untransfected cells has been subtracted. Significance 
determined by Student’s t test (*p<0.05; NS=not significant).
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subcellular distribution of the 5HT3b(SGER) construct was examined using an 
enzyme-linked antibody binding assay. Cells were transiently transfected with myc- 
tagged 5HT3b(SGER) alone and co-transfected with 5 HT3A-HA or 5 HT3B-HA and 
levels of 9E10 (anti-myc) binding quantified for both intact and permeabilised cells. 
When expressed alone, 5HT3B(SGER)-myc was not detected on the cell surface 
(Figure 3.7). Like wild-type 5 HT3B, when 5HT3B(SGER)-myc was co-expressed 
with 5 HT3A it was found to be expressed on the cell surface. When 5HT3b(SGER)- 
myc was co-expressed with 5 HT3B it was not expressed on the cell surface (Figure 
3.7). Levels of 9E10 binding in permeabilised cells were similar for all 
combinations of constructs (Figure 3.7).
3.6 Expression of truncated 5HT3b(SGER) constructs
The failure of 5HT3b(SGER) to reach the cell surface when expressed alone 
suggested the presence of additional retention signals in the 5 HT3B subunit. To 
investigate this, truncated constructs based on 5HT3b(SGER) were generated. 
5HT3b(SGER) was truncated after residue 270 (immediately following SGER), 
termed 5HT3b(SGER)270, and also just after M2, termed 5HT3b(SGER)TM2. The 
subcellular localisation of these subunits was investigated using an enzyme-linked 
antibody binding assay. Both truncated constructs were detected on the cell surface 
at a significant level (Figure 3.8). Wild-type 5HT3B truncated at M2 is not expressed 
on the cell surface (see Section 3.4, Figure 3.4). Performing the assay on 
permeabilised cells revealed that total levels of expression were similar for all 
constructs (Figure 3.8). These results confirm the ability of RAR to act as an ER 
retention signal in the 5HT3B subunit, and suggest that there are further retention 
signals beyond M2.
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Figure 3.7 Expression o f 5HT3b(SGER) in transfected tsA201 cells. Cells grown on 
coverslips were transiently transfected with the mutant 5HT3b(SGER) subunit (alone 
and with 5HT3A or 5HT3b) and levels of cell surface and total expression compared 
to 5HT3A and 5HT3B expressed alone. Cells were labelled with 9E10 (anti-myc) 
either as intact cell monolayers (Cell Surface) or after permeabilisation (Total). Data 
is mean (normalised to level of antibody binding to 5HT3A-myc), ± standard error, 
from at least 4 independent experiments performed in triplicate. The background 
signal from untransfected cells has been subtracted.
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Figure 3.8 Expression o f  truncated 5HT3b(SGER) subunits in transfected tsA201 
cells. Cells grown on coverslips were transiently transfected with myc-tagged 
5 HT3R subunits. Cells were labelled with 9E10 either as intact cell monolayers (Cell 
Surface) or after permeabilisation (Total). Data is mean (normalised to level of 
antibody binding to 5HT3A-myc), ± standard error, from at least 3 independent 
experiments performed in triplicate. The background signal from untransfected cells 
has been subtracted. Significance determined by Student’s t test (*p<0.05;
**/?<o.oi).
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3.7 Discussion
The 5HT3A (Maricq et a l , 1991; Belelli et a l , 1995; Miyake et al., 1995) and 5 HT3B 
(Davies et al., 1999; Dubin ef a/., 1999) subunits were examined in this study. The 
5HT3A subunit is capable of forming functional homomeric receptors in heterologous 
expression systems which exhibit a very low single channel conductance (sub- 
picosiemens (pS)) (Brown et al., 1998), unlike those of native receptors (Hussy et 
al., 1994). The discrepancies in conductance between recombinant heterologous and 
native receptors suggested the possible existence of other 5 HT3R subunits (Fletcher 
and Barnes, 1998). The cloning of the 5 HT3B subunit (Davies et al., 1999) helped to 
explain these differences. A heteromeric receptor composed of 5 HT3A and 5 HT3B 
has a much larger single channel conductance (9-17 pS). When recombinant 5 HT3B 
is expressed in heterologous expression systems, such as Xenopus oocytes or the 
HEK293 cell line, it is observed to modify the receptor kinetics, voltage dependence, 
pharmacology and ion permeability of 5HT3A (Dubin et al., 1999). Heteromeric 
receptors have a lower affinity for 5-HT than homomeric receptors (Davies et al., 
1999; Dubin et al., 1999; Hanna et al., 2000; Boyd et al., 2002). Homomeric 
receptors have a higher permeability to Ca2+ relative to monovalent cations than 
heteromeric receptors (Davies et al., 1999). Unlike 5 HT3A, 5HT3b is not capable of 
forming a functional homomeric receptor (Davies et al., 1999; Dubin et al., 1999; 
Hanna et al., 2000; Spier and Lummis, 2000). When expressed alone, 5 HT3B is 
retained within the ER unless co-expressed with 5 HT3A (Boyd et al., 2002). The 
inability of 5HT3B to reach the cell surface when expressed alone in a heterologous 
expression system has been confirmed in this study. Transient transfection of 5 HT3B 
in mammalian tsA201 cells followed by cell surface antibody labelling revealed that 
5 HT3B was not expressed on the cell surface. However, performing the assay on 
permeabilised cells indicated that the protein was expressed. The ability of 5 HT3A to 
enable 5 HT3B to reach the cell surface was shown by antibody labelling of cell 
surface 5HT3B subunits when co-transfected with 5 HT3A. When expressed alone in 
tsA201 cells and assayed using a FLIPR, 5HT3B did not show functional responses to 
the 5 HT3R agonist, CPBG, providing further evidence that this subunit does not form 
functional homomeric receptors.
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When expressed alone, 5 HT3B did not form a ligand binding site in tsA201 cells and 
membrane preparations from these cells did not bind the 5 HT3R specific antagonist 
[3H]-GR65630. It was previously reported that 5 HT3B expressed alone in tsA201 
cells or Xenopus oocytes could not bind the selective 5 HT3R antagonist [3H]- 
granisetron (Boyd et al., 2002). There are several possible explanations for the lack 
of specific binding to the 5 HT3B subunit. The binding site, which is thought to be 
contained in the N-terminal region, may not be fully formed in the ER, and, as 
described previously, 5HT3B is ER-retained unless 5 HT3A is present. However, 
studies performed with the nAChR, a member of the ligand-gated ion channel 
(LGIC) family that is structurally related to the 5 HT3R, have shown that the ligand 
binding domain is formed in the ER (Mitra et al., 2001). It has also been reported 
that some 5HT3A receptors retained in the ER can bind [3H]-granisetron (Green et al., 
1995) suggesting that the 5HT3R ligand binding site may also be formed in the ER. 
A second possibility for the lack of binding to 5 HT3B may be that the subunit cannot 
form a ligand binding site by itself. The 5 HT3B subunit might only be able to 
contribute to the ligand binding sites in heteromeric receptor complexes with 5HT3A. 
Drawing analogies with other members of the LGIC family it is likely that ligand 
binding sites are formed at different subunit interfaces. Ligand binding sites of the 
5 HT3R may be present at the 5HT3a/5HT3b subunit interface or at the 5HT3a/5HT3a 
subunit interface. Formation of the nAChR binding site is thought to require the 
contribution of a ‘principal’ binding site from one subunit and a ‘complementary’ 
binding site from another subunit (Changeux et al., 1992; Karlin and Akabas, 1995). 
As 5HT3B cannot form a binding site by itself it may lack the principal binding site, 
but contain a complementary binding site. It is evident that 5HT3B does contribute to 
ligand binding, as the pharmacological properties of heteromeric receptors differ 
from those of the homomeric 5HT3aR (Dubin et al., 1999). The 5HT3A subunit must 
possess and contribute the principal ligand recognition and binding site (Boess et al., 
1997; Hope et al., 1999; Spier and Lummis, 2000; Steward et a l, 2000).
The cell surface expression of multimeric protein complexes such as the 5 HT3R 
requires the proper folding, assembly and trafficking of the constituent subunits. 
Protein expression is tightly regulated by mechanisms such as ER retention, to 
prevent cell surface expression of monomers and incompletely or incorrectly 
assembled complexes. The ER retention of the 5HT3B subunit was investigated in
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this study. ER retention is an important quality control checkpoint; protein subunits 
must be correctly folded and assembled in order to exit. Studies of nicotinic receptor 
assembly suggest that exit from the ER is an important checkpoint for controlling 
receptor stoichiometry (Blount et al., 1990). ER resident chaperone proteins such as 
immunoglobulin binding protein (BiP) and calnexin interact with incompletely 
folded proteins, and through the ER localisation motifs within them, prevent ER exit. 
Both 5HT3A and 5 HT3B are reported to interact with BiP and calnexin (Boyd et al.,
2002). In particular, 5HT3A and 5 HT3B subunits which are not fully glycosylated, 
and are therefore unsuitable for cell surface expression, are shown to interact with 
BiP and calnexin (Boyd et al., 2002). Previous studies imply that 5 HT3B requires 
assembly with 5HT3A to exit from the ER (Boyd et al., 2002).
Membrane proteins themselves can contain ER retention/retrieval signals, as recent 
studies on a number of receptors have illustrated (Zerangue et al., 1999; Bichet et al., 
2000; Margeta-Mitrovic et a l , 2000). The masking of these motifs by assembly with 
another subunit, interactions with other proteins or phosphorylation may regulate the 
forward trafficking of such proteins (Zerangue et al., 1999; Bichet et al., 2000; 
Margeta-Mitrovic et a l , 2000).
To investigate the mechanisms involved in the retention of the 5HT3B subunit and in 
an attempt to identify regions responsible, chimeric subunits between 5 HT3A and 
5HT3B were constructed and analysed using immunofluorescence by Dr C. Connolly, 
University of Dundee (Boyd et al., 2003). One chimera, composed of 5 HT3A up to 
and including Ml fused to the remainder of 5 HT3B (5HT3A-3b), was found not to be 
capable of cell-surface expression (Boyd et al., 2003). However, a second chimera 
composed of 5 HT3B up to M3 fused to the remainder of 5 HT3A (5HT3b-3a)> was 
found to be expressed on the cell surface (Boyd et a l ,  2003). These findings 
demonstrate the presence of an inhibitory element involved in ER retention of the 
5 HT3B subunit beyond Ml of 5HT3B.
To determine whether retention signals were present in 5HT3B a number of truncated 
5 HT3B subunits were constructed. The rationale for this approach was that removal 
of C-terminal portions would eventually remove any retention signals and thereby 
result in cell surface expression. Analysis of the cellular localisation of the truncated
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5 HT3B subunits implied involvement of the region between Ml and M2 in the 
retention of 5HT3B. Alignment of the sequences in this region led to the 
identification of a potential RXR motif in 5 HT3B, RAR, which had previously been 
identified as an ER retention motif in a number of other receptors (Zerangue et a l , 
1999; Margeta-Mitrovic et al., 2000; Standley et a l, 2000; Scott et a l,  2001).
Introduction of this potential ER retention motif from 5 HT3B to the homologous 
position in 5 HT3A (5HT3a(CRAR)), prevented cell surface expression, thereby 
providing evidence for its role in ER retention. Like 5 HT3B, 5HT3a(CRAR) can 
reach the cell surface when co-expressed with 5 HT3A, but not 5HT3B. The reciprocal 
mutation was generated in 5 HT3B replacing CRAR with the homologous amino acids 
from 5HT3A creating 5HT3b(SGER). This mutant also did not reach the cell surface 
indicating the presence of additional retention signals downstream of M2.
To provide direct evidence for ‘RAR’ as a retention signal in 5 HT3B, the 
5HT3b(SGER) construct was truncated just after SGER (residue 270) and also just 
after M2. Both of these constructs were expressed on the cell surface. Together with 
the observation that wild-type 5HT3B truncated at M2 is not expressed on the cell 
surface, this data suggests that the RAR motif is capable of causing the retention of 
the 5HT3B subunit in the ER.
In an attempt to determine how the identified signal might be overcome, 
5HT3a(CRAR) and 5HT3b(SGER) were co-expressed and their cellular distribution 
determined by immunofluorescence. Neither subunit reached the cell surface 
suggesting that there is no direct masking between the homologous domains, 
CRAR/SGER (Boyd et a l,  2003). Other regions are likely to be required for 
masking of the motif which are likely to be provided by another neighbouring 
subunit.
To determine whether direct subunit interactions in the M l-M2 region mask the ER 
retention signal, constructs consisting of M l-M2 were generated for both 5 HT3A and 
5 HT3B (Boyd et a l,  2003). Co-expression of these with 5 HT3B did not result in its 
surface expression, suggesting that a direct interaction in this region alone does not 
mask the retention signal. The subunits were however shown to interact in this
103
region by co-immunoprecipitation following cross-linking. A number of other 
proteins were observed to co-immunoprecipitate with M l-M2 constructs, and may be 
potential novel interacting proteins (Boyd et a l , 2003).
The mechanism by which the RXR motif in 5HT3B is masked, resulting in the cell 
surface expression of the 5HT3B subunit is unclear. It has been shown that co­
expression of 5HT3B with 5 HT3A is necessary to allow exit of 5 HT3B from the ER 
suggesting that 5 HT3A is responsible for masking of the motif. From the data 
presented here, a region beyond M2 in 5 HT3A is predicted to mask the motif. Studies 
with the 5HT3a(CRAR) mutant suggest that the motif is masked by a neighbouring 
5 HT3A subunit. Further studies reported by Boyd et al., 2003 suggest that a region 
beyond M3, possibly the large intracellular loop between M3 and M4, may be 
responsible for masking the motif. This is based upon the observation that the 
5HT3B-3A chimera which, despite containing the RAR motif, is expressed on the cell 
surface. It may not be a direct interaction between 5 HT3A and 5HT3B that masks the 
motif; it may be that interaction of the subunits induces a conformational change that 
buries the motif and thereby allows cell surface expression. It may also be possible 
that association of 5 HT3A and 5 HT3B leads to the recruitment of an additional 
factor/protein which may mask the motif.
The RXR motif has been identified in a number of other receptors, for example the 
ATP-sensitive potassium ( K a t p )  channel (Zerangue et a l , 1999), the GABAb G 
protein-coupled receptor (Margeta-Mitrovic et a l , 2000) and the Kainate receptor 
(Jaskolski et a l ,  2004). The masking of the motif by a number of different 
mechanisms leads to the cell surface expression of subunits in fully assembled 
receptor complexes. The mechanism by which the unmasked motif retains proteins 
has not yet been determined.
The RXR motif differs from the more well characterised ER retention/retrieval 
signals such as KKXX and KDEL (Teasdale and Jackson, 1996). Unlike the KKXX 
motif, for example, which only functions when situated three residues from the C- 
terminus, the RXR motif functions at the N- or C- terminus of membrane proteins as 
well as in intracellular regions, and no specific spacing is required (Zerangue et a l , 
1999; Shikano and Li, 2003). The middle residue of the motif was reported to
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preferentially be a large neutral or positively charged amino acid (Zerangue et al., 
1999) but other data contradicts this finding (Schutze et a l , 1994).
The RXR motif has been shown to be regulated by phosphorylation. Protein kinase 
C (PKC) and protein kinase A (PKA) phosphorylation of serine residues flanking an 
RXR motif in the NR1 subunit of the NMD A receptor have been shown to suppress 
ER retention (Scott et al., 2001; Scott et al., 2003). There are no potential 
phosphorylation sites close to the RAR motif in 5HT3B-
Another proposed mechanism by which the RXR motif may function is through 
interactions with intracellular proteins. A type I PDZ-binding domain in the NR1 
subunit of the NMD A receptor is reported to suppress ER retention (Standley et al., 
2000; Scott et a l, 2001). Two isoforms of the 14-3-3 protein (e and £) have been 
shown to interact specifically with the RXR motif in the K a t p  channel (Yuan et a l,
2003). The binding of 14-3-3 is proposed to mediate ER release (Yuan et a l,  2003). 
A few potential interacting proteins were identified by co-immunoprecipitation 
following cross-linking with the M1-M2 region of 5HT3B (Boyd et al., 2003).
The mechanism behind retention in the ER via the unmasked RXR motif is not 
known. The KKXX motif is thought to function through its interactions with the 
coatomer protein (COPI) complex (Teasdale and Jackson, 1996). Recent studies 
have reported an interaction between the COPI vesicle coat and RXR (Yuan et a l,  
2003; Hermosilla et a l,  2004) and this may explain the ER localisation of proteins 
bearing this motif.
In summary, an ER retention motif of the RXR type has been identified in the 5HT3B 
subunit which can be overcome by co-expression with the 5HT3A subunit. The motif 
is sufficient to cause retention of the subunit, but is not the only factor involved in 
the ER retention of the subunit. Studies have implied the presence of additional 
mechanisms or retention signals in 5 HT3B involving regions beyond the M2 domain 
of the subunit.
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3.8 Future directions
It would be particularly interesting to continue this work and determine how the 
identified ER retention motif functions. Whilst it is clear that co-expression with 
5HT3A results in masking of the identified motif, as cell surface expression is 
observed, it is not clear how the motif is masked. The 5HT3A subunit may mask the 
motif through a direct interaction or may induce conformational changes resulting in 
masking indirectly. Determining how the RXR motif causes ER retention would 
also be interesting. Recent studies have shown that the RXR motif is capable of 
interacting with the COPI family of proteins (Yuan et al., 2003; Hermosilla et al.,
2004) which may explain the ER localisation of proteins containing this motif.
Proteins that interact with the RXR motif could be identified using a system such as 
the yeast 2-hybrid system. Cross-linking and co-immunoprecipitation experiments 
using 5 HT3A and 5 HT3B ‘M l-M2’ constructs identified a few potential interacting 
proteins (Boyd et al., 2003) which could be further characterised.
It would be interesting to determine why the 5 HT3B-3A chimera, which contains the 
RXR motif, is expressed on the cell surface whilst 5HT3a(CRAR) is not. The 
5HT3b(SGER) mutant could be used to generate a series of truncated subunits and 
their cell surface expression assayed to identify the next N-terminal ER retention 
signal present in the 5 HT3B subunit.
Some of the work presented in this chapter has been published: Cell Surface 
Expression of 5-Hydroxytryptamine Type 3 Receptors is Controlled by an 
Endoplasmic Reticulum Retention Signal. G. W. Boyd, A. I. Doward, E. W. 
Kirkness, N. S. Millar and C. N. Connolly Journal o f  Biological Chemistry 2003, 
278 (30), 27681-27687.
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CHAPTER 4
E ffe c ts  o f  5 -h y d r o x y  in d o le  o n  t h e  
5-H T -in d u ced  r e s p o n s e s  o f  
m o u s e  a n d  h u m a n  5H T 3A r e c e p t o r s
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4.1 Introduction
5-hydroxyindole (5-HI), the aromatic moiety of 5-hydroxytryptamine (5-HT) (Figure
4.1), is known to potentiate the ion current of native mouse 5HT3 receptors 
(m5 HT3R) in N1E-115 neuroblastoma cells (Kooyman et a l , 1993; Kooyman et a l , 
1994; van Hooft et a l, 1997). At low millimolar concentrations 5-HI is thought to 
potentiate currents and slow the ion current decay by binding to an allosteric site on 
the 5HT3R which stabilises the open state. At higher millimolar concentrations 
(greater than 10 mM) 5-HI blocks the 5 HT3R, and this effect is thought to be 
mediated by a competitive interaction with the agonist binding site (Kooyman et al., 
1994).
HOHO'
NH2
5-Hydroxytryptamine (5-HT) 5-Hydroxyindole (5-HI)
Figure 4.1 Chemical structures o f  5-hydroxytryptamine (5-HT; serotonin) and 5- 
hydroxyindole (5-HI).
There is high sequence similarity in the N-terminal ligand-binding domain between 
the 5 HT3A subunit of different species, but differences in pharmacological properties 
are observed. For example, d-tubocurarine is 1800-fold more potent at mouse than 
human 5 HT3RS (Hope et a l, 1999) and 2-Me-5-HT, a full agonist on human 5 HT3RS 
acts only as a partial agonist on mouse 5 HT3R (Miyake et al., 1995).
In addition to potentiating the mouse 5HT3R, 5-HI has been shown to potentiate 
homomeric a l  neuronal nicotinic acetylcholine receptors (nAChRs) (van Hooft et
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al., 1997; Gurley et al., 2000; Zwart et al., 2002). There is approximately 33% 
sequence homology between the ligand binding domains of the 5 HT3R and a  7 
nAChR and cross-reactivity of agonists and antagonists has been reported (Machu et 
al., 2001; Macor et al., 2001; Broad et al., 2002).
4.2 Preliminary studies performed at Eli Lilly
The work presented in this chapter is in collaboration with a research group based at 
Eli Lilly, Windlesham, UK. Studies carried out at Eli Lilly confirmed the 
potentiating effects of 5-HI on mouse 5 HT3A (m5HT3A) receptors stably expressed in 
HEK293 cells using a Fluorometric Imaging Plate Reader (FLIPR) assay 
(unpublished result; see Section 4.5.1, Figure 4.6). However, HEK293 cells stably 
expressing the human 5 HT3A (1i5HT3a) subunit were not potentiated by 5-HI. The 
aim of this project was to investigate this difference between 5HT3AR species 
variants and to determine the binding site of 5-HI. Defining the 5-HI binding site 
might be useful for rationalisation of drug design with the aim of generating a l  
nAChR selective compounds/potentiators which might be useful in the treatment of 
neurological disorders (Lloyd and Williams, 2002; Maelicke and Albuquerque, 
2000).
Unpublished studies, performed at Eli Lilly, using a7/5HT3A chimeric subunits 
suggested that the effects of 5-HI are mediated through the N-terminal extracellular 
domain of the receptor subunit. Epibatidine-induced responses in HEK293 cells 
stably expressing a human a  7/mouse 5 HT3A chimera ( a l  up to transmembrane 
region 1 joined to the C-terminal of mouse 5HT3A) are potentiated by 5-HI, as are (to 
a lesser extent) cells expressing a human a7/human 5 HT3A chimera suggesting that 
the extracellular N-terminal domain is responsible for mediating the effects of 5-HI.
4.3 Construction of chimeric 5HT3aR subunits
In order to confirm whether 5-HI acts by binding to the N-terminal domain, chimeric 
subunits of mouse and human 5HT3aR were constructed. A chimeric subunit cDNA 
was generated containing the extracellular N-terminal domain of h5HT3A fused to the
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transmembrane and intracellular domains of m5 HT3A (h/m5HT3A chimera) (Figure
4.2). A second, similar chimeric subunit cDNA containing the extracellular N- 
terminal domain of m5HT3A fused to the transmembrane and intracellular domains of 
h5HT3A (m/h5HT3A chimera) was also constructed (Figure 4.2). The long splice 
variant of mouse 5 HT3A (m5 HT3A(L)) was used in construction of these chimeras. 
The construction of these chimeras is detailed in Chapter 2, Section 2.2. If 5-HI was 
acting via the N-terminal region it was predicted that agonist-induced responses of 
the m/h5 HT3A chimera would be potentiated whilst the h/m5 HT3A chimera would 
not. It was hoped that these chimeras would be the basis for constructing further 
chimeras to determine residues and regions of the receptors responsible for 
conferring 5-HI sensitivity.
4.4 Expression of 5HT3A chimeras in tsA201 cells
4.4.1 Radioligand binding studies
To confirm that the chimeric subunits were capable of forming correctly folded 
ligand binding sites, radioligand binding studies using the 5 HT3R specific 
radioligand [3H]-GR65630 were performed, on membrane preparations o f cells 
transiently transfected with the human, mouse or chimeric 5 HT3aRs. Specific 
binding, determined by subtracting binding performed in the presence of a high 
concentration of 5-HT from that performed in its absence, was observed for the 
mouse, human and m/h and h/m5HT3A chimeras (Figure 4.3). Initially, no specific 
binding was detected for the h/m5HT3A chimera. Binding was also not detected with 
a h5HT3A subunit containing a BamHl site which had been introduced to enable 
construction of the h/m5 HT3A chimera. To investigate the reason for the lack of 
specific [ HJ-GR65630 binding, the amino acid sequences where the BamHl site was 
introduced by site-directed mutagenesis in h5 HT3A and the equivalent region in the 
h/m5HT3A chimera were examined. The mutagenesis had resulted in the substitution 
of a glycine (G) residue for a valine (V) residue which was found to be conserved
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M1 M2 M3 M4
mouse/human 
5HT3A chimera
Figure 4.2 Chimeric 5HT3A subunits. The mouse/human 5 HT3A chimera 
consisted of the extracellular N-terminal domain of the mouse 5HT3A subunit fused 
to the transmembrane and intracellular domains of the human 5HT3A subunit. The 
human/mouse 5HT3A chimera consisted of the extracellular domain of the human 
5 HT3A subunit fused to the transmembrane and intracellular domains of the mouse 
5 HT3A subunit. (Ml-M4=transmembrane domains)
m  human 5HT3A 
mouse 5HT3A
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Figure 4.3 Specific [SH]-GR65630 binding to chimeric 5HT3aRs expressed in 
tsA201 cells. Cells were transiently transfected with wild-type and chimeric 5HT3A 
subunits and binding performed on cell membrane preparations using 12.5 nM [3H]- 
GR65630. For brevity, chimeras are referred to using the Greek letter, chi (x). 
Specific binding data to cell membrane preparations are means, ± standard error, 
from 4 to 8 experiments performed in triplicate.
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between species. An alignment of the amino acids in this region in the different 
constructs is shown below.
Mouse 5 HT3A F Y V I I R
Human 5HT3A F Y V V I R
Human 5HT3A (BamRI) F Y 6 I L R
Human (ita/wHI)/mouse 5HT3A chimera F Y 6 I I R
Mouse/human 5HT3A chimera F Y V I L R
Corrected human/mouse 5HT3A chimera F Y V I I R
Using site-directed mutagenesis the glycine residue was replaced by the conserved 
valine residue in the h/m5 HT3A chimera. Radioligand binding was performed with 
[3H]-GR65630 and specific binding was observed for the h/m5HT3A chimera at a 
level not significantly different from mouse, human or m/h5HT3A chimera (Figure
4.3).
4.4.2 Metabolic labelling and immunoprecipitation
Cells (tsA201) were transiently transfected with the chimeric subunit cDNAs. 
Metabolic labelling and immunoprecipitation were performed on transfected cells to 
confirm expression of subunit protein. An antibody which recognises the 
extracellular domain of the mouse 5HT3aR (pAbl20; Spier et al., 1999), and an 
antibody which recognises a region within the intracellular loop of both the mouse 
and human 5 HT3aR (pAb5HT3; Turton et al., 1993) were used to detect wild-type 
and chimeric subunits.
Specific bands were detected for both chimeras and wild type subunits when 
immunoprecipitated with pAb5 HT3. Specific bands were detected for the m5HT3AR 
and m/h5 HT3A chimera with pAbl20 (Figure 4.4). The molecular weights of the 
chimeric subunits were predicted from their amino acid sequences using the Protein 
Inform ation Resource at G eorgetow n U niversity  M edical Center 
(http://pir.georgetown.edu/pirwww/search/comp_mw.shtml). The wild type and
113
pAb120 pAb5HT3A
66kDaH
46kDa-
< <
CO COh- I-
X XIf) if)
SI E
<COH
Xif)
E
£
oo
< <
CO CO
H h-
X Xif) if)sz E
<COI—
XIf)
E
Figure 4.4 Metabolic labelling and immunoprecipitation o f 5 H T R  chimeric 
subunits. Heterologous expression of 5 HT3aR chimeric subunits transiently trans­
fected in tsA201 cells. Cells were metabolically labelled, detergent-solubilised and 
the lysates immunoprecipitated with polyclonal antibodies against the extracellular 
domain of 5HT3A (pAbl20) and against a region within the intracellular loop 
between M3 and M4 (pAb5HT3). Specific immunoreactive bands were detected for 
each wild type and chimeric subunit. Positions of molecular weight markers are
indicated. This figure is representative of 3 similar experiements.
chimeric subunits were predicted to have an approximate molecular weight of 56 
kDa. The bands detected were as the approximate predicted size.
4.4.3 Functional characterisation by intracellular calcium (FLIPR) assay
To confirm that the chimeric subunits were capable of forming functional receptors 
they were transiently transfected into tsA201 cells and assayed by an intracellular 
calcium (FLIPR) assay. Transfected cells were replated in a 96-well plate, loaded 
with the Ca -sensitive dye, Fluo-4, and agonist-induced changes in intracellular 
calcium recorded. Both chimeric subunits showed agonist-induced (5-HT and 
CPBG) increases in intracellular Ca indicating that they had formed functional 
receptors (Figure 4.5).
4.5 Effects of 5-HI examined by intracellular calcium (FLIPR) assay
4.5.1 Studying the effects o f  5-HI on 5HT3A in stably transfected HEK293 cells
The potentiating effect of 5-HI on the 5-HT-induced responses of the m5 HT3AR, and 
the lack of effect on the 1i5 HT3aR, were confirmed in HEK293 cells stably 
expressing the mouse or human 5HT3AR subunit (Figure 4.6). The m 5 HT3AR 
responses, measured as agonist-induced changes in intracellular calcium using a 
FLIPR, were potentiated by approximately 100%.
4.5.2 Studying the effects o f  5-HI on 5HT3A in transiently transfected HEK293 cells
HEK293 cells were transiently transfected, using the FuGENE transfection reagent, 
with the human or mouse 5 HT3AR. The effects of 5-HI on 5-HT-induced responses, 
recorded as agonist-induced changes in intracellular calcium, were studied using a 
FLIPR. Co-application or pre-incubation (5 minutes) of 1 mM 5-HI inhibited the 5- 
HT-induced responses of both the human and mouse 5HT3aR (Figure 4.7). The lack 
of potentiation of the ui5 HT3aR by 5-HI was unexpected because (as described 
above, Sections 4.2 and 4.5.1) the responses of the m5 HT3AR, stably expressed in 
HEK293 cells, were potentiated by 5-HI.
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Figure 4.5 Functional study o f  wild-type and chimeric 5HT3A subunits, expressed
in tsA201 cells, using a FLIPR. Cells were transiently transfected with the wild-type 
mouse or human 5HT3A subunits or the chimeric 5HT3A subunits, and responses to 
10 pM  5-HT assayed using a FLIPR. Traces are average changes in 
fluorescence/baseline fluorescence (± standard error every 10 seconds) from at least 
6 wells, of cells loaded with the Ca -sensitive dye, Fluo-4, from a representative 
experiment. Both the h/m5HT3A chimera and the m/h5HT3A chimera were observed 
to form functional homomeric receptors.
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Figure 4.6 Effect o f 5-HI on 5HTu receptors stably expressed in HEK293 cells. 
Concentration-response curves of 5-HT alone or with 5-HI obtained from 
recombinant mouse and human 5HT3ARs stably expressed in HEK293 cells. 
Responses are expressed relative to maximal (30 pM) 5-HT control responses. 
Traces represent mean ± standard error of 8 experiments. 5-HI potentiated responses 
mediated by mouse 5HT3ARs, but had no effect on human 5HT3ARs stably 
transfected in HEK293 cells. Goodness of curve fits: Mouse (control, R2=0.9930; 
+5-HI, R2=0.9985); Human (control, R2 = 0.9984; +5-HI, R2 = 0.9996). Insets show 
example traces upon application of 10 pM 5HT in the presence (blue) or absence 
(red) of 1 mM 5-HI. Addition of buffer alone is shown by a black trace. Horizontal 
axis is time (72 seconds); Vertical axis is fluorescence units (7100 units for mouse 
and 15000 for human).
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Figure 4.7 Effect o f  5-HI on 5HT3A receptors transiently expressed in HEK293 
cells. Concentration-response curves of 5-HT alone or with 5-HI obtained from 
recombinant mouse and human 5HT3ARs transiently transfected in HEK293 cells. 
Responses are expressed relative to maximal (30 pM) 5-HT control responses. 
Traces represent mean ± standard error of 10 experiments. 5-HI did not potentiate 
mouse or human 5HT3A transiently transfected in HEK293 cells. Goodness of curve 
fits: Mouse (control, R2=0.9963; +5-H1, R2=0.9938); Human (control, R2 = 0.9995; 
+5-HI, R2 = 0.9968). Insets show example traces upon application of 10 uM 5HT in 
the presence (blue) or absence (red) of 1 mM 5-HI. Addition of buffer alone is 
shown by a black trace. Horizontal axis is time (60 seconds); Vertical axis is 
fluorescence units (6100 units for mouse and 12 0 0 0  for human).
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To ensure that the responses observed were not saturating the fluo-3 fluorescent dye 
used, and thereby obscuring any potentiation occurring, the concentration of Ca2+ in 
the assay buffer (Tyrodes) was reduced. The Tyrodes buffer routinely used 
contained 2.5 mM Ca . Tyrodes buffer containing Ca concentrations of 0.1 mM 
and 0.5 mM were tested. A decrease in the concentration of Ca2+ in the Tyrodes 
buffer resulted in a decrease in the size of the responses recorded, but no potentiation 
was observed. Ionomycin, which gives a measure of total cellular Ca , was added 
near the end of experiments to re-confirm that the responses observed were not 
saturating the fluorescent dye.
Although addition of 5-HI did not potentiate the peak of the 5-HT induced responses 
of the m5HT3AR as had been expected from previous studies, the ‘decay’ of the 
responses was slowed compared to control responses, indicating that 5-HI was 
having an effect on the receptor. It has previously been reported that 5-HI decreases 
the rate of desensitisation of the 5HT3R-mediated ion current in N1E-115 mouse 
neuroblastoma cells (Kooyman et al., 1993). The decay of the responses of the 
1i5HT3aR were not affected by 5-HI. This effect is studied further in Section 4.8.3.
4.6 Effects of 5-HI on 5HT3aRs expressed in Xenopus oocytes
The effects of 5-HI on 5HT3ARs expressed in oocytes were investigated to confirm 
the previously observed species-specific effects of 5-HI in an alternative assay.
4.6.1 Optimisation o f experimental conditions
To examine the functional properties of 5HT3RS in Xenopus oocytes, cDNA (2 ng) 
encoding the human or mouse 5HT3aR, resuspended in water, was injected per 
oocyte. Application of 5-HT induced large currents (about 40 pA) which were non­
desensitising. Typical responses are illustrated in figure 4.8B. The amount of cDNA 
injected was varied; with 0.2 ng/oocyte, large responses with the same kinetics as 
with the higher DNA concentration were observed, with 0.04 ng/oocyte responses 
could not be detected. All further experiments were carried out using 0.2 ng 
DNA/oocyte. The concentration-response curves for 5-HT were independent of the 
amount of DNA injected. Initial recordings were carried out in a saline solution
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Figure 4.8 Functional responses in Xenopus oocytes injected with 5HT3A subunit 
cDNA. A, Concentration-response curves of 5-HT obtained from oocytes expressing 
mouse and human 5 HT3aR yielding estimates of EC50 0.74 ± 0.004 pM and 0.8 ± 
0.002 (liM respectively, and Hill coefficient (nH) 2.4 ± 0.5 and 2.4 ± 0.2. All current 
amplitudes are normalised to the 100 pM 5-HT response, ± standard error. Each set 
of data points was obtained from the same oocyte, repeated 4 times with different
a
oocytes. Goodness of fit (R ) is indicated. B, Examples of the currents obtained 
with application of 10 pM 5-HT in Xenopus oocytes expressing the human and 
mouse 5HT3aRs. Application of 5-HT induced large, non-desensitising currents.
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containing barium. Replacing barium in the saline solution with calcium did not 
affect responses and so all further experiments were carried out using saline solution 
containing calcium. Barium is often used in preference to calcium to minimise the 
contribution of endogenous Ca -activated chloride channels.
Concentration-response curves were measured for the mouse and human 5 HT3aR 
expressed in oocytes. The normalised data are shown in figure 4.8A. Fitting a 
concentration-response curve (Equation: i/imax = l/{l+(EC 5o/[agonist])nH}) to the 
m5 HT3AR data yielded estimates of EC50 and Hill coefficient ( « h )  of 0.74 ± 0.004 
pM and 2.4 ± 0.5 respectively, and the 1i5HT3aR: 0.8 ± 0.002 pM and 2.4 ± 0.2 
(Figure 4.8A).
4.6.2 Effects o f 5-HI on human and mouse 5HT3aRs expressed in Xenopus oocytes
Application of a 20% effective concentration (EC20) of 5-HT (0.4 and 0.6 pM for 
mouse and human 5 HT3aRs respectively) to oocytes expressing the 5 HT3aRs evoked 
transient inward currents, whereas application of 1-10 mM 5-HI did not. Co­
application of increasing concentrations of 5-HI with an EC20 of 5-HT had no 
potentiating effect on the peak amplitude of the 5-HT-induced ion currents of either 
the mouse or human 5 HT3aR. Example traces illustrating currents obtained upon co­
application of 1 mM 5-HI with an EC20 of 5-HT are shown for mouse and human 
5HT3A (Figure 4.9A). At higher concentrations of 5-HI the 5-HT-induced responses 
were inhibited. Fitting an inhibition curve to the data yielded IC50 estimates of 4.5 ± 
0.09 mM for mouse and 1.8 ± 0.04 mM for human 5 HT3aR (Figure 4.10).
5-HI was also co-applied with 5-HT at an Emax concentration (10 pM) to oocytes 
expressing the m5HT3AR. Example traces are shown (Figure 4.9B). 5-HI did not 
potentiate the 5-HT-induced ion currents. When 5-HT was used at Emax, the 
inhibition of 5-HT-induced currents by 5-HI occurred at higher concentrations 
compared to when 5-HI was used at EC20. Fitting an inhibition curve to the data 
yielded an estimate for IC50 of 24 ± 1.01 mM (Figure 4.10). These results suggest 
that at higher concentrations 5-HI interacts in a competitive manner, as has been 
previously suggested (Kooyman et al., 1994).
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Figure 4.9 Example traces showing the effects o f  5-HI on 5HT$a expressed in 
Xenopus oocytes. A, Application of 5-HT at an EC20 induces ion currents in oocytes 
expressing either mouse or human 5 HT3A. Co-application of 1 mM 5-HI with an 
EC20 of 5-HT has no effect on 5-HT-induced ion currents. B, Co-application of 1 
mM 5-HI with an Emax of 5-HT. These traces are typical traces representative of 
several experiments.
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Figure 4.10 Effect o f  5-HI on 5HT3A receptors expressed in Xenopus oocytes. 
Concentration-response curves of 5-HI co-applied with a fixed concentration of 5- 
HT. Each set of data points was obtained from the same oocyte, repeated 3 times 
with different oocytes. Data are mean percentage of control response ± standard 
error. Co-application of 5-HI with an EC20 of 5-HT inhibits 5-HT-induced ion 
currents in oocytes expressing mouse or human 5 HT3A, with IC50S 4.5 ± 0.09 and 1.8 
± 0.04 mM respectively. When 5-HI is co-applied with an Emax concentration of 5- 
HT to oocytes expressing m5 HT3A, the inhibition by 5-HI occurs at a higher 
concentration (IC50 of 24 ± 1.01 mM). Goodness of curve fits: mouse (0.6 pM 5HT), 
R2=0.9466; mouse (10 (iM 5HT), R2=0.6872; human, R2=0.9227.
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There were no significant effects of 5-HI on the decay kinetics of the 5 HT3aRs 
expressed in oocytes. The 5-HT application time was increased from 10 to 75 
seconds to ensure that any differences could be measured, but no significant effects 
were observed (data not shown).
4.7 Splice variants of the mouse 5 HT3aR subunit
The stable HEK293 cell line which showed potentiation in the presence of 5-HI 
expresses the short splice variant of the mouse 5 HT3A subunit (m5 HT3A(s)). 
Transiently transfected HEK293 cells and oocytes which were not potentiated by 5- 
HI express the long splice variant of the mouse 5 HT3A subunit (m5HT3A(L))- The 
long m5 HT3A splice variant differs from the short by an additional 6  amino acids in 
the large intracellular loop between transmembrane regions 3 and 4 (Figure 4.11). 
This difference is reported to have little effect on the pharmacological properties of 
the receptors, although differences in the efficacy o f the agonist 2-Methyl-5- 
hydroxytryptamine have been reported (Niemeyer and Lummis, 1998). In the human 
genome only a single functional splice variant of the 5 HT3A subunit has been 
detected (5 HT3a(s)) (Miyake et al., 1995). It was thought that the reason for 
contradictory results observed for the m5HT3AR might be due to the use of different 
splice variants.
5HT3A(S) 375FQANKTDDCS_________ AMGNHCSHVG
5HT3A(L) 375f q a n k t d d c s g s d l l p a m g n h c s h v g
Figure 4.11 Alignment o f  the partial amino acid sequence from  the large 
intracellular loop o f  the mouse 5HT3A(S) and 5HTsa(L) subunits.
To examine whether differences in the ability of 5-HI to potentiate the mouse 
5 HT3aR could be attributed to the differential splicing of the subunit, Xenopus 
oocytes were injected with m 5 HT3A(s> (obtained from Dr Sarah Lummis). 
Application of 5-HT to oocytes expressing the m 5 HT3A(s) subunit resulted in
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transient desensitising inward currents. A concentration-response curve for 5-HT- 
induced ion currents with m5HT3A(S) was constructed yielding estimates of EC50 and 
«h of 1.3 pM and 2.6, respectively (n=l). Various concentrations of 5-HI were co­
applied with 5-HT at EC20 (0.8 pM). 5-HI did not potentiate the currents, but rather 
inhibited the 5-HT-induced ion currents with an IC50 of 1.3 mM, «h of -1.5. When 5- 
HI was co-applied with an EmaX concentration of 5-HT a slowing of the 
desensitisation kinetics was observed and there was no potentiation of the current 
peak. These results are consistent with those of Gunthorpe and Lummis, 1999 
(m5HT3A(s) expressed in HEK293 cells), but differ from those of van Hooft et al., 
1997 (native m5HT3Rs in N1E-115 cells). The experiments in this section were 
performed by Dr Ruud Zwart at Eli Lilly.
4.8 Comparison of the short and long mouse 5HT3A and human 5HT3A
subunits in transiently transfected tsA201 and HEK293 cells using a 
FLIPR
4.8.1 Comparison o f  m5HT3A(S), m5HT3A(L) and h5HT3A receptors in tsA201 cells
The effects of 5-HI on the 5-HT-induced responses of the m5 HT3A(s) receptor 
subunit were studied, alongside the m5 HT3A(L) and h5 HT3A receptors. The subunits 
were transiently transfected into tsA201 cells and assayed using a FLIPR. As 
previously observed, 1 mM 5-HI had no effects on the 5-HT-induced responses of 
the 1i5 HT3aR (Figure 4.12A(i)). However, the responses of both m5 HT3A(S) and 
m5HT3A(L) were slightly potentiated in the presence of 1 mM 5-HI (Figure 4.12A(ii) 
and (iii)). The responses were potentiated most at the higher 5-HT concentrations. 
The size of the responses of m5HT3A(L) were significantly increased in the presence 
of 5-HI by approximately 20% at 5-HT concentrations of 10 pM and above. The 
increases in the responses of m5 HT3A(s) in the presence of 5-HI were consistently, 
but not, significantly increased at 30 and 100 pM 5-HT, compared to controls. When 
assayed using a FLIPR, the responses of the m5HT3A(s> subunit were less robust than 
those of the m5 HT3A(L), for example, the baseline fluorescence decreased 
significantly over the time course of the experiment; therefore accurate extraction of 
data such as ‘maximum fluorescence -  minimum fluorescence’ was not possible.
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Figure 4.12 5-HT concentration-response curves showing the effects o f 5-HI on 
m5HT3A(S), m5HT3A(L) and h5HT3A transiently transfected in tsA201 and HEK293 cells. 
tsA201 (A) and HEK293 (B) cells were transiently transfected with the m5HT3A(S) (i), 
m5HT3A(L) (ii) and h5HT3A (iii) subunits. Responses to 5-HT in the presence or 
absence of 5-HI were assayed using a FLIPR. Responses are expressed relative to 
maximal 5-HT. Data is mean ± standard error for at least 3 independent 
experiments. Significance determined by Student’s t test (*p<0.05; **p<0.01). 
Goodness of curve fits: A(i) control, R2=0.9974; +5-HI, R2=0.9985; A(ii) control, 
R2=0.9958; +5-HI, R2=0.9977; A(iii) control, R2=0.9975; +5-HI, R2=0.9982; B(i) 
control, R2=0.9857; +5-HI, R2=0.9804; B(ii) control, R2=0.9944; +5-HI, R2=0.9960; 
B(iii) control, R2=0.9721; +5-HI, R2=0.9969. Insets show example traces upon 
application of 10 pM 5HT in the presence (blue) or absence (red) of 1 mM 5-HI. 
Addition of buffer alone is shown by a black trace. Horizontal axis is time (160 
seconds); Vertical axis is change in fluorescence/baseline fluorescence (0.8-2.1 units 
for A(i) and (ii); 0.8-1.5 units for A(iii) and B).
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The effects of 1 mM 5-HI on the 5-HT-induced responses of m5 HT3A(L) expressed in 
tsA201 cells (Figure 4.12A(ii)) differed from those of m5 HT3A(L> previously 
observed in transiently transfected HEK293 cells (Section 4.5.2, Figure 4.7) in that a 
significant increase in response size in transiently transfected tsA201 cells was 
observed. Also, an increase in responses to 5-HT in the presence of 5-HI of 
m5 HT3A(s) expressed in tsA201 cells was observed. To determine whether these 
differences were cell-type specific, the experiments were repeated using transiently 
transfected HEK293 cells.
4.8.2 Comparison o f  m5HT3A(s), m5HT3A(L) and h5HT3A receptors in HEK293 cells
HEK293 cells were transiently transfected with m 5 HT3A(S), m5 HT3A(L) or h5 HT3A 
and assayed using a FLIPR. Co-application of 1 mM 5-HI with 5-HT did not, as 
observed previously, potentiate responses when h5 HT3A was expressed in HEK293 
cells. The responses appeared to be slightly inhibited by 5-HI (Figure 4.12B(i)). 
The 5-HT-induced responses of mouse 5 HT3A(l) expressed in HEK293 cells were 
slightly and consistently increased when 1 mM 5-HI was co-applied with 5-HT, 
particularly at the higher 5-HT concentrations (Figure 4.12B(ii)). The increase was 
statistically significant at 5-HT concentrations of 10 \xM and above. The 5-HT- 
induced responses of the mouse 5 HT3A(s) expressed in HEK293 cells were highly 
variable. Co-application of 1 mM 5-HI with 5-HT did not have any significant effect 
on the responses (Figure 4.12B(iii)), although the concentration-response curve 
could not be fit well.
Generally, the responses from transiently transfected HEK293 cells were not as 
consistent as responses from tsA201 cells. The amplitudes of the responses from 
HEK293 cells varied significantly between wells, and frequently the baseline 
fluorescence decreased over the time course of an experiment which led to 
inaccuracies when data such as ‘maximum fluorescence -  minimum fluorescence’ 
were extracted using the FLIPR computer software. Usually, experiments were 
performed in HBSS. In an attempt to optimise experimental conditions for the 
HEK293 cells, Tyrodes buffer was used, as previously robust responses from 5HT3A 
receptors expressed in HEK293 cells were recorded in this buffer. However, the 
stability of the responses did not improve.
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4.8.3 Analysis o f  the decay o f  the responses o f  the mouse and human 5HT3aR in the 
presence and absence o f  5-HI
Although differences in potentiation of the peak responses between the m5 HT3A 
splice variants were observed as well as differences between cell types, the decay of 
the responses of both m5 HT3A(s> and m5 HT3A(L) were quite clearly affected by 5-HI 
in both tsA201 and HEK293 cells. If control responses are compared to responses in 
the presence of 5-HI then a decrease in the rate of decay of the responses where 5-HI 
is present can clearly be seen. Typical time-sequence traces illustrate this (Figure 
4.13 A and 4.13B). The responses of h5HT3A were never potentiated by 5-HI and it 
did not affect the decay of the responses as illustrated (Figure 4.13C).
To further investigate the effects of 5-HI on the decay of the responses, particularly 
of the hi5HT3aRs, the data from FLIPR assays was re-analysed. The sum of the area 
under the curve was extracted from the point of agonist addition to a point near the 
end of the experiment; the results are described below.
Analysis of the area under the curve of 5-HT-induced responses of h5 HT3A 
transiently expressed in tsA201 cells showed that it was not significantly affected by 
5-HI (Figure 4.14A(i)). The responses in the presence of 1 mM 5-HI were not 
significantly different from those in the absence of 5-HI. When h5 HT3A was 
expressed in HEK293 cells, 5-HT responses were inhibited slightly by 1 mM 5-HI. 
5-HI had no statistically significant effect on the responses (Figure 4.14A(ii)), but at 
5-HT concentrations of 3 pM and below responses were more evidently inhibited 
than at 5-HT concentrations greater than 3 pM.
In tsA201 cells expressing mouse 5HT3A(l), the area under the curve of responses at 
the higher 5-HT concentrations was clearly increased (35-60%; significant at some 
5-HT concentrations) in the presence of 1 mM 5-HI (Figure 4.14B(i)). In HEK293 
cells, there was a clear increase in the area under the curve (15-42%), but it was not 
statistically significant (Figure 4.14B(ii)).
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Figure 4.13 Typical responses showing the effects o f  5-HI on 5HTu receptors 
expressed in mammalian cells. Cells (tsA201) were transiently transfected with the 
m5HT3A(s) (A), m5 HT3A(L) (B) or h5 HT3A (C) subunit. Responses shown are with 
the addition of buffer (control), with the addition of 10 pM 5-HT and with the 
addition of 1 mM 5-HI and 10 pM 5-HT, assayed using a FLIPR. Responses are 
averages of 2 -6  wells from a typical experiment and are also representative of those 
observed in HEK293 cells.
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Figure 4.14 Effects o f 5-HI on 5-HT-induced responses o f 5HT3A receptors, 
expressed as area under the curve. HEK293 cells (right panel, (ii)) and tsA201 cells 
(left panel, (i)) were transiently transfected with h5HT3A (A), m5HT3A(L), (B), or 
m5HT3A(S) (C) and the effects of 5-HI on 5-HT-induced responses assayed using a 
FLIPR. Data was extracted as area under curve. The average percentage change, in 
the presence of 5-HI, compared to control (5-HT alone) is plotted for several 5-HT 
concentrations. Data is mean ± standard error for at least 3 independent experiments, 
except for C(ii) where n = 1. Significance was determined by Student’s t tests 
(*p<0.05); data at each 5-HT concentration was compared with control data (in the 
absence of 5-HI) of the same 5-HT concentration.
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In tsA201 cells expressing m5 HT3A(S) the area under the curve of responses was 
consistently increased (15-48%) in the presence of 1 mM 5-HI, but was not shown to 
be statistically significant (Figure 4.14C(i)). The responses of m5HT3A(s) in HEK293 
cells were variable and it was difficult to extract the area under the curve data from 
many experiments (Figure 4.14C(ii)), so conclusions cannot be drawn.
4.9 Effects of 5-HI on the 5HT3A chimeras assayed using a FLIPR
The 5 HT3A chimeras, described in Section 4.3, were studied using a FLIPR. The 
effects of 5-HI on the 5-HT-induced responses of the m/h5 HT3A chimera and 
h/m5HT3A chimera transiently transfected in both tsA201 and HEK293 cells were 
examined.
4.9.1 Effects o f 5-HI on the 5HT3A chimeras transiently transfected in HEK293 
cells
HEK293 cells were transiently transfected with the chimeric subunits using the 
FuGene transfection reagent. The effects of 5-HI on the 5-HT-induced responses of 
the chimeras were examined through the use of a FLIPR assay. Application of 5-HT 
evoked increases in intracellular Ca2+, whereas application of 5-HI did not. Co­
application of 1 mM 5-HI slightly inhibited the 5-HT responses (data not shown) as 
previously observed for the mouse 5HT3A(l) and human 5 HT3A subunits assayed in 
this way (Section 4.5.2).
4.9.2 Effects o f  5-HI on the 5HT3A chimeras transiently transfected in tsA201 cells
Cells (tsA201) were transiently transfected with the chimeric subunits and the effects 
of 5-HI studied using a FLIPR. Responses to 5-HT of both chimeras were slightly 
increased in the presence of 5-HI (Figure 4.15). Selected traces illustrate that 
although 5-HI did not always potentiate the peak of responses it did have an effect on 
the 5-HT induced responses of the chimeras (Figure 4.16). A slowing of the decay 
of the responses for both chimeras was observed in the presence of 5-HI. Analysis of 
the area under the curve of the responses showed that 5-HI potentiated the responses 
of both the m/h5 HT3A chimera and h/m5 HT3A chimera (Figure 4.17). The m/h5 HT3A
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Figure 4.15 Effects o f  5-HI on the 5HT3A chimeras expressed in tsA201 cells. 
Concentration-response curves of 5-HT alone or with 5-HI obtained from 
recombinant m/h5 HT3A chimera or h/m5 HT3A chimera transiently transfected in 
tsA201 cells. Responses are expressed relative to maximal (30 pM) 5-HT control 
responses. Traces represent mean ± standard error of at least 3 experiments. 
Significance determined by Student’s t test (*p<0.05). Goodness of curve fits: 
m/h5HT3A x control, R2=0.9927; +5-HI, R2=0.9921; h/m5HT3A x control, 
R2=0.9911; +5-HI, R2=0.9931.
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Figure 4.16 Typical responses showing the effects o f  5-HI on 5HT3A chimeras 
expressed in mammalian cells. Cells (tsA201) were transiently transfected with the 
m/h5 HT3A (A) and h/m5HT3A (B) chimeric subunits. Responses shown are with the 
addition of buffer (control), with the addition of 10 5-HT or with the addition of 
1 mM 5-HI and 10 pM 5-HT, assayed using a FLIPR. Responses are averages of 4 
wells. The trace in B shows potentiation of the peak response; this did not always 
occur, nor did the lack of potentiation illustrated in A.
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Figure 4.17 Effects o f  5-HI on the 5HTu chimeras, expressed as area under the 
curve. Cells (tsA201) were transiently transfected with the h/m5 HT3A chimera (A) 
or the m/h5 HT3A chimera (B). Responses to 5-HT in the presence or absence of 5-HI 
were assayed using a FLIPR. Area under curve data was extracted and the average 
percentage change compared to control plotted. Data is mean ± standard error for at 
least 4 independent experiments. Significance determined by Student’s t test 
(*p<0.05); data at each 5-HT concentration was compared with control data (in the 
absence of 5-HI) of the same 5-HT concentration.
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chimera responses were potentiated slightly more than those of the h/m5 HT3A 
chimera and at some 5-HT concentrations were shown to be significantly enhanced.
4.10 Discussion
In this study, the effects o f 5-HI at the mouse and human 5HT3aRs were 
investigated. 5-HI, the aromatic moiety of 5-HT, has been shown to potentiate the 
responses of the mouse 5 HT3aR (Kooyman et al., 1993; Kooyman et a l , 1994; van 
Hooft et a l , 1997) and is also reported to potentiate the a l  nAChR (Gurley et al., 
2000; Zwart et al., 2002). The potentiation of the 5 HT3R is accompanied by a 
slowing of the current decay (Kooyman et al., 1994). 5-HI (at concentrations up to 
10 mM) potentiates responses of 5HT3R, but at higher concentrations (greater than 
10 mM) blocks 5-HT-evoked currents. The potentiating effects of 5-HI are thought 
to be mediated via a non-competitive interaction whereby the open state of the 
receptor is stabilised (Kooyman et al., 1994; van Hooft et al., 1997). The blocking 
action of 5-HI is thought to be mediated by a competitive interaction (Kooyman et 
a l , 1994).
The action of 5-HI on the mouse and human 5 HT3aRs was previously investigated at 
Eli Lilly. Mouse 5 HT3a(s> receptor cDNA stably expressed in the HEK293 cell line 
was potentiated by 5-HI, whilst human 5 HT3A stably expressed in the HEK293 cell 
line showed no evidence of potentiation. The aim of this project was to investigate 
the different activity of 5-HI on the different 5 HT3aR species and in so doing 
identify regions or residues involved in 5-HI binding. The structural determinants of 
ligand binding at the 5 HT3R are not yet fully characterised. Several regions and 
some specific residues involved in ligand binding to the 5 HT3R have been identified. 
Evidence from studies with the nAChR, GABAa and glycine receptors suggest the 
extracellular N-terminal portion of the receptor to contain the ligand binding domain 
(Dunn et a l , 1994; Karlin and Akabas, 1995; Kuhse et a l , 1995). Further evidence 
has been provided by studies of a chimeric subunit consisting of the N-terminal 
region of a l  up to TM1, fused to the remainder of mouse 5HT3A (a 7/5 HT3A) (Eisele 
et a l , 1993). The a 7 /5 HT3A chimera displays the pharmacological properties of the 
nicotinic receptor, but ion channel properties of the 5 HT3R. Further evidence of the
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N-terminal domain of the 5 HT3R containing the ligand binding site was provided by 
human/mouse 5 HT3A chimeric constructs (Hope et al., 1999). The 5 HT3R 
antagonist, d-tubocurarine (d-TC), is more potent at mouse than at human 5HT3A 
receptors. Replacement of the entire extracellular N-terminal portion of the mouse 
5HT3A with that of the human, and vice versa, switches the differential potency of d- 
TC, indicating that the ligand binding site is contained within this region. A number 
of individual residues and groups of residues important in binding specific ligands 
have also been identified; for example glutamate 106 is found to be important in 
ligand recognition (Boess et al., 1997).
Defining the binding site of 5-HI would be useful for the rationalisation of drug 
design, with the final aim of generating a  7 nAChR selective potentiators which 
might be useful in the treatment of neurological disorders such as neurodegeneration 
(Maelicke and Albuquerque, 2000; Dani et al., 2004). From previous studies 
(unpublished data, Eli Lilly), it was thought likely that 5-HI would act via the 
extracellular N-terminal domain of the 5HT3R. Through the use of human/mouse 
5 HT3A chimeric subunits it was hoped that residues and/or regions implicated in the 
binding of this compound could be identified.
The potentiation of the mouse 5HT3a(s>R, stably expressed in the HEK293 cell line, 
by 5-HI was confirmed. Using a FLIPR, the 5-HT-induced elevations in intracellular 
calcium were enhanced in the presence of 1 mM 5-HI; the peaks of responses were 
significantly increased. Human 5HT3A, stably expressed in the HEK293 cell line, 
was not potentiated by 5-HI as had been seen in previous studies (unpublished data, 
Eli Lilly). However, when the experiments were repeated in HEK293 cells 
transiently expressing the subunits, the results were not consistent with those 
obtained with stably transfected cells. Surprisingly, the peaks of the 5-HT-evoked 
responses of mouse 5HT3A(l> were not potentiated in the presence of 5-HI. The 
responses of both mouse 5HT3a(l) and human 5HT3aR were inhibited by 1 mM 5-HI. 
To ensure that the fluo-3 calcium-sensitive dye was not being saturated, and 
therefore obscuring any potentiation of the mouse 5 HT3A(l>R, the calcium 
concentration of the assay buffer was reduced. Response size decreased with 
reduced calcium concentrations, yet no potentiation was observed. The presence of 1 
mM 5-HI did however cause a slowing of response decay for the mouse 5HT3a(l>R.
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This effect of 5-HI has previously been reported (Kooyman et a l, 1993; Kooyman et 
a l, 1994; van Hooft et a l, 1997; Gunthorpe and Lummis, 1999).
To investigate the effects of 5-HI on the 5-HT-evoked responses of the 5HT3aR in an 
alternative expression system, Xenopus oocytes were utilised. 5-HI (1 mM) did not 
potentiate the amplitude of 5-HT-evoked currents of human 5HT3A, mouse 5HT3a(l) 
or mouse 5HT3a(s) expressed in Xenopus oocytes. At higher concentrations, 5-HI 
was seen to inhibit responses of both mouse and human 5HT3aRs. The blocking 
effect of 5-HI was surmounted with increasing 5-HT concentrations suggesting that 
5-HI was interacting in a competitive manner. The blocking effect of 5-HI has 
previously been reported to be mediated by a competitive interaction with the 
agonist/antagonist recognition sites of the 5 HT3R (Kooyman et a l, 1994). 5-HI (1 
mM) did not appear to effect the decay kinetics of m5HT3A(L) or h5HT3A. In order to 
examine a possible effect of 5-HI on the decay kinetics of 5-HT-evoked currents the 
application time of 5-HI was extended; no effects were observed. The current decay 
kinetics of m5HT3A(S) were slowed by 3 mM 5-HI which is consistent with some 
reports (Gunthorpe and Lummis, 1999). The 5-HT-evoked currents of h5HT3A and 
m5HT3A(L) expressed in Xenopus oocytes were non-desensitising, but those of 
m5HT3A(S) did desensitise. This difference may explain why a slowing of decay 
kinetics was observed in the presence of 5-HI for m5HT3A(s>, but not for m5HT3A(L)-
To eliminate the possibility that the differing effects of 5-HI on the m5HT3AR, 
expressed in HEK293 cells, were due to differences between splice variants, both 
m5HT3A(s) and m5HT3A(L) (and 1i5HT3a) were compared in parallel. Transiently 
transfected HEK293 cells and a subclone, the tsA201 cell line, were used. The 
responses in HEK293 and tsA201 cells were comparable, although generally the 
responses from HEK293 cells were less stable and less consistent than those from 
tsA201 cells. It was not the expression of 5 HT3A in HEK293 cells which caused this 
as untransfected cells behaved similarly.
The absence of an effect of 5-HI on the h5HT3A receptor was observed consistently. 
In HEK293 cells, 1 mM 5-HI slightly inhibited 5-HT-induced responses. This 
finding suggests that 5-HI is capable of interacting with the human 5HT3aR in a 
competitive manner, thereby inhibiting binding of 5-HT. Although not always
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statistically significant, 5-HI did have potentiating effects on both m5 HT3A(L) and 
m5 HT3A(s> Potentiation of the peaks of responses (up to 36% (m5 HT3A(L)) and up to 
84% (m5HT3A(S))) was observed at the higher 5-HT concentrations (above 3 pM) in 
the presence of 5-HI. Increases in the area under the curve of responses for both 
m5HT3A(L) and m5 HT3A(s) were observed. The results from m5HT3A(s) transiently 
expressed in HEK293 cells were very difficult to analyse, but there was evidence of 
5-HI potentiating responses. Taken together, these further experiments provided 
evidence to reconfirm the original finding that m5HT3A is potentiated by 5-HI, whilst 
h5HT3A is not.
Through the use of mouse/human 5 HT3A chimeras it was originally hoped that the 
regions involved in 5-HI binding could be defined. The m/h5 HT3A chimera 
consisted of the extracellular N-terminal domain of mouse 5 HT3A(l) fused to the 
remainder of human 5 HT3A from M l. The h/m5 HT3A chimera consisted of the 
extracellular N-terminal domain of h5 HT3A fused to the C-terminal of m5 HT3A(L> 
from M l. Based on previous experimental data (Eisele et al., 1993; Hope et al., 
1999) suggesting that the N-terminal domain contained the ligand binding site it was 
predicted that the m/h5HT3A chimera would be potentiated by 5-HI and that the 
h/m5 HT3A chimera would not. It was hoped that these chimeras would be the basis 
for creating further chimeric subunits and mutants to narrow down regions and 
residues involved in conferring 5-HI sensitivity to the m5 HT3AR.
The results obtained with the 5 HT3A chimeric subunits were not as expected. The 
peaks of 5-HT-induced responses of both chimeras were slightly potentiated in the 
presence of 5-HI. Analysis of the area under the curve of responses in the presence 
of 5-HI increased for both chimeras suggesting that 5-HI affected the decay kinetics 
of the responses. These results suggested that both the C- and N-terminal regions of 
5 HT3A may be involved in mediating the effects of 5-HI. Evidence for both the C- 
and N-terminal regions mediating the actions of 5-HI is also provided by studies 
using a 7 /5 HT3A chimeras performed at Eli Lilly (see Section 4.2). Although both 
human a7/mouse 5 HT3A and human a7/human 5HT3A chimeras were potentiated by 
5-HI, the potentiation of the human a  7/human 5 HT3A chimera was less significant, 
suggesting the C-terminal region to be involved.
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A recent study has identified a residue in the a l  nAChR subunit, mutation of which 
results in the loss of potentiation by 5-HI (Placzek et al., 2004). The mutation 
(threonine to phenylalanine) is at the beginning of M2 (in the 6 ’ position according 
to the numbering scheme proposed by Miller (1989)). These results suggest that the 
action of 5-HI could be mediated by a region outside of the extracellular N-terminal 
domain, although it was not shown whether this mutation abolishes 5-HI binding. 
The binding of 5-HI may induce a conformational change involving M2 which could 
result in an agonist remaining bound to a receptor for longer. This threonine residue 
is conserved in both mouse and human 5 HT3A and so cannot explain the species 
differences observed.
An alternative approach to identify residues important in 5-HI sensitivity has been 
used in studies performed by a research group at Eli Lilly. A sequence alignment of 
the mouse and human 5HT3A receptor subunits and the human and rat a l  neuronal 
nAChR subunits was made. Three residues which were found to be conserved 
between the rat and human a l  nAChRs and m 5 HT3AR, but not h5 HT3A were 
identified in the extracellular N-terminal domain of the subunits. These residues 
were identified as possibly conferring 5-HI sensitivity. Molecular modelling studies 
using the predicted structure of the nAChR binding site deduced from the ACh 
binding protein (Smit et al., 2001; Brejc et al., 2001) suggested that the residues 
identified were likely to be involved in ligand binding. Mutant h5HT3A subunits 
were constructed where the differing residues were replaced by the conserved 
homologous mouse 5 HT3a/cx7  nAChR residues. Single, double and triple point 
mutations were made in h5 HT3A. The mutants were introduced by transient 
transfection into HEK293 cells and the effects of 5-HI on 5-HT responses studied 
using a FLIPR. All of the mutants tested were functional, but none were potentiated 
by 5-HI, suggesting that these residue differences were not responsible for sensitivity 
to 5-HI (unpublished results, Eli Lilly).
In summary, the species specific activity of 5-HI at the mouse and human 5 HT3ARs 
has been confirmed; 5-HI potentiates the 5-HT induced responses of the m5 HT3A(L) 
and m5 HT3A(s), but not of the h5 HT3A. Studies using human/mouse chimeric 
subunits have provided evidence for the involvement of regions other than the
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extracellular N-terminal domain in conferring 5-HI sensitivity, possibly by an 
allosteric mechanism.
4.11 Future directions
The ligand binding site of the 5 HT3R requires extensive further characterisation. 
The binding site and mechanism of action for 5-HI are still to be characterised.
Studies, conducted by others at Eli Lilly, identified residues that were not conserved 
between mouse and human 5HT3A, but which were conserved between mouse 5HT3A 
and rat and human a l  (which are all potentiated by 5-HI). None of the residues 
identified were shown to be responsible for conferring 5-HI sensitivity (unpublished 
data, Eli Lilly). There are a number of residues which are not conserved between 
mouse and human 5HT3A (or a l )  in the extracellular N-terminal domain. It would 
be interesting to study these residues further using site directed mutagenesis to 
determine whether they are responsible for conferring sensitivity to 5-HI and its 
analogues. By drawing analogies with the a l  nAChR many of these unconserved 
residues are predicted to be in ‘loop 3’, or ‘C’, of the principal binding component. 
This loop region has been identified as involved in the binding of several other 
5 HT3R ligands (Lankewicz et al., 1998; Hope et al., 1996; Hope et al., 1997; Hope 
eta l., 1999).
Human 5 HT3A differs from mouse 5 HT3A by a five amino acid deletion in the 
extracellular N-terminal domain. The homologous residues could be deleted in 
mouse 5HT3A to determine whether these residues are important in ligand binding, 
particularly in conferring 5-HI sensitivity.
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CHAPTER 5
In v estig a tio n  o f  th e  e f f e c t s  o f  th e  RIC3 
p r o te in s  o n  th e  a 7  nA C hR  a n d  5HT3AR 
e x p r e s s e d  in m a m m a lia n  c e l l s
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5.1 Introduction
The folding, assembly and cell-surface expression of ligand-gated ion channels is a 
complex and poorly understood process. The a l  nicotinic acetylcholine receptor 
(nAChR) subunit forms functional homomeric receptors when expressed in Xenopus 
oocytes (Couturier et al., 1990) and in some cultured mammalian cells lines 
(Puchacz et al., 1994; Gopalakrishnan et al., 1995). However, the inefficient 
expression of the a l  subunit in a number of other mammalian cell lines has 
suggested cell-specific factors to be required for the folding, assembly and correct 
subcellular localisation of this protein (Cooper and Millar, 1997; Dineley and 
Patrick, 2000; Sweileh et a l , 2000).
Recent studies investigating proteins required for nAChR activity in Caenorhabditis 
elegans (C. elegans) identified the RIC3 protein (CeRIC3) (Halevi et al., 2002). 
CeRIC3 and its human homologue (hRIC3) have been shown to enhance the currents 
of both C. elegans DEG-3/DES-2 and mammalian a l  nAChRs expressed in Xenopus 
oocytes (Halevi et al., 2002; Halevi et al., 2003). The RIC3 proteins have been 
shown to have no effect on the functional expression of the GABA, glutamate and 
glycine receptors (Halevi et al., 2003). However, hRIC3 has been shown to reduce 
whole-cell current amplitudes of the a4|32 and a3|34 nAChR and 5HT3aR expressed 
in Xenopus oocytes (Halevi et al., 2003).
The CeRIC3 protein is encoded by the ric-3  gene (resistant to inhibitors of 
cholinesterase). Mutations in the ric-3 gene result in the intracellular accumulation 
of nAChRs suggesting that the CeRIC3 protein plays a role in the maturation of the 
nAChRs (Halevi et al., 2002).
The RIC3 proteins are a family of conserved proteins, in vertebrates and 
invertebrates, and all members are predicted to have two transmembrane domains, 
separated by a proline-rich spacer, followed by at least one coiled-coil domain 
(Halevi et al., 2003). According to these predictions the RIC3 proteins are located 
on membranes with their N-terminal domain and C-terminal coiled coil domain(s) in 
the cytoplasm (Figure 5.1) (Halevi et al., 2003).
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In this chapter the effects of the RIC3 proteins co-expressed with the al nAChR and
5HT3aR in a mammalian cell line have been investigated.
membrane
cytoplasm
Figure 5.1 Structure and topology o f  the RIC3 proteins (predicted by Halevi et 
al., 2002; Halevi et al., 2003). Structure predictions suggest the RIC3 proteins to 
consist of two transmembrane domains separated by a proline-rich domain, followed 
by at least one coiled coil region (CC), with their N- and C-termini being 
cytoplasmic.
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5.2 Co-expression of the RIC3 proteins with the a7 and a8 nAChRs
5.2.1 Co-expression o f  the R1C3 proteins with a l  examined by [I25I]-a-BTX  
binding
To investigate the effects of the RIC3 proteins on a  7 nAChRs heterologously 
expressed in a mammalian cell line, rat or human a l  subunit cDNAs were transiently 
co-transfected into tsA201 cells with CeRIC3 or hRIC3 cDNA. Binding studies 
were performed on both intact cells and cell membrane preparations with iodinated 
a-bungarotoxin ([125I]-a-BTX), a nAChR antagonist which binds with high affinity 
to nAChRs containing the a l  subunit. When expressed alone, neither rat a l  (ra7), 
human a l  (ha7), CeRIC3 or hRIC3 gave specific [125I]-a-BTX binding. However, 
when a l  was co-expressed with either CeRIC3 or hRIC3, specific binding was 
detected, both to cell membrane preparations and to cell surface receptors on intact 
cells (Figure 5.2). In the absence of RIC3, a l  failed to form a high affinity binding 
site for a-BTX in this cell line (Cooper and Millar, 1997).
A number of hRIC3 splice variants have been identified, but their functions have not 
been defined (Halevi et al., 2003). When hRIC3 was cloned, in this laboratory, an 
alternatively spliced variant was also identified and isolated. This partial hRIC3 
clone consisted of the first transmembrane domain spliced to the C-terminal portion. 
A consequence of this was that this clone lacked a second transmembrane domain 
and coiled coil domain according to the structure predicted by Halevi et al., 2003. 
The effects of co-expression of this partial hRIC3 with a l  were examined by 
performing [ I]-a-BTX binding studies. Co-transfection of the partial hRIC3 clone 
with a l  did not result in any specific binding of [125I]-a-BTX (n=3, data not shown).
5.2.2 Co-expression o f the RIC3 proteins with a8 examined by [125I]-a-BTX  
binding
The a l  nAChR shares a high sequence similarity with the chick a 8 nAChR subunit 
(Schoepfer et al., 1990). Similar difficulties in efficient heterologous expression of 
the a 8 subunit are also observed (Cooper and Millar, 1998). Therefore, the effects of
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Figure 5.2 Specific [I251]-a-BTX binding to a 7  nAChR subunits co-expressed 
with the RIC3 proteins. Cells (tsA201) were transiently transfected with 
combinations of human or rat a l  with or without CeRIC3 or hRIC3, and binding 
performed using 10 nM [ I]-a-BTX. A, Specific binding to intact cells and B, to 
cell membrane preparations are mean values ± standard error from 3 independent 
experiments performed in triplicate.
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the RIC3 proteins on the a 8 subunit were examined. Cells (tsA201) were co- 
transfected with a 8 and the RIC3 proteins and [ I]-a-BTX binding studies were 
performed. Specific cell-surface binding of [ I]-a-BTX was detected in cells co­
transfected with a 8 and the RIC3 proteins (Figure 5.3). The experiment was only 
performed once.
5.2.3 Co-assembly studies o f  the RIC3 proteins with a.7
To enable detection of the RIC3 proteins a FLAG epitope (Hopp et al, 1988) was 
introduced in the C-terminal region of the proteins (CeRIC3FLAG‘A and hRIC3FLAG'A; 
see Chapter 2, Section 2.4). To investigate whether the RIC3 proteins co-assemble 
with the a  7 nAChR subunit, tsA201 cells were transiently transfected with 
combinations of a l  and RIC3 cDNAs and examined by immunoprecipitation. The 
a7-specific antibody mAb319 (raised against a linear intracellular epitope) and 
mAbFLAG-M2, which recognises the FLAG epitope, were used.
A single band of approximately 58 kDa, absent in untransfected cells, was detected 
using mAbFLAG-M2, in cells transfected with hRIC3FLAG'A. This band was also 
detected in cells co-expressing hRIC3FLAG‘A with ha7 as well as a co-precipitating 
band the correct size for a 7 (-50 kDa) (Figure 5.4A). Co-precipitation of 
hR ic3FLAGA with ha7 was observed in cells co-transfected with ha7 and hRIC3FLAG* 
A using mAb319. In cells co-transfected with untagged hRIC3 a band of 
approximately 55 kDa was found to co-precipitate with a l  (Figure 5.4B). T h e  
absence of cross-reactivity of mAbFLAG-M2 with ha7 , and of mAb319 with 
hRIC3FLAG'A was confirmed (Figure 5.4).
The FLAG-tagged RIC3 proteins appeared to have higher molecular masses than the 
wild-type proteins. The introduction of a FLAG epitope has previously been 
reported to lead to an apparent increase in the molecular weight of tagged proteins, 
such as nAChR subunits (Lansdell and Millar, 2002), and is discussed in Section 5.5.
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Figure 5.3 Specific [125I]-a-BTX binding to the chick a8 nAChR subunit co­
expressed with the RIC3 proteins. Cells (tsA201) were transiently transfected with 
chick a 8 with or without CeRIC3 or hRIC3, and binding performed using 10 nM 
[125I]-a-BTX. The mean value of specific binding to intact cells is shown from one 
experiment performed in triplicate.
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Figure 5.4 Co-assembly o f  hRIC3 with the human a 7 nAChR subunit 
demonstrated by co-immunoprecipitation. Cells (tsA201) were transfected with 
combinations of ha7 and hRIC3/hRIC3FLAG'A. Proteins were immunoprecipitated 
from metabolically labelled cells and analysed by SDS-PAGE, followed by 
autoradiography. The ha7 subunit was detected by mAb319 (B). hRIC3FLAG'A was 
detected by mAbFLAG-M2 (A). A, A band (-58 kDa), absent in untransfected cells, 
was detected in cells transfected with hRIC3FLAG’A. A band of the size expected of 
ha7 (~50 kDa) was co-precipitated with hRIC3FLAG'A from cells co-transfected with 
ha7 and hRIC3FLAG*A. The absence of cross-reactivity of mAbFLAG-M2 with ha7 
was confirmed. B, A band corresponding to ha7 (-50 kDa) was detected in cells 
expressing h a 7, and absent in untransfected cells. A band corresponding to 
hRIC3FLAG'A (-58 kDa) and to hRIC3 (-55 kDa) were observed to co-precipitate 
with ha7. The absence of cross-reactivity of mAb319 with hRIC3/ hRIC3FLAG'A was 
confirmed. The positions of molecular weight markers are indicated. The images 
are representative of at least 3 independent experiments.
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Co-im m unoprecipitation o f r a 7  with hRIC3 was not observed. Co- 
immunoprecipitation of CeRIC3 with rat or human a 7 was not observed, but 
CeRIC3FLAG'A could be detected with mAbFLAG-M2. Results not shown (n=3).
5.3 Co-expression of the RIC3 proteins with the 5HT3AR
Previous studies have reported that the co-expression of hRIC3 with mouse 5HT3AR 
in Xenopus oocytes leads to 5-HT-induced currents being abolished (Halevi et al., 
2003). In the present study, the effects of co-expression of the RIC3 proteins with 
the mouse and human 5HT3AR in mammalian cells (tsA201) were investigated.
5.3.1 Co-expression o f the R1C3 proteins with 5HT3A examined by radioligand 
binding
Radioligand binding studies using [ H]-GR65630, a 5 HT3R specific antagonist, were 
performed to investigate the effects of the RIC3 proteins on the 5HT3AR. Binding 
was performed on cell membrane preparations of tsA201 cells transiently transfected 
with mouse 5HT3A (m5HT3A) or human 5HT3A (1i5HT3a) with or without CeRIC3 or 
hRIC3. Co-expression of the RIC3 proteins with both m5HT3A and h5HT3A 
significantly increased levels of specific binding (Figure 5.5). The increase in 
specific binding was greater when 5HT3A was co-transfected with CeRIC3 than with 
hRIC3.
5.3.2 Effect o f  the RIC3 proteins on cell surface expression o f  5HT3A
An enzyme-linked antibody binding assay was used to examine the effects of the 
RIC3 proteins on expression levels of the mouse and human 5HT3aR. The pAbl20 
antibody, which recognises a region in the extracellular domain of the 5HT3aR, was 
used to study the cell surface expression of the m5HT3AR. CeRIC3 and hRIC3 had 
no significant effect on the cell surface levels of the m5HT3AR (Figure 5.6). Total 
levels of iu5HT3aR, using permeabilised cells, could not be measured because the 
pAbl20 antibody gave too high a level of non-specific binding.
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Figure 5.5 Specific [SH]GR65630 binding to 5HT3A co-expressed with the RIC3 
proteins. Cells (tsA201) were transiently transfected with combinations of mouse 
(A) or human (B) 5 HT3A with or without the RIC3 proteins. Specific binding, using 
12.5 nM [3H]GR65630, to cell membrane preparations are mean values ± standard 
errors from 6  independent experiments performed in triplicate. Significance 
determined by Student’s / test (*p<0.05; **p<0.01).
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Figure 5.6 Effects o f  the RIC3 proteins on the cell surface expression o f  the 
m5HT3AR. Cells (tsA201), grown on glass coverslips were transfected with the 
m5HT3A subunit alone or with CeRIC3 or hRIC3. Cells were labelled with pAbl20, 
a polyclonal antibody raised against an extracellular epitope of the m5 HT3AR and 
levels of antibody binding determined through the use of an enzyme-linked assay. 
Data are means ± standard error of 4 independent experiments performed in 
triplicate. The background signal measured in mock-transfected cells has been 
subtracted.
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To study the effects of the RIC3 proteins on the expression levels of the human 
5 HT3AR, cells were co-transfected with an HA-tagged h5 HT3A subunit (h5 HT3A-HA) 
and CeRIC3 or hRIC3. The expression level of the h5 HT3A-HA construct was 
quantified through detection by an anti-HA antibody. CeRIC3 and hRIC3 were 
observed to increase both cell-surface and total levels of the h5HT3A-HA receptor 
expression (Figure 5.7).
5.3.3 Effect o f  the RIC3 proteins on 5HT3aR function assayed using a FLIPR
The effects of the RIC3 proteins on 5 HT3AR function were investigated by 
measurement of agonist-induced changes in intracellular Ca2+, using a Fluorometric 
Imaging Plate Reader system (FLIPR). Cells (tsA201) were transiently transfected 
with 5 HT3A alone or together with CeRIC3 or hRIC3. Transfected cells were 
replated on to 96-well plates and grown for at least 24 hours. Cells were loaded with 
the Ca2+-sensitive dye, fluo-4, and 5-HT-induced changes in intracellular Ca2+ 
recorded.
Co-expression of CeRIC3 with the m5 HT3AR had no significant effect on the 5-HT- 
induced responses (Figure 5.8A). However, co-expression of hRIC3 with m 5HT3A 
significantly decreased the size of the 5-HT-induced responses (Figure 5.8A). Co­
expression of CeRIC3 with the h5 HT3AR increased responses, but hRIC3 had no 
significant effect on the responses (Figure 5.8B).
5.3.4 Co-assembly studies o f  hRIC3 with 5HT3A
To investigate whether hRIC3 co-assembles with the 5 HT3AR subunit tsA201 cells 
were transiently transfected with combinations of mouse or human 5 HT3A and 
FLAG-tagged or untagged hRIC3 and examined by immunoprecipitation. An 
antibody to the putative intracellular loop between M3 and M4 of the 5 HT3AR 
(pAb5HT3; Turton et al., 1993), and mAbFLAG-M2 which recognises the FLAG 
epitope were used. A band of approximately 58 kDa, which was absent in 
untransfected cells, was detected using mAbFLAG-M2, in cells transfected with 
hRIC3FLAG'A. This band was also detected in cells co-expressing hRIC3FLAG*A with 
mouse and human 5 HT3A as well as a faint co-precipitating band
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Figure 5.7 Effects o f  the RIC3 proteins on the subcellular distribution o f  human 
5HT3A. Cells (tsA201), grown on coverslips, were transfected with a human HA- 
tagged 5HT3A subunit alone or with CeRIC3 or hRIC3. Cells were labelled with an 
anti-HA antibody either after membrane permeabilisation or as intact cell 
monolayers. Data are presented as total antibody binding to permeabilised cells (A) 
and as the proportion of cell surface antibody binding sites (B). Data are means ± 
standard error of 3 independent experiments each carried out in triplicate. 
Significance determined by Student’s t test (**p<0.01).
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Figure 5.8 Effects o f  the RIC3 proteins on 5HT3aR function assayed using a 
FLIPR. Transiently transfected cells (tsA201) plated on to poly-L-lysine-coated 96- 
well plates were loaded with the calcium-sensitive dye, fluo-4, and changes in 
fluorescence measured upon addition of 10 pM 5-HT. A, mouse 5 HT3A alone or 
with CeRIC3 or hRIC3 and B, human 5HT3A alone or with CeRIC3 or hRIC3. Data 
are means (normalised to mouse (A) or human (B) 5HT3A) ± standard error, of the 
‘maximum fluorescence -  minimum fluorescence’, of 6 wells per experiment, from 5 
independent experiments. Baseline fluorescence from addition of buffer to cells has 
been subtracted. Significance determined by Student’s t test (**p<0.01).
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the correct size for 5HT3A (Figure 5.9A). Co-transfection of hRIC3FLAG‘A with 
5HT3A and co-immunoprecipitation with pAb5HT3 resulted in precipitation of a band 
corresponding to hRIC3FLAG'A and of another slightly unclear band of the correct size 
for mouse or human 5HT3A. In cells co-transfected with untagged hRIC3 a band of 
approximately 55 kDa was found to co-precipitate with both mouse and human 
5HT3A (Figure 5.9B). A band of approximately 55 kDa was also detected by 
pAb5HT3 in untransfected cells. The absence of cross-reactivity of mAbFLAG-M2 
with 5 HT3A and of pAb5HT3 with hRIC3/hRIC3FLAG'A was confirmed (Figure 5.9).
5.4 Investigation into RIC3 topology through the use of epitope tags
A conserved membrane topology for the RIC3 family of proteins, consisting of two 
transmembrane domains followed by at least one coiled coil domain, has been 
proposed (Halevi et al., 2002; Halevi et al., 2003; see Figure 5.1). The proteins are 
predicted to be located on membranes with their N-terminal and C-terminal coiled 
coil domains in the cytoplasm, but no experimental evidence has been provided to 
support this prediction. Immunofluorescence studies using a GFP-tagged CeRIC3 
construct suggested the protein to be localised to the endoplasmic reticulum (ER) 
(Halevi et al., 2002). However, recently the presence of hRIC3 has been detected on 
the cell surface (Williams et a l., 2005). Also, use of a new ‘combined 
transmembrane topology and signal peptide predictor’ has suggested hRIC3 to 
possess only a single transmembrane domain with its N-terminal extracellular 
(Williams et a l, 2005). Evidence has been provided to support the idea that the C- 
terminal of hRIC3 is cytoplasmic (Williams et al., 2005).
5.4.1 Epitope tagging o f  hRIC3
To investigate the transmembrane topology of the RIC3 proteins the FLAG epitope 
tag was introduced at several positions. For tagging purposes the topology of the 
RIC3 proteins was assumed as that predicted by Halevi et al., 2002 and 2003 (Figure 
5.1). The FLAG epitope was introduced into the C-terminal region (FLAG-A), in 
between the two predicted transmembrane domains (FLAG-B) and close to the N-
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Figure 5.9 Co-immunoprecipitation studies o f  hRIC3 co-expressed with 5HT3A. 
Cells (tsA201) were transfected with combinations of h5HT3A or m5HT3A and 
hRIC3/hRIC3FLAG'A. Proteins were immunoprecipitated from metabolically labelled 
cells and analysed by SDS-PAGE, followed by autoradiography. The 5 HT3A 
subunits were detected by pAb5HT3 (B). hRIC3FLAG'A was detected by mAbFLAG- 
M2 (A). A, A band (-58 kDa), absent in untransfected cells, was detected in cells 
transfected with hRIC3FLAG‘A Faint bands of the size expected of h5HT3A and 
m5HT3A (~ 56 kDa) were co-precipitated with hRIC3FLAG'A from cells co-transfected 
with h5HT3A/m5HT3A and hRIC3FLAG'A. The absence of cross-reactivity of 
mAbFLAG-M2 with the 5HT3A subunits was confirmed. B, Faint bands likely to be 
corresponding to h5HT3A (-50-56 kDa) were detected in cells expressing h5HT3A 
alone, and absent in untransfected cells. A band corresponding to hRIC3FLAG'A (-58 
kDa) and a band corresponding to hRIC3 (-55 kDa) were observed to co-precipitate 
with h5HT3A. Upon co-expression of h5HT3A with hRIC3/hRIC3FLAG‘A, the bands 
corresponding to h5HT3A were stronger than h5HT3A expressed alone. Bands 
corresponding to m5HT3A (-50-56 kDa) were detected in cells expressing m5HT3A, 
and absent in untransfected cells. A band corresponding to hRIC3FLAG'A (-58 kDa) 
and a band corresponding to hRIC3 (-55 kDa) were observed to co-precipitate with 
m5HT3A. Upon co-expression of m5HT3A with hRIC3/hRIC3FLAG'A, the bands 
corresponding to m5HT3A were fainter than when m5HT3A was expressed alone. A 
band of approximately 55 kDa (the same apparent size as hRIC3) was also detected 
in untransfected cells. The absence of cross-reactivity of pAb5HT3 with 
hRIC3/hRIC3FLAG'A was confirmed. The positions of molecular weight markers are 
indicated. The images are representative of at least 3 independent experiments.
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terminal (FLAG-C) of hRIC3. The construction of these FLAG-tagged proteins is 
detailed in Chapter 2, Section 2.4 and Figure 2.4.
5.4.2 Heterologous expression o f  the tagged hR!C3 constructs
To confirm that introduction of the FLAG epitope did not disrupt the function of 
hRIC3, in facilitation of cell surface expression of the a 7 nAChR, the tagged 
constructs were co-transfected into tsA201 cells with a7  and the effects assayed by 
[125I]-a-BTX binding. Co-expression of all FLAG-tagged hRIC3 constructs with 
ha7 gave specific [125I]-a-BTX binding (Figure 5.10).
Co-expression of ha7 with hRIC3FLAG‘A or hRIC3FLAG'B gave levels of specific cell
I
surface [ I]-a-BTX binding, performed on intact cells, not significantly different to 
that observed upon co-expression of wild type hRIC3 (Figure 5.10A). However, co­
expression of ha7 with hRIC3FLAG'c resulted in a significantly reduced level (~ 5- 
fold) of specific cell surface [ I]-a-BTX binding compared to that observed upon 
co-expression of wild type hRIC3 (Figure 5.10A). Levels of [125I]-a-BTX binding to 
membrane preparations of cells co-transfected with combinations of ha7 and FLAG- 
tagged hRIC3 constructs were also assayed. All hRIC3 FLAG-tagged constructs,
iwhen co-expressed with h a 7, gave levels of specific [ I]-a-BTX binding not 
significantly different to that observed upon co-expression of wild type hRIC3 
(Figure 5.1 OB).
5.4.3 Investigation o f subcellular location ofhRIC3 using FLAG epitope tagged 
subunits
The expression of the FLAG-tagged hRIC3 constructs was investigated using an 
enzyme-linked antibody binding assay (Section 2.11). Cells (tsA201) grown on 
poly-L-lysine and collagen-coated glass coverslips, were transiently transfected with 
the FLAG-tagged hRIC3 constructs. Expression of the constructs was analysed 
using an anti-FLAG antibody, mAbFLAG-M2. Cell surface expression was assayed 
using intact cells and total cellular expression using permeabilised cells.
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Figure 5.10 Specific [125I]-a -B T X  binding to h a 7  co-expressed  with F LA G -tagged  
hRIC3 constructs. Cells (tsA 201) were transiently transfected with combinations of  
h a7  and FLAG-tagged hRIC3 and binding performed using 10 nM [125I]-a-BTX . 
Specific binding to intact cells (A) and to cell membrane preparations (B) are mean ±  
standard error from at least 3 independent experiments each performed in triplicate. 
Significance determined by Student’s t test (**p<0.01).
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The hRIC3FLAG*A construct was found to be expressed on the cell surface at a low 
level. This result was unexpected because the FLAG tag was presumed to be 
intracellular, based on the membrane topology predicted by Halevi et al., 2002 and 
Halevi et al., 2003 (Figure 5.11 A). In addition, the hRIC3FLAG'c construct, which 
was not expected to be detectable on intact cells, was found to be expressed on the 
cell surface at a similar level to hRIC3FLAG'A (Figure 5.11 A). The hRIC3FLAG*B 
construct was detected on the cell surface, although at approximately a third of the 
level seen for hRIC3FLAG'A and hRIC3FLAG'c (Figure 5.11 A). The total levels of 
expression of the three FLAG-tagged hRIC3 constructs were not significantly 
different from each other (Figure 5.1 IB).
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Figure 5.11 Analysis o f  the subcellular location o f  hRIC3 using FLAG-tagged 
hRIC3 constructs. Cells (tsA201) grown on glass coverslips were transfected with 
the various FLAG-tagged hRIC3 constructs. Cells were labelled with an anti-FLAG 
antibody (mAbFLAG-M2) as intact cell monolayers (A) or after membrane 
permeabilisation (B). Data are presented as means ± standard error, normalised to 
a4xP2FLAG (data not shown), of at least 4 independent experiments each carried out 
in triplicate. Significance determined by Student’s t test (*p<0.05).
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5.5 Discussion
The expression of functional ligand-gated ion channels requires that the receptor 
subunits adopt an appropriate membrane topology, and associate with other subunits 
to form pentamers in the endoplasmic reticulum (ER) before export through the 
Golgi apparatus to the plasma membrane. This maturation process is slow and 
relatively inefficient (Merlie and Lindstrom, 1983). It has been suggested that the 
formation of pentameric complexes is a strict requirement before exit from the ER, 
but there is evidence for the occurrence of further folding events after exit from the 
ER (Green and Wanamaker, 1998; Green, 1999).
In contrast to most nAChR subunits, which form only heteromeric complexes, the a l  
nAChR subunit has been shown to form homomeric assemblies (Chen and Patrick, 
1997). The a l  nAChR subunit forms functional receptors when expressed in 
Xenopus oocytes (Couturier et al., 1990b; Seguela, 1993) and in some cultured 
mammalian cells lines (Puchacz et al., 1994; Gopalakrishnan et al., 1995). However, 
the inefficient expression of the a l  subunit has been observed for a number of other 
mammalian cell lines (Cooper and Millar, 1997; Kassner and Berg, 1997). The 
reason for the poor heterologous expression of the a l  nAChR is not well understood. 
In contrast, the 5 HT3R, a closely related member of the ligand-gated ion channel 
family which is also capable of assembling as a homomeric receptor, efficiently 
forms functional receptors in several cell lines, for example HEK293 cells (Hope et 
al., 1996). These data suggest that cell-specific factors are required for the correct 
and efficient folding, assembly and subcellular localisation of the a l  nAChR 
(Cooper and Millar, 1997; Dineley and Patrick, 2000; Sweileh et a l, 2000).
The recently identified C. elegans protein CeRIC3 has been shown to be important in 
the maturation of a number of nAChR subtypes (Halevi et al., 2002). Co-expression 
of CeRIC3, and its human homologue, hRIC3, in Xenopus oocytes was shown to 
enhance the activity of the C. elegans DEG-3/DES-2 and rat and human a l  nAChRs 
(Halevi et al., 2002; Halevi et al., 2003). CeRIC3 was shown to have no effects on 
the function of GAB A and glutamate receptors (Halevi et al., 2002). hRIC3 reduced
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human a4|32 and a3(34 nAChR current amplitudes, totally abolished those of mouse 
5HT3A, but had little effect on a l  glycine receptor currents (Halevi et al., 2003).
CeRIC3 was identified in a screen for suppression of a dominant mutation in the 
DEG-3 nAChR subunit. The DEG-3 mutation results in a non-desensitising nAChR 
channel which leads to cell death. Mutations in CeRIC3 were found to prevent this 
cell death and were characterised by an intracellular accumulation of DEG-3 protein 
suggesting a role for RIC3 proteins in maturation pathway of nAChRs (Halevi et al., 
2002).
5.5.1 RIC3 and a7 nAChR
The effects of the RIC3 proteins on the a7  nAChR expressed in the mammalian
tsA201 cell line were investigated in this study. Co-expression of CeRIC3 or hRIC3
with both rat and human a l  enabled the a l  subunits to form a ligand-binding site as
illustrated by specific [125I]-a-BTX binding to cell membrane preparations of
10^transiently transfected tsA201 cells. When [ I]-a-BTX binding was performed on 
intact cells, specific binding was observed indicating that the a l  subunit was 
expressed as a ligand-binding pentamer on the cell surface of tsA201 cells. Previous 
studies had shown that the a l  subunit could be expressed in this cell line, but could 
not bind [125I]-a-BTX (Cooper and Millar, 1997). Co-expression of the RIC3 
proteins with the avian a8  subunit also resulted in this subunit forming a correctly 
folded receptor complex which was expressed on the cell surface.
Evidence for the co-assembly of human a l  with hRIC3/hRIC3FLAG'A was obtained 
by co-immunoprecipitation. A band o f approximately 58 kDa, absent in 
untransfected cells, was detected using the anti-FLAG antibody, mAbFLAG-M2, in 
cells transfected with hRIC3FLAG'A. This band was also seen in cells co-expressing 
hRIC3FLAG'A with ha7 as well as a co-precipitating band the correct size for a l .  
Further evidence for the co-assembly of ha7  and hRIC3 was provided using an 
antibody to a l  (mAb319). In cells co-transfected with ha7 and hRIC3FLAG‘A a band 
corresponding to hRIC3FLAG*A was observed to co-precipitate with ha7. In cells co-
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transfected with untagged hRIC3 a band of approximately 55 kDa was found to co­
precipitate with a l.
The molecular weight of hRIC3FLAG'A based on its primary amino acid sequence, is 
predicted to be approximately 42 kDa. However, the apparent molecular weight is 
greater (~58 kDa). The FLAG tag is predicted to add about 0.9 kDa, but the actual 
increase in apparent molecular weight observed is greater. The reason for this is not 
fully understood, but has been described before (Lansdell and Millar, 2002). 
However, it is not only the addition of the FLAG tag which is responsible for the 
increase as the apparent molecular weight of untagged hRIC3 (~55 kDa) is also 
much greater than predicted (41 kDa). In a recent study the hRIC3 protein is also 
reported to be of this apparent molecular weight in co-immunoprecipitation and 
Western blotting experiments (Williams et al., 2005). The reason for this increase 
from predicted size is unclear, it is possible that hRIC3 is post-translationally 
modified. There are no potential AM inked glycosylation sites (N-X-S/T) in hRIC3, 
so the high apparent molecular weights cannot be attributed to this. hRIC3 contains 
five cysteine residues which could possibly be palmitoylated resulting in an 
increased molecular weight. Also, occasionally the hRIC3 proteins appear as a 
double band. This could be explained by the existence of two differently modified 
forms, both of which co-associate with a l.
Studies conducted by others in this laboratory indicate that co-expression of the 
RIC3 proteins with rat or human a l  in the mammalian tsA201 cell line results in the 
expression of functional receptors (Lansdell et a l , manuscript submitted). Cells co­
expressing RIC3 and a l  were examined by whole-cell patch-clamp recording. 
Application of 200 pM acetylcholine evoked rapidly desensitising responses 
(Lansdell et al., manuscript submitted). The responses were characteristic of native 
a l  nAChRs, for example those in areas such as the hippocampus (Jones and Yakel, 
1997). Similar results for a l  expressed in HEK293 cells were also recently reported 
by Williams et al., 2005.
A correlation between the endogenous expression of the RIC3 proteins and the 
ability to express functional a l  nAChR, either endogenously or by heterologous
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expression of a l  cDNA has been observed (Lansdell et al., manuscript submitted). 
In cell lines that endogenously express a  7, or which are capable of expressing 
functional recombinant a7 , for example the SH-SY5Y human neuroblastoma cell 
line (Lukas et al., 1993, Cooper and Millar, 1997), RIC3 mRNA was detected using 
RT-PCR. No evidence of RIC-3 mRNA could be detected in the human embryonic 
kidney tsA201 cell line which has previously been shown to be incapable of 
expressing functional a  7 receptors (Cooper and Millar, 1997; Lansdell et al., 
manuscript submitted). Similar results were also recently reported by Williams et 
a l ,2005.
Many receptor-associated/chaperone proteins which mediate folding, assembly and 
trafficking of receptors have been identified (Nishimune et al., 1996). However, 
there are relatively few specific for nAChR which is surprising as nAChRs are 
widely expressed and have numerous functions. The proteins reported to associate 
with nAChRs so far are chaperones such as calnexin, BiP and 14-3-3 (Blount and 
Merlie, 1991; Forsayeth et al., 1992; Gelman et al., 1995; Chang et al., 1997, 
Jeanclos et al., 2001), or regulatory proteins such as Lynxl and VILIP which directly 
effect function (Miwa et al., 1999; Ibanez-Tallon et al., 2002; Lin et al., 2002). 
Rapsyn (or 43K) causes clustering of nAChRs at the neuromuscular junction and in 
the electric organ of fish such as Torpedo, but is not thought to associate with 
neuronal nAChRs (Phillips et al., 1991a). PDZ-containing proteins of the PSD-95 
family have also been shown to associate with neuronal nAChRs (Conroy et al., 
2003). RIC3 is not an ubiquitously expressed protein and has varying effects on 
different subtypes of nAChRs, but appears not to effect other members of the ligand- 
gated ion channel family except for the closely related 5 HT3aR (Halevi et al., 2002; 
Halevi et al., 2003).
Another factor recently identified to be important in a  7 expression has been the 
illustration of a correlation between palmitoylation of the a l  nAChR and expression 
of functional a l  nAChRs (Drisdel et al., 2004). In cell lines such as HEK293 which 
are incapable of expressing functional, a-BTX-binding a 7 nAChRs, receptors are 
not significantly palmitoylated. However, in cell lines such as PC 12 where a l  is 
functionally expressed, the receptors are shown to be palmitoylated. Also, the
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5HT3aR and a 7 /5 HT3A chimeric receptor is shown to be palmitoylated in HEK293 
cells (Drisdel et al., 2004). Palmitoylation of membrane proteins has been shown to 
be important in trafficking of proteins to the plasma membrane (reviewed in Smotrys 
and Linder, 2004). Perhaps a l  has to be folded/assembled to a certain extent, which 
requires association with RIC3, before palmitoylation and trafficking to the plasma 
membrane can occur. It would be interesting to determine whether the a l  nAChR is 
palmitoylated in the presence of RIC3 in cell lines such as HEK293.
In summary, it has been observed that the RIC3 proteins enable correct subunit 
assembly and cell surface expression of rat and human a l  (and chick a 8 ) in the 
mammalian tsA201 cell line, which is not usually capable of functional a l  
expression. Williams et al. (2005) reported that a l  could be detected on the cell 
surface of the HEK293 cell line in the absence of RIC3, but the receptors were 
incapable of binding a-bungarotoxin and not functional. However, co-expression 
with RIC3 enables functional expression of a l .  The presence of a 7 on the cell 
surface in the absence of RIC3 (Williams et al., 2005) suggests that RIC3 does not 
play a direct role in regulating traffic of a l  receptors to the cell surface. Williams et 
al. (2005) also report that RIC3 does not alter a l  expression levels implicating that 
the increase in cell surface functional receptors is not due to a general increase in cell 
surface receptors. Together the results described suggest RIC3 to be an a l -  
associated protein which is necessary for the efficient folding and assembly of a l  
nAChR into functional receptors.
5.5.2 RIC3 and 5HT3A
The effects of the RIC3 proteins on other members of the ligand-gated ion channel 
family were investigated by Halevi et al. (2003). Of particular interest was the 
observation that co-expression of hRIC3 with the mouse 5 HT3aR subunit in Xenopus 
oocytes led to the abolishment of agonist-induced currents. In this chapter the effects 
of hRIC3 and CeRIC3 on both human and mouse 5 HT3A expressed in the 
mammalian tsA201 cell line were investigated.
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There was some evidence for the co-assembly of hRIC3 with both the mouse and 
human 5HT3ARs, although the co-immunoprecipitation data was not particularly 
clear. This may be due to the interaction being transient or may be because RIC3 
only interacts with a small proportion of 5HT3AR, for example, immature receptor 
subunits/complexes.
In contrast to the complete inhibition of hRIC3 on m5HT3AR function (Halevi et al., 
2003) an approximately 50% reduction of 5-HT-induced elevations in intracellular 
calcium assayed using a FLIPR was observed in tsA201 cells. CeRIC3 had no 
significant effect on the function of m5HT3A. However CeRIC3 significantly 
increased functional responses of h5HT3A, whilst hRIC3 had no significant effect. 
Differences in the expression systems used (oocytes versus mammalian tsA201 cells) 
may explain the different result for co-expression of hRIC3 with m5HT3A compared 
to Halevi et al. (2003). A Xenopus leavis RIC3 homologue has recently been 
identified (Halevi et al., 2003). Over-expression of the RIC3 protein could therefore 
be creating an inhibitory effect. There is no endogenous RIC3 in tsA201 cells 
(Lansdell et al., manuscript submitted) and so the potential inhibitory effect of RIC3 
would be reduced.
RIC3 increased levels of specific [3H]-GR65630 binding to membrane preparations 
of tsA201 cells expressing mouse or human 5HT3A. Cell surface expression levels of 
m5HT3A, assayed by antibody binding, were not affected by co-expression with 
RIC3. However, the cell surface expression of human 5HT3A, assayed by antibody 
binding, was increased by co-expression with RIC3 as was total expression. In the 
antibody binding assay, CeRIC3 and hRIC3 were seen to enhance the total level of 
h5HT3A to a similar extent. However, in radioligand binding studies, CeRIC3 
increased h5HT3A levels significantly more than hRIC3. This suggests that not all of 
the additional 5HT3ARs formed in the presence of hRIC3 are completely or correctly 
formed and therefore capable of ligand binding.
Unlike the a  7 nAChR, co-expression of RIC3 is not required for functional cell- 
surface expression of either mouse or human 5HT3A in the tsA201 cell line. The 
effects of CeRIC3 and hRIC3 on the level of protein expression, cell-surface 
expression and radioligand binding are conserved. There are species differences
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between mouse and human 5HT3A in the effects of the RIC3 proteins. Generally, the 
RIC3 proteins enhance the expression of the 5HT3aR possibly by promoting subunit 
folding and assembly resulting in 5HT3aR stabilisation. However, with the increased 
expression levels observed an increase in 5HT3aR function was expected. Only 
CeRIC3 was observed to increase h5HT3A function, by an increase in 5-HT-induced 
responses.
Like the a 7 nAChR, few 5 HT3R associated proteins have been identified. The 
chaperone proteins BiP and calnexin have been shown to interact with 5HT3aR 
(Boyd et al., 2002), but these are ubiquitously expressed and their action is not 
specific to 5 HT3R.
5.5.3 Topology o f RIC3
Halevi et a l (2002) identified CeRIC3 as a novel protein. Structure predictions 
(using programs on http://www.expasy.ch and http://psort.nibb.ac.jp) suggested that 
it contained no signal peptide and was composed of two transmembrane domains, 
separated by a proline-rich spacer, followed by coiled coil domains resulting in the 
N- and C-termini being cytosolic (Halevi et al., 2002). Cloning of hRIC3 and 
homologues from a number of other species revealed that CeRIC3 belonged to a 
conserved gene family which shared the predicted structure and topology for 
CeRIC3 (Halevi et al., 2003). Immunofluorescence studies using an N-terminal 
GFP-tagged CeRIC3 suggested CeRIC3 to be localised to the ER (Halevi et al., 
2002).
The methods used by Halevi et al. (2002) to predict the structure of the RIC3 
proteins do not distinguish between a transmembrane domain and a signal peptide. 
Using more recent protein structure prediction programs, such as SignalP3.0 
(http://www.cbs.dtu.dk/services/SignalP/), a signal peptide predictor, suggests that 
the first transmembrane domain of hRIC3 predicted by Halevi et al. (2002, 2003), to 
be a signal peptide. This implies that hRIC3 contains only a single transmembrane 
domain. Sequence analysis by Williams et al. (2005) using SignalP2.0, and Phobius, 
a combined transmembrane topology and signal peptide predictor (Kail et a l , 2004), 
also suggest that hRIC3 contains a signal peptide and a single transmembrane
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domain. Using SignalP3.0, CeRIC3 is suggested not to contain a signal peptide. The 
use of an N-terminal GFP-tagged CeRIC3 construct supports this result (Halevi et 
a!., 2002).
The topology of hRIC3 was further investigated through the use of epitope tags. The 
FLAG epitope tag was introduced into hRIC3 at three positions based upon the 
topology predicted by Halevi et al. (2002). To determine whether the tags interfered 
with the function of RIC3, the constructs were co-expressed with human a 7 and 
[125I]-a-BTX binding studies performed. Co-expression of h a 7 with hRIC3 tagged 
at the N-terminal (hRIC3FLAG‘c) resulted in a reduced level of specific cell surface 
[125I]-a-BTX binding compared to that observed upon co-expression of wild type 
hRIC3. Total levels of binding did not differ. hRIC3FLAG‘c was shown to be capable 
of facilitating a l  folding and assembly in tsA201 cells, but either less a l  reached the 
cell surface or fewer a l  receptors capable of ligand/a-BTX binding reached the cell 
surface resulting in the observed decrease in binding.
Using the FLAG tagged hRIC3 constructs, the presence of hRIC3 at the cell surface 
was detected. Unexpectedly, all of the tags appeared to be detected on the cell 
surface. Antibody binding to the constructs tagged at the N- and C- termini was 
greater than that to the construct tagged in between the two predicted transmembrane 
domains (hRIC3FLAG'B). These results weakly suggested the topology of hRIC3 to be 
opposite to that predicted by Halevi et al. (2002) with the N- and C-termini 
extracellular. However, the presence of a coiled coil domain in the C-terminal 
domain would suggest this region to be intracellular as coiled coil domains are often 
seen to mediate intracellular protein-protein interactions (Stefancsik et al., 1998). 
The weak presence of hRIC3FLAG‘B on the cell surface could be explained if the cells 
had become slightly permeabilised. If the cells had become permeabilised then the 
detection of all three differently tagged subunits would be more likely. The level of 
antibody binding to hRIC3FLAG‘B could be reduced compared to the other tagged 
constructs if  the tag was obscured. The loop between the two transmembrane 
domains is rich in proline residues which may form a rigid structure that obscures the 
FLAG tag.
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The detection of the N-terminal tag on the cell surface would suggest that there is no 
cleaved signal peptide which disagrees with the SignalP3.0 predictions and Williams 
et al. (2005). Williams et al. (2005) provide evidence for the expression of hRIC3 
on the cell surface, but suggest that hRIC3 contains a single transmembrane domain 
with an extracellular N-terminus. Further studies are required before firm 
conclusions about the topology and the localisation of the RIC3 proteins can be 
made.
5.5.4 Summary
In summary, the RIC3 proteins have been shown to enable functional cell-surface 
expression of a7  nAChRs in a mammalian cell line (tsA201) in which a 7  is not 
usually efficiently expressed. Correlation between expression of RIC3 and ability to 
express functional a l  nAChRs strongly suggests that the lack of RIC3 is the primary 
cause of inefficient functional expression. Although not essential for the functional 
cell surface expression of the 5HT3aR, the RIC3 proteins have been shown to 
enhance expression. These effects on both the a  7 nAChR and the 5HT3aR are 
suggested to be mediated by a promotion of folding and assembly resulting in the 
production of stable receptor complexes. The exact mechanisms by which ligand- 
gated ion channels fold, assemble and traffic are unknown. The precise role of 
RIC3, its mechanism of action, and location are still to be determined.
5.6 Future directions
Reports defining the cellular location of RIC3 have been contradictory and further 
investigations are required. Selective permeabilisation of cells expressing RIC3 
could help to determine whether RIC3 is plasma membrane- or ER-localised. The 
compound Streptolysin O which selectively permeabilises the plasma membrane, but 
not Golgi or ER membranes (Crystal et al., 2003), could be used. The use of 
techniques such as immunofluorescence with antibodies to RIC3 itself or to epitope 
tags, introduced into the RIC3 proteins, may prove useful in investigating RIC3 
expression and distribution. Co-staining with ER markers, such as BiP and calnexin, 
may help in these studies.
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Glycosylation scanning mutagenesis could be used to examine the topology of the 
RIC3 proteins. The method involves the introduction of glycosylation sites into 
proteins of interest by site-directed mutagenesis, followed by an analysis of the 
glycosylation state of the expressed proteins by methods such as Western blotting 
The method takes advantage of the fact that membrane proteins are glycosylated only 
on the lumenal side of the ER (Crystal et al., 2003).
Site-directed mutagenesis could be used to determine residues and regions involved 
in interactions with RIC3. The yeast 2-hybrid system could be used to identify 
binding partners of RIC3 and to determine whether RIC3 interacts directly with the 
a l  nAChR and 5HT3AR.
To further characterise the role and function of the RIC3 proteins, it would be 
interesting to investigate the effects of RIC3 on other members of the nAChR and 
5 HT3R families. RIC3 has been reported to inhibit the whole-cell currents of the 
a4p2 and a3p4 nAChRs expressed in Xenopus oocytes (Halevi et al., 2003). It 
would therefore be of interest to examine the effects of the RIC3 proteins on these 
nAChR subtypes, and others, in mammalian cell lines.
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CHAPTER 6
CONCLUSION
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The neuronal nAChRs and 5HT3RS play numerous roles in physiological processes 
such as neurotransmission and the modulation of neurotransmitter release. In 
addition, both have been implicated in several neurological disorders. Nicotinic 
receptors have also been implicated in mediating addiction to nicotine from tobacco 
smoking, and the 5HT3RS are involved in mediating emesis. The nAChR and 5 HT3R 
subunits assemble into pentameric structures, and form both heteromeric and 
homomeric complexes. The muscle-type nAChR has been studied extensively and 
many of its defined structural and functional characteristics serve as a model for 
other members of the ligand-gated ion channel family, including the neuronal 
nAChRs and 5HT3RS.
In this study, aspects of nAChR and 5 HT3R expression, assembly and function were 
investigated through heterologous expression of cloned receptor subunits in 
mammalian cell lines and Xenopus oocytes. Further knowledge of these receptors is 
important in understanding their functional roles as native receptors, and may 
provide insight into the function of other ligand gated ion channels. Also, gaining 
further insight into the function of these receptors will aid in understanding their 
potential as therapeutic targets.
The assembly of the nAChR or 5 HT3R subunits leading to the expression of a 
functional receptor is a complex and poorly characterised process. Individual 
subunits must fold with the correct membrane topology, and assemble with other 
subunits, within the endoplasmic reticulum (ER), before functional expression at the 
cell surface (Green and Millar, 1995). Throughout the assembly process, the 
receptor subunits undergo several post-translational modifications, such as 
glycosylation and phosphorylation. A number of other factors are also required for 
receptor assembly, for example, chaperone proteins play a role in ‘quality control’ by 
interacting with folding receptor intermediates, and by preventing incorrectly and 
incompletely folded and assembled complexes from reaching the cell surface.
The efficient heterologous expression of the nAChRs has proved difficult. The a 7 
nAChR can be expressed as a functional homomeric receptor in some expression 
systems, such as Xenopus oocytes (Couturier et al., 1990b), but there are relatively 
few reports of its functional expression in mammalian cell lines (Puchacz et al.,
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1994; Gopalakrishnan et al., 1995; Quik et al., 1996). The functional expression of 
the a  7 nAChR has been reported to be dependent upon host-cell specific factors 
(Cooper and Millar, 1997; Sweileh et al., 2000). Several approaches have been used 
to attempt to overcome these difficulties in expression, for example, the use of 
chimeric subunits between the nAChR a7-subunit and 5HT3A subunit (Eisele et al., 
1993; Blumenthal et al., 1997; Rangwala et al., 1997; Cooper and Millar, 1998). 
The a7/5HT3A subunit chimera is able to generate a functional receptor efficiently in 
diverse cell types, and has proven to be a very useful tool in the pharmacological 
characterisation of the a l  receptor. However, the chimeric receptor is not native and 
its use in studies such as drug discovery are limited. Unlike the a l  nAChR, the 
ability of the 5HT3AR to generate a functional receptor is independent of host-cell 
type. The reason for the difference in expression of nAChRs and 5HT3RS is unclear, 
but may be due to a requirement for interactions with different intracellular proteins 
to aid in folding and assembly.
The RIC3 family of proteins was recently identified and studies suggested its
involvement in the maturation of several nAChR subtypes, when expressed in
Xenopus oocytes (Halevi et al., 2002; Halevi et al., 2003). RIC3 has been observed
to enhance the functional responses of the a l  nAChR expressed in Xenopus oocytes
(Halevi et al., 2002; Halevi et al., 2003). In this study, the effects of RIC3 on a l
nAChR expression in a mammalian cell line (tsA201), which is not capable of
functional a l  expression, were investigated. Co-expression of RIC3 with a7, in the
tsA201 cell line, resulted in the cell-surface expression of an a l  nAChR capable of 
10 ^[ I]-a-BTX binding. The a l  subunit protein was also shown to co-associate with 
RIC3. Studies by others in this laboratory have shown that co-expression of RIC3 
with a l  results in the expression of functional a l  receptors. A correlation between 
the expression of RIC3 and the ability to express functional a l  nAChRs has also 
been shown. Together these data suggest that RIC3 may be a protein required for 
efficient a l  nAChR expression. Studies by Williams et al. (2005) reported the 
presence of the a l  nAChR on the cell surface of HEK293 cells in the absence of 
RIC3, but the receptors were non-functional and could not bind a-BTX. Upon co­
expression with hRIC3 the same level of a l  was observed at the cell surface, but the 
receptors were reported to be functional and could bind a-BTX (Williams et al.,
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2005). This data, together with the data in this study, suggests the RIC3 proteins to 
be involved in the efficient folding and assembly of the a l  nAChR, and not in the 
trafficking of the receptor to the cell surface. The ability to efficiently express a 
functional a l  nAChR, by co-expression with RIC3, in non-neuronal cultured cell 
lines will be extremely useful for high-throughput screening purposes as well as to 
enable further characterisation of the functional and pharmacological properties of 
the a l  nAChR.
The structure of the RIC3 proteins and their mechanism of action require further 
characterisation. Through the use of different structure prediction programs, various 
membrane topologies of the RIC3 proteins have been suggested (this study; Halevi et 
al., 2002; Halevi et al., 2003; Williams et al., 2005). RIC3 contains at least one 
transmembrane domain. The location of the RIC3 proteins also requires further 
characterisation. One study suggests RIC3 to be localised to the ER (Halevi et al., 
2002), whilst others have reported its expression at the cell surface (this study; 
Williams et al., 2005).
The effects of RIC3 are not limited to the nAChR family. The function of the 
5 HT3R has also been observed to be effected by RIC3 (Halevi et al., 2003). In 
Xenopus oocytes, co-expression of hRIC3 with the mouse 5HT3A subunit resulted in 
an abolition of 5-HT-induced responses (Halevi et al., 2002). The effects of the 
RIC3 proteins on the expression of the mouse and human 5HT3aRs in mammalian
cells were investigated in this study. There was some evidence for the co-assembly
♦ •  • 1of the RIC3 proteins with 5HT3A, shown by immunoprecipitation. Levels of [ H]-
GR65630 binding to membrane preparations of cells expressing 5HT3A were 
significantly enhanced in the presence of the RIC3 proteins. An enhancement of the 
levels of cell-surface and total expression of human 5HT3A upon co-expression with 
RIC3 was shown through an enzyme-linked antibody binding assay. The level of 
cell-surface mouse 5 HT3A was not affected by RIC3. A decrease in the size of 
functional responses of mouse 5 HT3A, when co-expressed with hRIC3 in tsA201 
cells, was observed when assayed by FLIPR, but function was not totally abolished 
as reported for expression in Xenopus oocytes by Halevi et al. 2003. Response size 
was increased for human 5HT3A in the presence of CeRIC3. From these studies the
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RIC3 proteins are suggested to play a role in stabilising or promoting the efficient 
folding and assembly of the 5HT3aR, but further studies need to be performed to 
clarify the effects of the RIC3 proteins on 5HT3aR expression and function.
Whilst the 5 HT3A subunit, when expressed alone, forms functional homomeric 
receptors, the 5HT3B subunit, when expressed alone, does not form a functional 
receptor (Davies et al., 1999; Dubin et al., 1999; Hanna et al., 2000; Spier and 
Lummis, 2000). The 5 HT3B subunit alone does not reach the cell surface, but is 
retained within the ER (Boyd et al., 2002). Co-expression of 5 HT3A and 5 HT3B 
enables 5HT3B to reach the cell surface (this study; Boyd et al., 2002). In this study, 
the mechanism for the retention in the ER of the 5 HT3B subunit was investigated and 
an ER retention motif of the RXR type was identified in the 5 HT3B subunit, in 
between Ml and M2. The presence of ER retention/retrieval motifs such as the one 
identified here have been shown to play a role in regulating the expression of a 
number of receptors (Zerangue et al., 1999; Bichet et al., 2000; Margeta-Mitrovic et 
al., 2000). When these motifs are exposed/unmasked, then the protein containing 
them is retained within the ER by an, as of yet, unknown mechanism. The motifs 
may be masked by assembly with another subunit, interactions with other proteins or 
other modifications, such as phosphorylation, resulting in release from the ER. 
When 5HT3B is co-expressed with 5 HT3A, it can be detected on the cell surface as 
part of a functional receptor complex. It appears therefore, that the 5 HT3A subunit 
masks the RXR motif within the 5HT3B subunit, upon assembly, resulting in the 
generation of a functional heteromeric receptor. Although this motif is capable of 
retaining the 5HT3B subunit within the ER, it has been shown not to be the only 
factor involved in the retention of the subunit. Further studies are required to 
identify other retention motifs in the 5 HT3B subunit and to identify regions or 
residues in the 5HT3A subunit or other proteins/factors responsible for masking the 
RXR motif.
As described previously (Section 1.8; Chapter 4), the a  7 nAChR and 5HT3aR are 
structurally and functionally related proteins and share approximately 33% amino 
acid sequence identity in their N-terminal ligand binding domains. Cross-reactivity 
of some ligands is observed and this is thought to be due to similarities of the ligand 
binding sites. Many site-directed mutagenesis and affinity labelling studies have
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identified residues and regions of the nAChR and 5HT3R involved in ligand binding 
(see Section 1.3.3). The six loops, A-F, identified as important in forming the ligand 
binding site contain several residues which are conserved between the nAChR and 
5HT3R (see Section 1.3.3).
The aromatic moiety of 5-HT, 5-hydroxyindole (5-HI), has been shown to potentiate 
the responses of both the a l  nAChR and the mouse 5HT3AR (Kooyman et al., 1993; 
Kooyman et al., 1994; van Hooft et al., 1997; Gurley et al., 2000; Zwart et al., 
2002). However, 5-HI does not potentiate the human 5HT3AR (unpublished result, 
Eli Lilly). There is approximately 84% amino acid sequence identity between the 
human and mouse 5HT3A receptors, but differences in their pharmacological 
properties are observed. For example, the 5 HT3R antagonist <7-tubocurarine (d  -TC) 
is significantly (1800-fold) more potent at mouse 5HT3A, than human 5HT3A. In this 
study the differing effects of 5-HI on mouse and human 5HT3A were investigated, 
with the aim of determining the ligand binding site for this compound. Mammalian 
tsA201/HEK293 cells were transfected with mouse or human 5HT3A and the effects 
of 5-HI assayed using a FLIPR. The responses of the mouse 5HT3A were potentiated 
by 5-HI, whilst the responses of human 5HT3A were unaffected by 5-HI. The effects 
of 5-HI on chimeric subunits (containing human and mouse 5HT3A subunit domains) 
were investigated. It was hoped that these chimeras would be the basis for further 
chimeras to identity regions and residues conferring sensitivity to 5-HI. However, 
both the human/mouse and mouse/human 5HT3A chimeras were potentiated slightly 
suggesting both the N- and C-terminal domains of the receptors to be important in 
binding or mediating the actions of 5-HI. Previous studies have suggested that there 
may be more than one binding site for 5-HI. At low concentrations, 5-HI potentiates 
the responses of the 5HT3R, but at higher concentrations 5-HI blocks 5-HT-evoked 
currents (Kooyman et al., 1994; van Hooft et al., 1997). The results in this study 
suggest that the actions of 5-HI may be mediated by regions in both the N- and C- 
terminal of the 5 HT3R.
Defining the ligand binding site for 5-HI would be useful to enable the creation of 
receptor specific and subtype-specific compounds. Defining the binding site of 5-HI 
as a potentiator of the a l  nAChR would be useful for rationalisation of drug design
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with the aim of generating a l  nAChR-selective potentiators for the treatment of 
neurological disorders such as neurodegeneration (Maelicke and Albequerque, 2000; 
Dani et al., 2004). The cross-reactivity of ligands between 5HT3A and a 7 needs to 
be considered when designing potential receptor subtype-specific compounds, for 
example, the 5HT3R antagonist tropisetron, which is used in the treatment of emesis, 
has also been reported to act as a partial agonist at the a l  nAChR, when expressed in 
Xenopus oocytes (Macor et al., 2001).
Summary
The aim of this project was to gain a better understanding of the structural and 
functional properties of the nAChRs and 5 HT3RS. Through three different studies, 
aspects of the assembly, trafficking and pharmacological properties o f these 
receptors have been investigated. Through co-expression of the a l  nAChR subunit 
with RIC3, the cell-surface expression of an a l  receptor, capable of a-BTX  binding, 
in a non-neuronal mammalian cell line, has been demonstrated. The characterisation 
of the effects of the RIC3 proteins on a l  have identified RIC3 as a protein involved 
in the facilitation of efficient folding and assembly of the a l  nAChR. These results 
will allow further characterisation of a receptor which has previously been very 
difficult to express in heterologous expression systems. The observation that the 
RIC3 proteins also interact with the 5HT3AR subunit and, to an extent, promote its 
expression suggest that they may have a conserved role in ligand gated ion channel 
assembly. Aspects of the assembly of the heteromeric 5HT3A/5HT3b receptor have 
been revealed in the identification of an ER retention motif in the 5 HT3B subunit. 
The RXR motif in 5 HT3B has been shown to require masking by 5HT3A to achieve 
cell-surface expression. The differing effects of 5-HI at the human and mouse 
5HT3A receptors previously observed by Eli Lilly (unpublished results) have been 
confirmed in this study through expression in mammalian cell lines and Xenopus 
oocytes. The use of human/mouse 5HT3A subunit chimeras suggest the effects of 5- 
HI to be mediated by both N- and C-terminal domains of 5HT3A. A number of 
residues observed to be present in mouse 5HT3A and the a l  nAChR which are 
potentiated by 5-HI, but not in human 5HT3A which is not potentiated by 5-HI, have 
been shown not to be responsible for conferring 5-HI sensitivity.
181
Further elucidation of the mechanisms by which the nAChRs and 5HT3RS assemble 
is not only important in understanding the native functions of these receptors, as well 
as their potential as therapeutic targets, but also in gaining insight into the assembly 
and function of other ligand gated ion channels. The identification of residues and 
regions involved in ligand binding is critical to enable development of receptor- 
specific and receptor subtype-specific compounds for the treatment of neurological 
disorders.
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